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Abstract 
 
For many years, Tuberculosis (TB) has plagued the human race claiming millions, if not billions, 
of lives. With the advent of short-course chemotherapy TB has become a manageable disease, 
however in recent times Mycobacterium tuberculosis has developed resistance to a number of 
established and trusted antibiotics. This coupled with severe forms of extra-pulmonary TB, has 
placed significant emphasis on the development of new anti-TB agents. 
The drug development process is a long and costly affair, with less than 1% of new drugs reaching 
clinical trials. This is where molecular imaging, in particular mass spectrometry imaging (MSI), 
is fast becoming a promising tool in the evaluation of drug candidates. MSI can be used to 
streamline the drug development process by fast tracking areas of target identification, target 
quantification, pharmacokinetics, drug distribution and tissue localization. MSI possesses some 
distinct advantages in terms of sample preparation and the lack of the need for radiolabeling, 
making it the ideal technique for in vivo tissue drug distribution studies. 
The objectives of this study were to demonstrate the value of MSI in the development and 
evaluation of new and existing TB antibiotics, focusing on central nervous system (CNS) 
manifestations of the disease. In order to achieve these objectives, two of the most promising anti-
mycobacterial agents, clofazimine (CFZ) and linezolid (LIN), were selected. Initially, the 
distribution of these agents in a healthy animal model was investigated, since these would represent 
the minimum tissue concentrations achievable. The single-dose study for both drugs were similar, 
in that there was poor penetration into the brain after a 100mg/kg dose in a healthy murine and 
rodent model, respectively. A four-week multiple dose study was conducted, each of the 
antibacterials showed excellent accumulation in the CNS, with preference to specific areas of the 
brain, demonstrating the neuroprotective potential of these drugs (Chapters 2 and 3). 
For the effective evaluation of anti-TB drugs, the lung has to be taken into consideration since this 
is the primary site of M.tb infections. However, the lung poses problems in terms of sample 
preparation for MSI. Since the lung is responsible for gaseous exchange, it is made up of a number 
of air-filled spaces that are kept “open” by a fine balance in pressure, inside and outside the lung. 
When this balance is disturbed, such as when the thoracic cavity is pierced, to collect tissue, the 
lung collapses. This results in distortion of tissue structure and subsequent distribution information 
can be misleading. For this reason, we evaluated various established cryoprotectants as lung 
inflation media. This inflation procedure would main structural integrity of the lung and provide 
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accurate tissue distribution data. From the cryoprotective agents tested in this experiment we found 
that 10% DMSO was ideal, in terms of structural preservation and accurate drug distribution 
(Chapter 4). 
As part of this series of experiments other anti-bacterial agents were also evaluated, to demonstrate 
the value of MSI in drug development. These drugs also appear in the antibiotic pipeline; 
tetracyclines, tigecycline (TIG) and doxycycline (DOX), rifampicin (RIF), gatifloxacin (GAT) and 
pretomanid (PA-824).  The findings were very interesting in that each agent displayed a unique 
pattern of distribution, this is due to the chemical nature of these drugs and their interaction with 
the blood-brain-barrier (BBB). In addition to this, we have demonstrated how MSI can be used to 
determine various aspects of drug-tissue interaction for drug development. MSI was used to prove 
that the chemical properties of a drug do not always govern its movement across the BBB. RIF is 
a large drug molecule that one would not expect to permeate the brain, however this experiment 
has demonstrated its time-dependent distribution in the brain (Chapter 5). The results show how 
the tetracyclines have widespread tissue distribution in the brain, which contributes to their 
efficacy in the treatment of brain damage (Chapters 6 and 7). This technique was also used to 
understand how GAT enters the brain and contributes to the proven neurotoxicity of the 
flouroquinolones (Chapter 8). In the final chapter, we showed how MSI can be used in the tissue 
evaluation of novel antibiotics, such as pretomanid (Chapter 9). These findings emphasize the need 
to evaluate the drug distribution of antibiotics, since pathogens manifest themselves in different 
areas of the brain and cause damage. This information will be invaluable in our pursuit of effective 
treatments to CNS diseases and disorders, allowing medical practitioners to develop more targeted 
treatment programmes. 
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Chapter 1 - Introduction 
 
1.1 Importance of molecular imaging in drug development 
 
The development of a new drug is a long, labour intensive and costly enterprise. This process takes 
on average about 10 years from an investigational new drug to regulatory approval. Five out of 
every 10,000 new compounds make it to clinical trials and only one of these five candidates gets 
approved for patient use (Figure 1) [1]. Even with the increased demand for new active compound 
classes and large amounts of investments into drug development, only two to three new drugs 
classes enter the market each year. This coupled with the high costs needed to bring a drug to the 
end of Phase III clinical trials, now standing at approximately $1.9 billion [1], emphasizes the need 
for new strategies to aid in the early selection or elimination of new compounds in the drug 
pipeline, thereby dramatically shortening the time taken for final regulatory approval. 
 
 
Figure 1. The general timeline for the processes involved in the drug development process. In the 
US, the mean time for drug approval by the Food and Drug Administration (FDA) is 14.20 years. 
This schematic also demonstrates how molecular imaging can be used at various stages (which 
include target localization, target quantification, efficacy testing, pharmacokinetics) in the process 
to shorten the time taken to reach regulatory approval [1]. 
 
Throughout the scientific domain, medical researchers rely on various molecular imaging (MI) 
modalities in order to quantify and identify biomolecules (endogenous molecules and exogenous 
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probes) and drugs [2]. MI at the early stages of the drug development process allows for the high-
throughput screening of cell and animal-based assays while providing essential evidence on 
biological activity, target identification, drug efficacy and toxicity [1]. All of this combined allows 
the researcher to evaluate drug treatments and understand the mechanistics that underline the 
associated biological responses such as enzyme activity, gene expression, ligand/receptor binding, 
receptor distribution and transporter activity. 
 
Commonly used MI techniques are computed tomography (CT), positron emission tomography 
(PET), magnetic resonance imaging (MRI), single photon emission computed tomography 
(SPECT), ultrasound and optical imaging [1-4]. These technologies have wide application ranges 
and are used for diagnostics, therapeutics and the pre-clinical evaluation of drug candidates. Each 
technique possesses its own pro’s and con’s for example, many provide excellent clinical 
translation however are very expensive to conduct and some have limited spatial resolution (Table 
1). In addition to this, those that use radiolabeled tracers (PET, CT) have the added occupational 
hazards associated with exposure to radioactive materials. A new MI modality that has come to 
the forefront of drug development investigations in the form of mass spectrometry imaging (MSI) 
[3]. 
 
Table 1. The average resolution of the most commonly used molecular imaging technologies, the 
resolution may vary from instrument to instrument. 
 
Molecular imaging modality 
 
Average resolution 
(mm) 
PET 
 
4-5 
CT 
 
<1 
MRI* 
 
0.10 
SPECT 
 
10 
* This resolution is possible on the Tesla 11.74 INUMAC Imager; resolution of other MRI 
instruments will be significantly higher. 
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1.2 Mass Spectrometry Imaging: the latest technology in molecular imaging 
 
Scientists are beginning to see the value of MSI and its myriad of potential applications. This can 
be evidenced by the large number of recent publications in various disciplines ranging from food 
chemistry to drug discovery [5, 6]. MSI possesses some distinct advantages over the more popular 
imaging technologies such as PET, CT, MRI and SPECT [2]. These more conventional techniques 
require the use of radiolabeled compounds or agents (radiotracers) which are expensive to produce 
and some requiring a cyclotron for production. With specific radiochemicals having their own 
shortcomings, example flourodeoxyglucose [18FDG], having non-specific binding and localizing 
in any region of high glucose metabolism. 68Ga has a particularly short half-life (68 min) meaning 
that labelling and imaging has to be conducted within a very small time window or radioactivity 
would decrease and radiolabeling and subsequent image quality would be compromised.  
 
With MSI all of these potential shortcomings are eliminated since there is no requirement for 
radiolabeling, pre-treatment or modification of the drug and the ability to achieve single-cell 
resolution. MSI can be used at various stages during the drug development process which include 
pharmacological target identification as well as the distribution of drugs and drug metabolites in 
tissue. This is possible since all of the processes in a biological system involve the interaction and 
spatial redistribution of molecules or molecular complexes. This technique also allows for the 
identification of multiple numbers of known and unknown compounds. This is of great value since 
target compounds vary greatly in terms of size, physiochemical properties, concentrations, 
structure and chiral variability (in biological proteins and peptides) [3]. MSI overcomes many of 
these challenges by detecting the atomic mass of a compound of interest, which is a universal 
parameter based on the molecules atomic composition [3]. 
 
MSI combines the analytical power of mass spectrometry and histology to create chemical images 
of the tissue distribution of endogenous biomolecules, drugs and their metabolites, in tissue 
sections. The accumulation of spectra, during the data acquisition stage, allows for the 
retrospective identification of unknown molecules.  Applications have evolved tremendously, with 
a number of technological advancements in the available hardware and software [6, 7]. This 
coupled with a number of research groups striving to create standardized protocols has led to the 
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development of many MSI protocols with varying applications. Most workflows are very 
streamlined and normally include a washing and sectioning step before subsequent image 
acquisition and analysis (Figure 2). The washing improve sensitivity by removing any possible 
endogenous suppressants that may be present in the tissue section. Specificity of the technique is 
unquestionable since tandem mass spectrometry (either MS/MS or TOF/TOF) can be used to 
obtained fragmentation patterns which allow for the positive identification of the analyte of 
interest. Tissue biopsies for MSI can be stored for long periods of time, at the appropriate 
conditions, with the integrity preserved.  
 
 
Figure 2. A simplified overview of the workflow used for an MSI experiment involving animal 
tissue. Examples of MSI images showing drug distribution (A) axial section of mouse brain treated 
with clofazimine; (B) coronal section of rat brain treated with linezolid; (C) rat lung treated with 
gatifloxacin [8-10].  
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Currently there are a number of techniques available for MSI analysis, the most popular technique 
is matrix assisted laser desorption ionization (MALDI), followed by secondary ion mass 
spectrometry (SIMS) and desorption electrospray ionization (DESI). Each of these ionization 
methods can be combined with a number of possible mass analyzers, increasing the potential of 
MSI to measure a large array of molecules, ranging from small drug metabolites to large 
endogenous proteins [11]. MALDI has become the most popular technique since it allows for the 
label-free identification of a variety of molecular species, directly from tissue sections. This 
technique uses a uniform layer of a crystalline matrix which coats the tissue sections (normally 
10-20µm). A laser is used to generate ions via a transfer of energy through the matrix. One 
disadvantage of this technique is that it is seen as destructive since tissue sections cannot be re-
analysed [12]. DESI is advantageous as it requires no sample preparation beyond tissue sectioning 
and it has proven to have excellent sensitivity for small molecules. This technique uses an 
electrically charged solvent mist for the ionization and desorption of analytes. Therefore, DESI-
MSI can be used to generate 2D-images and for the determination of relative abundance of the 
analytes of interest. DESI is also less destructive and allows for the reuse of tissue sections [13]. 
SIMS was the first ionization technique investigated for MSI applications, this technique works 
by focusing a primary ion beam onto the tissue section in order to generate and desorb ions [14]. 
When SIMS is combined with TOF, the analyst is able to measure large biomolecules with high 
levels of sensitivity and spatial resolution [11]. However, this is a very expensive and labour 
intensive approach which has more applicability to specific investigations, rather than being a 
general MSI technique. 
Each MSI experiment is tailor made and for this reason there are now guidelines on the reporting 
of MSI which allows for the dissemination of knowledge throughout the scientific community 
[15]. Of the many applications currently available, our group has focused on the use of MSI in 
drug development and pharmacokinetic studies [16, 17]. The technique was used with great 
efficacy in the imaging of anti-TB agents in the brain of small rodents [16-18]. The results were 
very intriguing where different classes of drugs showed preferential distribution in the brain; this 
is an important point to consider when prescribing treatments for neurological disorders.  
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1.3 LC-MS/MS: the gold standard in drug quantitation 
 
Over the years’ liquid chromatography-tandem mass spectrometry (LC-MS/MS) has become the 
preferred technique in drug quantitation studies. This combines the specificity of chromatography 
with the sensitivity of mass spectrometry to provide accurate quantification data for a wide range 
of analytes. The value of this technique has been seen by pharmaceutical drug development 
agencies and has become the gold standard for drug quantitation during all stages of drug 
development (Figure 1). Due to its accuracy, precision, specificity and sensitivity; LC-MS/MS is 
the ideal complementary technique to MSI for its ability to provide reliable information on exact 
tissue concentrations of the desired drug [19]. 
 
Each mass spectrometry (MS) system has the same basic components (Figure 3), however with 
technological advancements each system can be configured based on the nature of the analyte 
being investigated.  
Sample introduction is typically achieved via a liquid chromatography (LC) system, which is ideal 
since it allows the efficient separation of the analyte from endogenous proteins and lipids that 
would interfere with subsequent MS analysis. LC set-ups are standardised across analytical labs, 
with most consisting of a degasser (to prevent unwanted gas from the mobile phase from entering 
the LC system), a binary pump (for efficient mixing of mobile phases), an autosampler (to 
introduce samples for analysis), a column compartment (to keep the column temperature constant) 
and a column (for separation of the analyte from complex biological matrices). There are a number 
of column technologies available, such as the C8, C18, HILIC and diol, all of which allow for the 
retention of a wide range of analytes with varying physiochemical properties [20].   
The mobile phase containing the compound to be measured then enters the ion source, which 
results in the formation of ions that can be easily detected. As with other parts of the analytical 
MS, there are a number of source options available for the analysis of different analytes. The most 
commonly encountered ionisation sources are the electro-spray ionisation (ESI), atmospheric 
pressure chemical ionisation (APCI) and atmospheric pressure photoionisation (APPI). Each of 
these sources can be operated in either positive or negative mode based on the analyte to be 
quantified [21].  
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The sample then continues its journey through the MS by entering the mass analyser, where again 
there are a number of options available, based on the intended application. Researchers have the 
option of a quadrupole, time-of-flight (TOF), ion trap and magnetic selector mass analysers. Each 
uses a different principle to separate and filter the ions. It is not uncommon for modern instruments 
to have a combination of two mass analysers, such as a quadrupole-TOF system [22,23]. The mass 
analyser can be operated in MS mode or MS/MS mode. In MS mode only a signal product ion is 
detected whilst in MS/MS mode, a precursor ion is selected, which is then subjected to physical 
breakdown (either electrical as in a collision cell or gaseous as in collision induced dissociation) 
resulting in product ions, known as molecular fragments. MS/MS mode is preferred for drug 
analysis as it is highly specific, the precursor ion is also known as the qualifier ion while the 
fragment ion is the quantifier ion [24]. 
Once the ions have passed the mass analyser, they need to be detected and transformed into a 
usable signal for analysis. There are 2 major classes of detectors ie. point and array detectors. They 
are able to convert the number of ion hits into a signal that can be amplified and analysed using a 
data system. The data system used in conjunction with MS systems are typically high-powered 
computers with specialised software that can collect, collate and analyse spectral data. 
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Figure 3. A simplified schematic representation of the basic components of an MS system. Due 
to technological advancements, there are many different configuration options available to the user 
based on their specific research needs. 
 
1.4 Tuberculosis 
 
Early in the 1990’s, the World Health Organisation (WHO) released a statement declaring 
tuberculosis (TB) as a global health emergency [25], and more than 20 years on, the disease 
continues to plague many regions of the world. Mycobacterium tuberculosis (M.tb), the causative 
agent has been a scourge of the human population for many years. Over the decades, TB has 
established itself as a leading cause of mortality and morbidity [26]. The focal point of the disease 
is normally the lung, since the bacteria can be spread through the air. This is referred to as 
pulmonary TB; however, bacteria are often spread haematogenously to other regions of the body 
leading to the development of extra-pulmonary TB.  M. tb is able to easily enter the brain, 
manifesting itself in a number of ways, which lead to the formation of intracranial tuberculoma’s, 
tubercular encephalitis and brain abscesses [27]. One of the most severe types of extra-pulmonary 
TB is TB meningitis (TBM), where bacilli are able to colonize the meningeal membranes 
surrounding the brain[27]. 
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TB continues to plague South Africa, with approximately 1% of the population (54 million) 
contracting the disease each year, with a further 80% suspected to have latent TB. While current 
treatment programs are effective in some cases, they have a maximum success rate of 78% [28]. 
This is further complicated by extra-pulmonary TB where studies have shown that TBM 
constitutes approximately 28% of all reported meningitis cases [29]. Despite the initiation of 
effective anti-TB chemotherapy for pulmonary cases, the mortality rate amongst TBM patients 
remains high. This is largely due to the lack of penetration of TB drugs into the central nervous 
system (CNS) which is imperative for the treatment of TBM. Permeability of the blood brain 
barrier (BBB) is a major obstacle for potential drug candidates in the treatment of TBM. Passage 
through the BBB is dependent on the chemical properties of the drug with lipophilic, low molecular 
weight compounds being favoured [30]. Previous studies involving the investigation of anti-
mycobacterial agents have primarily been determined by the concentrations of these drugs in the 
cerebrospinal fluid (CSF) of patients as an indicator of CNS penetration. However, antibiotics do 
not display homogenous distribution in the compartments of the CNS (viz. the CSF and brain 
compartments). This method of using CSF drug concentrations as an indicator of CNS penetration 
is also flawed in that the brain and spine (where CSF sampling is conducted via lumbar puncture) 
contain two distinctively different CSF networks. Coupled with the fact that CSF is turned over 
every 3 hours makes this data very unreliable, emphasising the need to establish and develop new, 
more effective techniques to investigate drug penetration through the BBB. 
 
The current TB short course chemotherapy is effective in managing the disease. However these 
regimens last up to 12 months and place emphasis on patient compliance. This has contributed to 
the rapid increase in extremely- and multi-drug resistant TB (XDR-and MDR-TB) strains. This 
highlights the need for new, more effective anti-mycobacterial agents.  
Current TBM treatment guidelines  vary, with the British Infection Society proposing a first-line 
2 month program consisting of isoniazid, rifampicin, pyrazinamide and ethambutol followed by 
10 weeks of rifampicin and isoniazid treatment [31,32]. The World Health Organisation 
recommends substituting ethambutol for streptomycin in adults. Both organisations also advocate 
for adjunctive therapy using corticosteroids to decrease the potential neurological deficits seen in 
meningitis patients [33,34].  
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The inclusion of bedaquiline in MDR-treatment regimens show that other promising anti-TB 
agents have great potential in the treatment of TB and TBM [35]. Clofazimine (CFZ) and linzezolid 
(LIN) are two such drugs that remain as unknown quantities in the treatment of mycobacterial 
infections. 
 
1.5 Clofazimine 
 
Clofazimine (CFZ) (Figure 3) is a riminophenazine dye that was discovered in 1954 [36], and 
possesses both anti-inflammatory and anti-mycobacterial efficacy [37]. Initially, the drug showed 
encouraging in vitro results against M. tb [38, 39],  however, these findings could not be replicated 
in animal models [40]. 
 
Figure 3. Chemical structure of Clofazimine (MW: 473.94 g/mol) 
 
CFZ was then found to be effective against another member of the Mycobacterium family and 
subsequently used to treat infections caused by M. leprae [41]. Since then CFZ in combination 
with rifampicin and dapsone have become the gold standard in leprosy treatment [42]. The drug’s 
mechanism of action is not clearly understood, but it is widely believed that the main site of action 
is the outer membrane of the bacterial cell wall [43].  
With the growing concern of XDR and MDR-TB, there is renewed interest in the use of CFZ as 
an anti-TB treatment since there are no known cases of resistance [44]. A recently observational 
study reported that the addition of CFZ to the standard therapy for MDR-TB resulted in a relapse-
free cure rate of 87.9% in 206 patients [44]. In addition to this, using a murine model of pan-
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susceptible TB, a 4-month CFZ containing regimen was compared with the standard 6-month 
therapy. The CFZ containing regiment showed relapse-free cure after 3 months of treatment when 
compared to 6 months of the standard treatment [45]. CFZ has showed limited penetration into 
caseous lesions in the lung, but exhibits a lethal bactericidal effect [46, 47]. Its penetration into the 
CNS of both the healthy and unhealthy brain is yet to be elucidated. 
Given its proven efficacy against members of the Mycobacterium family, its lipophilicity and low 
molecular weight, CFZ has great potential for crossing the BBB for the treatment of TBM. 
 
1.6 Linezolid 
 
The discovery of the oxazolidinones, the first new class of antibiotics since 1980 has led to the 
discovery of Linezolid (Figure 4) (LIN) [48], one of the most promising antimicrobial agents in 
recent times. 
 
 
Figure 4. Chemical structure of Linezolid (MW: 337.35 g/mol) 
 
 
The drug has a unique mechanism of action which involves the inhibition of protein synthesis by 
preventing the formation of the 70s ribosomal subunit (Figure 5) during the translation step [48].  
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Figure 5. The mechanism by which LIN inhibits protein synthesis by disrupting the formation of 
the 70s initiation complex. 
 
It’s bioavailibity and serum pharmacokinetic (pK) profile makes LIN a more promising drug 
candidate than other members of this family [49-53]. Since this family of  drugs are synthetic, 
there are no naturally occurring resistance genes thereby making them effective against a broad 
spectrum of microbes [49]. This has been further justified by multiple  studies which have 
demonstrated that LIN has potent activity against antibiotic resistant strains of bacteria [50]. This 
has aided in the treatment and management of central nervous system (CNS) associated infections, 
many of which are caused by resistant microorganisms [50, 54-56]. There are multiple reports 
showing the elimination of multi-drug resistant Enterococci sp., Staphylococci sp., Streptococci 
sp., Bacillus sp., Corynebacterium sp., Listeria sp. systemic infections with LIN treatment [48, 50, 
54, 56, 57]. A few studies have proven that LIN can also be used in the treatment of CNS infections 
[55].  
 
LIN has displayed excellent efficacy in the treatment of drug resistant TB, both in vitro and in vivo 
[58, 59]. This is especially significant since these patients were initially on failing treatment 
regimens, and showed no remission post treatment [60]. However, investigations into the 
penetration of LIN into caseous TB lesions in the lung [47], its distribution in the brain of healthy 
and infected individuals remain unknown. These findings and those involving other resistant 
  13 
microbes, indicate that LIN could present a strong possibility for the treatment of tuberculosis 
meningitis (TBM).  
 
1.7 Rifampicin 
 
Since the development of TB chemotherapy, rifampicin (RIF) (Figure 6) has been an integral part 
of SCC, since it displays potent bactericidal activity against viable metabolizing and latent bacilli 
[61]. It’s mechanism of action involves the inhibition of bacterial RNA polymerase of the bacteria 
thereby preventing DNA transcription and preventing replication [62]. Despite having low oral 
administration bioavailability due to the effects of its metabolism in the gastro-intestinal tract, RIF 
has proven efficacy in the treatment of M.tb [63]. However, its role in the treatment of CNS-TB 
remains unclear. 
 
Figure 6. The chemical structure of RIF (MW: 882.95 g/mol) 
 
RIF does not satisfy the criteria of a drug that would typically enter the brain since it is a large 
molecule and most drugs that are able to enter the brain are normally < 400 Da and have fewer 
than 8 hydrogen bonds [64]. Surprisingly, RIF is still able to permeate the BBB, which can be 
attributed to its high degree of lipophilicity [65]. There have been many reports showing the 
presence of RIF in CSF after oral dosing, these showed concentrations that were only slightly 
above its MIC for M.tb [66-70]. These studies have also demonstrated that with i.v. administration, 
one can greatly increase RIF concentration in CSF. [67, 69]. Unfortunately, the brain and spinal 
cord possess two significantly different CSF pathways, therefore drug concentrations measured in 
the spine are not a true representation of brain drug concentrations therefore it becomes paramount 
that direct tissue measurements be done. A recent study used PET to quantify amounts of radio-
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labeled RIF in the brain. Despite the drug concentration being 4 times the MIC for TB, RIF 
displayed poor permeability when compared to other frontline drugs.  [71].  
Given its proven efficacy against TB and its penetration into the CNS, it is important to investigate 
RIF’s distribution in the brain, using MSI and correlating this to PET investigations using radio-
labelled forms of the drug. 
 
1.8 Tetracyclines: Tigecycline and Doxycycline 
 
The tetracyclines are a class of antibacterial agents that were developed in the 1940s and have a 
broad-spectrum of activity against both gram-positive and gram-negative bacteria. Their 
mechanism of action involves its attachment to the 30S ribosomal subunit thereby inhibiting 
protein synthesis by preventing the binding of transfer RNA to its associated acceptor [72].   
1.8.1 Tigecycline 
 
Tigecycline (TIG) (Figure 7) is a member of this promising class of antimicrobial agents, it is a 
synthetic minocycline derivative and the first member of the novel glycylcycline? sub-class of 
antibiotics. In addition to having a wide range of activity against gram-positive and gram-negative 
bacteria, TIG has proven effective against both aerobic and anaerobic microbes.ref The main 
advantage associated with the use of this drug, is that it is unaffected by the most common bacterial 
resistant mechanisms, this is attributed to steric  hindrance caused by its bulky D-ring substituent 
[73]. TIG is the focal point in the treatment of infections of the gastro-intestinal tract (GIT), 
respiratory system as well as skin disorders [74-76]. Despite having proven its efficacy against 
drug-resistant microorganisms, the role TIG in the treatment of CNS infections have been centered 
around measurements in the CSF [77-79]. In some cases, the CSF concentrations of TIG were 
found to be below its MIC [78, 79], while most reports have claimed the converse [80-82].   
 
 
  15 
 
Figure 7. The chemical structure of TIG (MW: 588.65 g/mol) 
These conflicting results necessitates the need for investigations into the penetration of TIG in the 
CNS by means of direct tissue measurements, rather than relying on CSF quantitation. 
 
1.8.2 Doxycycline 
 
During the past decades, investigations into the neuro-protective potential of tetracyclines gained 
major popularity. This was after initial findings in rodent models proved promising [83-85]. Many 
of these studies focused on the semi-synthetic tetracyclines viz. minocycline and doxycycline 
(DOX) (Figure 8). Both of these drugs are able to easily cross the BBB, making them ideal 
candidates for the treatment of infections of the CNS, particularly meningitis [86-89]. A large 
number of basic and advanced techniques, basic histology and MRI, have been able to demonstrate 
the neuroprotective properties of DOX [89-93].  
 
Figure 8. Chemical structure of DOX (MW: 444.43 g/mol) 
A shortfall in all of these studies, is their inability to provide accurate drug localization and 
distribution data, since it relies on the measurement of histological markers as an indicator of drug 
presence. Therefore, direct visualization of DOX in the brain, using MSI, will provide great 
insights into why it is such a useful antibiotic in the treatment of CNS infections. 
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1.9 Gatifloxacin 
 
Gatifloxacin (GAT) (Figure 9) belongs to a promising drug-class, known as the flouroquinolones. 
This family has demonstrated a broad spectrum of bactericidal activity and their mode of action 
focuses on the inhibition of the bacterial DNA gyrase and topoisomerase IV, that are responsible 
for the coiling of genetic material [94, 95].  Despite their efficacy against a wide range of 
microoraganisms, this class of drugs are notorious for the side effects that occur with chronic 
administration. These adverse effects could include a combination of dizziness, restlessness, 
insomnia, tremors, hallucinations, depression, anxiety and convulsions [96-98]. These significant 
findings led to the FDA issuing a warning that the flouroquinolones may lead to permanent 
peripheral neuropathy [99].   
 
Figure 9. Chemical structure of GAT, a fluoroquinolone (MW: 375.40 g/mol) 
 
In order for a chemical agent to display such high degrees of neurotoxicity and lead to such severe 
neurophysiological impairment, it would mean that the drug has a high degree of brain tissue 
permeability. This makes MSI the ideal tool to investigate the permeability of GAT through the 
BBB, as well as providing an understanding on its tissue distribution. 
 
1.10 Pretomanid 
 
Pretomanid (formerly PA-824) (Figure 10) belongs to a class of anti-mycobacterial agents, known 
as the nitroimidazoles. Like delamanid, another member of this family, they are in the later stages 
of clinical development [100].  This class of drugs inhibit mycolic acid synthesis and have shown 
efficacy against, both drug-susceptible and drug-resistant strains of mycobacteria [101-104]. One 
of the most promising recent findings, is that pretomanid has displayed bactericidal activity which 
is comparable to that of isoniazid, an established anti-TB agent [105]. Studies have also provided 
promising evidence that this drug could be incorporated into existing treatment regimens for 
treatment of drug resistant TB [106].  
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Figure 10. The chemical structure of Pretomanid (MW: 359.26 g/mol) 
 
Being a novel drug class, there is a lack of information regarding the CNS effects of pretomanid, 
MSI investigations of its distribution in the brain will provide insight on its potential for treating 
extra-pulmonary TB. 
 
1.11 Drug Penetration in the Brain 
 
The brain poses a very difficult problem for pharmaceutical scientists in their pursuit of ideal 
treatments for the many brain diseases that affect the population. In cases, such as HIV and TB, 
the causative agents are able to enter the brain and lead to an array of neurodegenerative changes 
that cause severe debilitation. Drugs used to treat these diseases have limited penetration into the 
brain, allowing them to persist and continue their pathogenic processes [107].  
Due to the complex nature of the brain and its physiological functions, it is surrounded by a highly 
selective membrane that forms a barrier between brain tissue and the circulating blood, which is 
thus referred to as the blood-brain-barrier (BBB) [108]. This barrier (Figure 11) has a dual 
function; in that it allows useful molecules into the brain via endothelial tight junctions, while 
preventing the entry of unwanted substances and microbes [108]. To combat such conditions, 
treatment drugs need to be able to penetrate the BBB and reach levels that are sufficient enough to 
fight such infections. Drug penetration into the CNS is governed by a number of factors including 
the molecular size (with smaller molecules favoring diffusion across the BBB) [109], lipophilicity 
(since the brain is lipid in nature, more lipophilic compounds are favored) [110] and plasma protein 
binding. 
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Figure 11. The blood brain barrier. Endotheial tight junctions govern the movement of substances 
from blood into the brain, while astrocytes are responsible for selective permeability in the 
opposite direction [111]. 
 
This highlights the need for the pharmaceutical scientist to measure drug concentrations in the 
brain and to investigate tissue distribution of drug candidates in order to better guide clinical 
treatment regimens. At this point it is also important to measure drug concentrations in the absence 
of an infection, since these values would represent the minimum concentrations reached during 
the early stages of a CNS infection [107].  
This is especially important since other MI techniques such as PET and MRI have been used to 
identify areas of the brain that are susceptible to damage during infection but studies involving the 
distribution of treatment drugs are limited. 
 
1.12 Molecular Imaging of the Lung and its Associated Difficulty 
 
As with any disease in which the lung forms the focal point of its infection, it is paramount to 
understand how the drug behaves in this tissue. Bacteria initially colonize the lung before 
spreading haematogenously and leading to the development of more severe extra-pulmonary forms 
of the disease [27]. Therefore, drug distribution information will aid in our understanding of how 
the compound will interact with the TB bacilli in tissue.  
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The lung itself poses difficulty during sample preparation for MI, especially MSI. Due to the nature 
of its function, the lung is made up of a number of air-filled spaces to facilitate gaseous exchange. 
In order for this process to occur the lung is maintained in an “open” state by the balance of 
pressures inside and outside the thoracic cavity [112]. When tissue is harvested from experimental 
animals, the thoracic cavity is pierced, this pressure balance is offset causing these air-filled spaces 
to collapse (Figure 12).  
 
 
Figure 12. A collapsed lung vs. an inflated lung. This figure shows how the lung collapses when 
the thoracic cavity is pierced causing air to flow into the cavity and the subsequent loss of lung 
structure [113]. 
 
Collapsing of the lung will result in the folding together of multiple cell layers. MI of this tissue 
will result in false distribution data since the lung is primarily composed of single cell layers. This 
emphasizes the need for a sample preparation technique that will preserve the structural integrity 
of the lung, while providing true distribution data. Such a technique has been available to 
histologists for many years and this involves the inflation of lung tissue using neutral buffered 
formalin [114, 115]. However, for MSI, the tissue needs to be frozen to prevent post-operative 
changes, therefore other inflation media are needed for this specific application. This provides the 
ideal opportunity for the use of cryoprotectants which are commonly used in the cryopreservation 
of biological samples. 
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1.13 Cryopreservation and Cryoprotectants 
 
Cryopreservation is a well-established technique with many applications in the scientific 
community. It involves the use of extremely low temperatures to preserve biological cells, keeping 
them intact and in their native form [116]. The major issues with freezing live cells is the water 
content of the tissue. As water freezes it crystallizes and forms crystals that pierce and tease cells 
apart causing them to lose structural integrity [116]. In order to circumvent this problem, scientists 
have developed a number of cryoprotective agents (cryoprotectants), which increase the solute 
content of the media and minimizes the effects of freezing [116]. As this technique, has developed 
over the years, the number of cryoprotective media has also increased proportionately, with many 
commercial cryoprotectants also becoming available [117-120]. This combined with the inflation 
technique that has been in practice could provide the answer for sample preparation of lung tissue 
for MSI.  
There are currently many cryoprotective agents employed for the cryopreservation of various 
sample types, which maintain tissue structural integrity during storage at sub-zero temperatures 
[117-120]. However, their applicability to MSI remains unknown, therefore we proceeded to 
conduct a study which investigated the use of various cryoprotectants as lung inflation media. 
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1.14 Research Questions 
 
1. Can we provide evidence for the presence of Clofazimine (CFZ), in the brain? 
Objectives: to determine the presence of CFZ in the brain using MSI and LC-MS. 
2. What is the distribution of Linezolid (LIN), in the brain? 
Objective: to determine the distribution of LIN in the brain using MSI. 
3. Can lung inflation be used as a suitable sample preparation technique for lung MSI? 
Objective: to evaluate the use of various cryoprotectants as inflation media for MSI of lung tissue. 
4. What is the distribution of Rifampicin (RIF), in the brain? 
Objective: to determine the time-dependent distribution of RIF in the brain using MSI. 
5. What is the degree of brain penetration of the Tetracycline class of drugs? 
Objective: to determine the brain penetration of Tigecycline (TIG) and Doxycycline (DOX), using 
LC-MS and MSI, respectively. 
6. How does the distribution of the Flouroquinolones contribute to their neurotoxicity? 
Objective: To determine the brain distribution of Gatifloxacin (GAT), using MSI. 
7. What is the brain distribution of Pretomanid (PA-824), in the brain? 
Objective: To determine the distribution of PA-824 in the brian, using MSI. 
 
1.15 Outline of thesis 
 
The main aim of these series of experiments is to demonstrate the value of MSI during the early 
stages of the TB drug development process. First, by assessing the brain drug distribution of CFZ 
and LIN, two promising anti-TB agents, in healthy animal models.  These results are presented in 
Chapters 2 and 3. Second, we attempted to create a sample preparation protocol for molecular 
imaging of drug distribution in animal lung tissue in Chapter 4. In Chapters 5, 6, 7, 8 and 9, we 
demonstrate how MSI can be used to evaluate other antibiotics in the drug pipeline. In Chapter 5, 
we show the time-dependent distribution of RIF. In Chapters 6 and 7, we present the brain 
penetration of the Tetracyclines, TIG and DOX. In Chapter 8, we demonstrate how MSI can be 
used to evaluate the neurotoxic potential of the Flouroquinolones, using GAT as the candidate 
drug. Finally in Chapter 9, MSI is used to investigate the brain distribution of PA-824, a 
nitroimidazole. 
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Abstract 
 
This is the first report of clofazimine (CFZ) penetration and distribution in normal mouse brain.  
Mice were administered 25mg/kg CFZ or 100mg/kg CFZ orally, daily for 2 weeks. Animals were 
sacrificed and blood and brain tissues were harvested. LC/MS/MS (liquid chromatography tandem 
mass spectrometry) showed high concentrations of CFZ in homogenized brain, with 100mg/kg 
dose having significantly higher concentration than 25mg/kg. MALDI (matrix-assisted laser 
desorption/ionization) imaging of brain sections showed widespread tissue distribution of CFZ. 
Our results show dose dependent localization in brain. 
Keywords: Clofazimine, brain distribution, MALDI-MSI 
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Introduction 
 
Since its discovery in 1954 [1], CFZ has had an eventful history when compared to other 
antibiotics.  Initially, the drug showed promising in vitro results against Mycobacterium 
tuberculosis (MTB) [2, 3], but disappointing in vivo results halted its progress [4].  However, CFZ 
was subsequently used to treat against Mycobacterium leprae [5], and combined with rifampicin 
and dapsone has become the gold standard in leprosy treatment [6].  With the emergence of XDR 
and MDR-TB there is currently renewed interest in the use of the drug as an anti-TB agent mainly 
because there is no known resistance against CFZ [7].  Recently in an observational study in 
Bangladesh, the addition of CFZ to standard therapy for MDR-TB resulted in a relapse-free cure 
rate of 87.9% in 206 patients [8].  Additionally, a murine model of pan-susceptible TB comparing 
a 4-month CFZ containing regimen with standard 6-month therapy reported relapse-free cure after 
3 months in the CFZ regimen as compared to 6 months with standard treatment[9]. 
MTB classically affects the lungs, but other organs can become infected by the haematogenous 
spread of bacilli.  Tuberculosis (TB) of the CNS occurs frequently in immunocompromised 
patients and is often fatal, and occurs in 20-70% of HIV co-infected patients [10].   Therefore it is 
important for anti-TB drugs to also enter the CNS of infected patients in therapeutic 
concentrations, in order to fight these infections.  Previous reports have stated that CFZ does not 
enter the brain [11-14], however, in the latest to do so, a low dose of CFZ was administered 
(10mg/kg/day) [11].  Hence in our study we have opted to use 2 significantly higher doses, which 
have been shown to be effective in a mouse model of TB [15], in order to properly investigate 
CFZ’s brain penetration and distribution, which will help in understanding if the drug can be used 
as a therapeutic agent in the treatment of TB of the CNS. 
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We are currently investigating the tissue distribution and penetration of various antibiotics using 
liquid chromatography mass spectrometry (LC/MS) and matrix assisted laser desorption ionization 
(MALDI) mass spectrometry imaging (MSI).  CFZ has a low molecular weight, high lipophilicity 
and LogP of 7.132 [16], which should aid its brain penetration.  Therefore this study was 
undertaken to determine if CFZ administered orally at 25 and 100 mg/kg for two weeks to healthy 
mice, penetrates the brain.  
Materials and Methods 
 
Ethical approval was obtained from University of KwaZulu-Natal Institutional Animal Ethics 
Committee (027/02/15).  The study cohort consisted of 30 female Balb/c mice (6-8 weeks; 18-
20g) divided into 3 groups (n=10).  The first group received only the vehicle (control), the second 
group received 25mg/kg CFZ and the third 100mg/kg.  CFZ suspension was prepared in 0.05% 
(w/v) agarose and administered orally 5 days a week for 2 weeks.  Following treatment, animals 
were sacrificed; and blood samples and whole brain were harvested.  Plasma and brain samples 
were stored at -80o C until analysis.  
LC/MS/MS analysis was done with homogenized tissue suspended in 3 volumes of water.  
Methanol (800µL) was added to homogenate (200µL), and centrifuged for 15 minutes at 15,000 
rpm at 4oC. 800µL of supernatant was filtered through a Supelco Hybrid SPE cartridge, prior to 
analysis.  Analysis was carried out on a Bruker Q-TOF MS coupled with an Agilent 1100 HPLC 
equipped with an YMC Triart C18 (3.0 mm x 150 mm).  Mobile phase A was 5mM ammonium 
acetate (pH 10) and mobile phase B was acetonitrile, the chromatographic conditions were as 
follows: the flow rate was 0.4mL/min with a linear gradient from 50% to 100% phase B over 5 
min, with a hold at 100% phase B for 2 min, followed by re-equilibration at 50% phase B for 3 
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min.  The mass spectrometer was used in positive ion mode, with a dry gas flow rate of 8.0 L/min, 
nebulizer pressure of 1.5 bar, capillary voltage of 5500V and a drying temperature of 200oC.  The 
MS/MS was conducted using MRM and the transition monitored was 473.1 to 431.9 m/z.  Plasma 
samples were processed and quantified as previously described [15].  The results from the 
quantitative analysis were analyzed using GraphPad Prism V5 using the t test, a p value of less 
than 0.05 was considered statistically significant. 
MSI analysis was conducted on the Bruker Autoflex III Smartbeam system. Brain tissues were 
sectioned using the Leica CM 1100 cryotome; 10µm sections were dried and fixed onto ITO coated 
slides.  The slides were then prepared using HCCA matrix and the Bruker ImagePrep automated 
system.  The images were acquired using an optimized LIFT method for CFZ with a spatial 
resolution of 100 µm and a mass window of 473 ± 0.1 m/z, thus giving a clear distinction of the 
drug from other endogenous substances that are present in the brain. 
Results and Discussion 
 
The mean (SD) CFZ concentration in plasma were 444.80 (78.07) ng/ml and 3357.50 (93.91) 
ng/ml in the 25mg/kg and 100mg/kg group, respectively (Figure 1).  The mean (SD) CFZ 
concentration in brain were 156.16 (5.49) ng/ml and 719.50 (10.45) ng/ml after 25 mg/kg and 100 
mg/kg dosing, respectively (Figure 1).  CFZ concentration was significantly higher with a 
100mg/kg dosing regimen (p < 0.01), showing that the concentration of the drug in the brain may 
be dose related, however this is in opposition with another recent study investigating the 
pharmacokinetics and pharmacodynamics of CFZ in the mouse model of TB, which reported that 
lung, liver and spleen concentrations are independent of the dose administered [15]. 
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Figure 1. Clofazimine concentration in plasma and brain, in normal mouse brain after two weeks 
of continuous dosing with 25mg/kg and 100mg/kg.
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The MSI study showed widespread distribution of CFZ in the healthy mouse brain.  Using the 
spectrum obtained in the LIFT method as shown in supplementary information figure 1 and 
figure 2, we utilized m/z 473 for the visualization of the drug and to distinguish them from 
other biomolecules, since the brain is expected to contain predominantly heme and lipids, 
which would only be detected around m/z 600-800, allowing for the specificity of CFZ. 
Clofazimine localization is shown in the axial and coronal view for both 25mg/kg and 
100mg/kg doses (Figure 1). However, greater accumulation is noted in the lateral ventricle 
with the higher dose.  This might be a significant finding, as the lateral ventricle houses the 
choroid plexus which produces CSF and may explain the widespread distribution of CFZ [17], 
however there is lack of information on CFZ’s availability in CSF.  It has been shown that CFZ 
requires approximately 2 weeks to reach tissue saturation levels[15], once a steady state is 
reached the drug persists in tissues for a long time given its long half-life, and is slowly released 
from tissue.  However, many studies have reported on CFZ’s ability to form crystal-like drug 
inclusions (CLDI’s) in tissue [11], which limit its antimicrobial activity.  The concentrations 
detected in our study are above the MIC for Mycobacterium tuberculosis [18], but recent results 
suggest that tissue concentrations are not reflective of the amount of active drug present but 
instead the bound drug and CLDI’s [15].  It is unclear if the concentration of CFZ we observed 
are CLDI’s or the drug in its active form.  This means once peak concentrations are reached 
they are maintained for a prolonged period as the drug is slowly released from tissue deposits. 
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Figure 2. MALDI MSI of Clofazimine in normal mouse brain. A and B shows the axial 
view of the 25mg/kg and 100mg/kg dose, respectively, while C and D represent the drug 
distribution in the coronal view. E and F are optical H&E images showing the orientation of 
the brain sections in the axial section (E) and coronal section (F). (LV-lateral ventricle; I-
isocortex; CC-corpus callosum) 
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Conclusion 
 
This is the first study to confirm the penetration and distribution of CFZ in the brain of healthy 
mice.  MALDI MSI is an ideal technique for determining the exact tissue distribution of drugs, 
this does not allow us to provide information on the route of entry into the brain.  However, we 
can prove the presence of CFZ in the brain, using a method that was previously shown to be 
effective in the imaging of rifampicin and pretomanid [19, 20].  This is a powerful tool in 
pharmacokinetic and pharmacodynamic studies especially when coupled with LC/MS/MS, 
which is more specific than conventional LC/MS.  Thus there is a possibility that CFZ 
combined with other treatment regimens may be used in the treatment of CNS TB, since it has 
been shown to shorten the treatment of first-line pulmonary TB in mice [9]. This study was 
conducted using healthy mice in order to determine if CFZ is able to reach therapeutic 
concentrations in the brain, which we have demonstrated. However, more studies are required 
to determine the efficacy of CFZ as a neuroprotective agent. 
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Abstract  
 
A study was undertaken to determine the neuroprotective potential of Linezolid (LIN) in an animal 
model. Female Sprague-Dawley rats were either given a single (100 mg/kg) dose or treated daily 
for 4 weeks. A validated LC-MS/MS method was used to measure LIN levels in plasma and brain, 
this was paired with mass spectrometry imaging (MSI) to determine the tissue spatial distribution 
of the drug. The results showed that after a single dose there was poor penetration of the drug into 
the brain. With multiple doses there were high tissue levels, with the drug reaching steady state in 
subsequent weeks. LIN displayed a promising distribution pattern with localisation in the 
brainstem. Systemic circulation is fed into the brain by the carotid and vertebral arteries which 
enter through the brain stem, therefore high drug concentrations is this area may protect against 
infectious agents entering via this route. 
Keywords: linezolid, brain, MSI, LC-MS/MS, neuroprotection, molecular histology 
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Introduction 
 
Oxazolidinones, the first new class of antimicrobial agents since 1980 has led to the discovery of 
Linezolid (LIN) [1], one of the most promising antibiotics in recent years. Its mechanism of action 
involves the inhibition of protein synthesis during the translation stage [1].Its excellent 
bioavailibity and serum pharmacokinetic (pK) profile sets it apart from other members of this 
family [2-6]. Since these drugs are synthetic, there are no naturally occurring resistance genes, 
making LIN effective against many life threatening bacterial infections [2]. This has been 
reinforced by multiple  studies which have demonstrated its in vivo and in vitro activity against a 
number of resistant strains [3]. In recent times, this advantage has been used in the effective 
treatment and management of central nervous system (CNS) associated infections [3, 7-9].After 
initial results in a rabbit model of meningitis were discouraging, follow-up human studies have 
proven to be much more promising, with a number of case studies reporting the complete 
eradication of multi-drug resistant Enterococci sp., Staphylococci sp., Streptococci sp., Bacillus 
sp., Corynebacterium sp., Listeria sp. systemic infections[1, 3, 7, 9, 10]. A few studies have 
demonstrated the ability of LIN to effectively combat neurological disorders such as brain 
abscesses and meningeal infections[8]. Quantitative investigations using cerebrospinal fluid (CSF) 
measurements have been conducted [7, 9-11], however, these are not a true representation of tissue 
concentrations since the brain possesses its own independent CSF pathway [12]. A study involving 
brain penetration has been conducted [13] but can be misleading since only a small tissue biopsy 
was used for quantification and as previously shown, many drugs show preferential tissue 
distribution, particularly in the brain [12, 14-17].  Many recent reports have shown LIN 
effectiveness against drug resistant TB both in vitro and in vivo [18, 19], there was the remission 
of symptoms in these patients, who were initially on failing treatment regimens [20].  A concern 
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is hematologic toxicity, which can be mitigated when treatment is supplemented with vitamin B6 
[19, 21]. Paired with these findings and those involving other resistant microbes, LIN may have 
strong applications for the treatment of tuberculosis meningitis (TBM), a disease that is responsible 
for a large number of deaths each year, and other neurological disorders. A positron emission 
tomography/ computed tomography (PET/CT) imaging study demonstrated its beneficial effect on 
pulmonary tuberculosis (TB) infections in macaques and human subjects[18]. This shows that 
there is a strong correlation between LIN behaviour in human and experimental models. 
Even with these promising results, the distribution and localisation of LIN in the brain is not yet 
fully understood. A deeper understanding of LIN´s mechanism of action in the CNS will help 
researchers to develop new treatments to fight neurological disorders and effectively combat life 
threatening meningeal infections. 
For these reasons, the purpose of this study is to investigate the brain tissue pharmacokinetic 
properties of LIN following single and multiple does using an accurate and sensitive LC-MS/MS 
method. The second aim was to determine tissue distribution using mass spectrometry imaging 
(MSI) which was successfully applied in the investigation of other potential anti-TBM agents [12, 
14, 16, 17]. This will aid in understanding the role of LIN in the treatment of neurological 
disorders.  
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Materials and Methods 
 
Reagents and standards 
LIN was purchased as ZyvoxR IV infusion (Pharmed Pharmaceuticals, Durban, South Africa) and 
extracted using dichloromethane (the yield was > 98%), purity was then determined using a 
Shimadzu LC-MS before being used for analytical method development. Bedaquiline (TMC-207) 
was used as the internal standard (IS) (synthesised in our laboratory, its 1H and 13C NMR spectra 
corresponded to that in literature[22].All solvents were LC-MS grade and purchased from Sigma 
Aldrich (Steinham, Germany); Ultra-pure water was obtained using a Milli-Q water purification 
system (Bedford, MA, USA). 
Animal study 
The animal study was approved by the institutional Animal Research Ethics Committee (AREC) 
of the University of KwaZulu-Natal (UKZN) (approval reference: 001/15/Animal). For the short 
term study, the animals received a single dose of LIN (100mg/kg) which was prepared in 10 % 
DMSO, this was based on a previous study in which this amount was well tolerated in rodents and 
showed excellent kill characteristics in a murine model of septicaemia [23]. In the short term study, 
female Sprague-Dawley rats (with ad libitum access to food and water throughout the study) were 
given a single dose of LIN via oral gavage thereafter they were periodically sacrificed (0, 0.25, 
0.5, 1, 2, 4, 6, 8 and 24 hours; n = 3 per time-point) post-dose to determine the short term plasma 
and brain pK profile of LIN. For the long term study, the animals were orally administered LIN 
five days weekly, for a period of four weeks. After each week, the animals were terminated (n = 
5), at a single time point, to investigate the pK changes following each treatment period. The 
sacrifice was the same in both studies, animals were euthanized using Halothane (Safeline 
Pharmaceuticals, South Africa) overdose and blood collected via cardiac puncture. The brain was 
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then surgically removed and gradually frozen in liquid nitrogen to preserve the brain structure for 
MSI. The samples were then stored at -80oC, until analysis.  
 
LC-MS/MS Quantification 
Instrumentation 
The LC-MS system consisted of a Dionex Ultimate 3000 LC (ThermoScientific, USA) coupled to 
a Bruker amaZon speed Ion Trap mass spectrometer fitted with an electrospray ionization (ESI) 
unit (Bruker Daltonics, Bremen, Germany). All data was collected and stored using Data Analysis 
4.0 SP 5 and Quant Analysis (Bruker Daltonics, Bremen, Germany). 
LC-MS/MS Quantification 
Chromatographic Conditions. Chromatographic separation was achieved using an YMC Triart 
C18 Column (150mm x 3.0mm; 3µm particle size) (YMC Europe Gmbh, Dislanken, Germany) 
fitted with a compatible 4.0mm x 3.0mm guard cartridge. This was connected to a Thermo 
Scientific Dionex Ultimate 3000 LC system. Mobile phase A was Milli-Q water (0.1% v/v FA) 
and mobile phase B was ACN (0.1% v/v FA), the flow rate was set at 0.4 ml/min and column 
compartment at 25oC.  A multi-step gradient was used, it was initially increased from 30 – 90 % 
B for 10 min, held for 2 min before being returned to 30% B over 3 min. The column re-
equilibration time was 5 min. 
Mass spectrometric analysis. Mass spectrometric analysis was done using a Bruker AmaZon 
Speed IonTrap mass spectrometer fitted with an electrospray ionisation (ESI) unit (Bruker 
Daltonics, Bremen, Germany). The acquisition parameters were as follows: ion polarity – positive; 
nebulizer – 1.5 bar; capillary voltage – 5500 V; dry gas – 8.0 l/min; dry heater – 180oC; end plate 
offset – 500 V; scan range – 100 – 1600 m/z. The MRM parameters for LIN was: isolation width 
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- 4.0; amplification – 0.8; and for IS: isolation width – 5.0; amplification – 0.5. LLOQ, LOD, 
accuracy and precision were determined as per the EMA guidelines. 
Sample preparation. Each sample (100µL; either brain homogenate or plasma) was spiked with 
the appropriate concentration of LIN and IS, ACN (up to 1mL) was then added as the precipitating 
agent before centrifugation (15, 000 x g for 10 min at 4oC). Recovery and matrix effect was then 
determined by spiking known concentrations of the analyte into blank matrix. For quantification, 
the brain and plasma samples were diluted so that the measured concentration fell within the 
calibration range. This dilution factor was then used to determine the final drug concentrations 
which are presented. 
Mass spectrometry imaging (MSI) 
MSI was done on the Bruker MALDI-TOF AutoFlex SmartBeam II system (Bruker Daltonics, 
Bremen, Germany). Frozen tissue sections (12µm thickness) were prepared using a Leica CM 
1100 (Wetzlar, Germany) cryostat, the sections were collected on indium titanium oxide (ITO)-
coated slides (Bruker Daltonics, Bremen, Germany) and allowed to fix at room temperature before 
being dried overnight in a vacuum desiccator. All of the commonly used MALDI matrices (α-
cyano-4-hydroxycinnamic acid (HCCA), dihydroxy-benzoic acid (DHB) and sinapinic acid (SA)) 
were tested to determine which would give the best signal intensity and be used for slide 
preparation. The slides were then coated with matrix using the Bruker ImagePrep (Bruker 
Daltonics, Bremen, Germany), an automated slide preparation instrument as previously described 
by us [16, 17]. An optimised LIFT method (MALDI-TOF/TOF) method was created. The mass 
spectrometer was operated with a 61% laser strength, using a mass range of 100 – 700 m/z and a 
detector gain of 23x. Images were acquired using a raster width of 200 µm and a 0.1 m/z mass 
window monitoring the 338 → 296 m/z transition of LIN.  
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Results and Discussion 
 
LC-MS/MS Quantification 
After optimization of the separation conditions, a reproducible separation of LIN and the IS was 
achieved in the biological matrices. Subsequently, the spectrometer was tuned to produce good 
sensitivity and signal reproducibility, using these optimized conditions an MS method was created 
to monitor the 338.11 → 296.10 m/z (Figure 1) transition for LIN and 555.10 → 523.08 m/z for 
IS (Figure 2). The LLOQ and LOD for this method was 100ng/ml and 1ng/ml, respectively. 
The calibration curve was created over a concentration range of 100 – 1500 ng/mL, the linear 
regression analysis (y = 9.038689 + 0.493295x) showed the curve to be linear over this range, with 
an r2value of 0.9996. Before separation using HPLC, endogenous proteins and lipids were 
removed from the samples to prevent unwanted interferences during quantification. This was 
effectively achieved using protein precipitation (using ACN) coupled with filtration through a 
Supelco HyBrid SPE cartridge, which yielded excellent recovery rates (Table 1.). Matrix effects 
are referred to any undesired ion enhancement or suppression that may be caused by the biological 
matrix (brain homogenate) on the target analyte (LIN), these results are also summarised in Table 
1. 
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Figure 1. Mass spectra and chromatograms. Showing the 338.11 → 296.10 m/z transition of 
LIN (A), which was used for quantification together with its HPLC chromatogram (C) showing 
its retention time (4.8 min). Showing the 555.10 → 523.08 m/z for IS (B) and its respective HPLC 
chromatogram with its retention time at 11.1 min (C). 
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Table 1. Extraction recovery, using ACN as the precipitant coupled with filtration through the 
Supelco HyBrid SPE cartridge. 
Sample Mean Recovery 
(%) 
% RSD Matrix Effect 
(%) 
% RSD 
LQC 91.4 1.7 -6.7 5.3 
MQC 91.9 2.5 -10.1 2.1 
HQC 92.2 1.5 -8.3 4.7 
 
 
Table 2. Accuracy and precision of the method for LIN in brain homogenate. 
 Theoretical 
concentration 
(µg/ml) 
Mean 
concentration 
(µg/ml) 
% Accuracy % RSD 
Intra-day 100 93.2 93.2 4.6 
 150 141.5 94.3 3.1 
 800 756.7 94.6 6.3 
 1400 1289.3 92.1 3.8 
Inter-day 100 92.9 92.9 1.8 
 150 139.1 92.7 2.9 
 800 755.6 94.4 5.2 
 1400 1287.9 92.0 2.6 
 
 
Pharmacokinetic analysis and MSI analysis 
The optimised LC-MS/MS method was then used to determine plasma and brain concentrations 
of LIN after single (100mg/kg.b.w.) and multiple doses (100mg/kg.b.w daily; 5 days weekly for 4 
weeks).After the initial 24 hour single dose study significant amounts of the drug was detected in 
rat plasma samples with a maximum concentration (Cmax) of 70.36 ± 5.3µg/mL that was reached 
after time of maximum concentration (Tmax) of 2 hours. This was consistent with a study 
investigating the neurological effects of LIN in a rat model[24]. Pharmacokinetic parameters were 
determine using Stata13 (StataCorp LP, Texas, USA) and are summarised in Table 2. 
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Table 3. Plasma pharmacokinetics of LIN following a 100mg/kg single dose. 
Pharmacokinetic parameters 
Cmax (µg/ml) 70.36 
Tmax (hrs) 2 
Keq (h-1) 0.15 
Half-life (hrs) 4.51 
AUC 0→T(µg.h/mL) 480.75 
AUC 0→∞(ng.h/mL)  481.49 
 
 
 
 
 
Figure 2. Plasma concentration-time profile for LIN after a single 100mg/kg dose, 
monitored for 24 hours. Peak plasma concentrations were reached 2 hours post-dose and reach 
trough values after 24 hours. (All values are represented as a mean ± SD). 
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No detectable amounts of LIN were found in the brain sampled at 0.25, 0.5, 1, 2, 4, 6, 8, 24 hours 
post dose following a single 100mg/kg.b.w dose of LIN (Figure 4). This is in opposition with a 
mouse study that reported a Tmax of 0.5 hours in the brain after a single 10mg/kg.b.w dose [25]. 
The animals were then treated with the same dose for a further four weeks, to determine the effects 
of multiple dosing on brain penetration. The drug was administered daily, five days a week. The 
analytical method was then applied to quantify plasma and tissue levels of LIN, significantly high 
amounts were detected in the brain (Figure 5). After a week of treatment the Cmax was reached in 
the brain (30.31 ± 6.3µg/mL), as dosing continued drug concentrations began reaching a steady 
state. Brain/ plasma ratios peaked after one week of treatment (1.7) and were maintained in the 
1.4-1.3 range when steady state was reached in the brain. The higher ratios are suggestive of non-
specific binding to the hydrophobic brain tissue, with repeated dosing. The lowest values were 
reached after week 4 (23.58 ± 6.1µg/ml), these values were still significantly higher than the MIC’s 
for a number of bacterial agents which cause central nervous system infections[3, 23]. This is 
demonstrated by studies which have showed the drug’s efficacy against a large number of resistant 
CNS infections. Patients in these studies showed excellent remission rates with no incidence of 
resistance.MSI was then applied as a means to determine the tissue distribution of the analyte in 
the brain. LIN displayed a very unique distribution pattern, which has not been seen before during 
our investigations of other drugs. The cortical regions have a homogenous distribution of the drug 
with a relatively low intensity (Figure 6). However, in the brain stem extremely high levels of the 
drug can be seen after week 1 (Figure 4). After the initial spike in drug concentration after one 
week of treatment, the drug reaches a steady state in the brain from week 2 to week 4, until the 
LIN spreads homogenously throughout the brainstem and cortical areas. This advocates for the use 
of LIN as a neuroprotective agent since the main arteries that supply the brain from systemic 
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circulation enter through the brainstem. These are the carotid and vertebral arteries which 
contribute 80% and 20% of the blood flow entering the brain, respectively[26]. They come 
together at the level of the pons in the brainstem, to form the midline basilar artery that branches 
into the rest of the brain[26]. This means that the large concentrations of the drug in the brainstem 
may be able to combat the entry of infections, from systemic circulation, into the brain; thus, 
preventing the establishment of CNS infections in patients with a predisposition to develop 
neurological illness. The added benefit of using LIN for such cases is its proven safety profile, 
with no pro-convulsive properties and no effect on nervous system function [4, 24]. 
 
 
 
Figure 3. MSI image of rat brain after 2 hours with a single 100 mg/kg dose. A1 and A2 show 
the axial and coronal view, respectively. Minute amounts of the drug, which was below the limit 
of quantification, can be seen after 2 hours which was the Tmax in plasma. B1 and B2 are the 
histological images (x 2.5 mag), for spatial correlation. 
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Figure 4. LIN brain and plasma concentrations, following four weeks of treatment with a 
100mg/kg dose. (All values are represented as a mean ± SD).Brain concentrations peaked after 
1 week of treatment and plateaued out to the end of the treatment period, representing a steady 
state. Plasma levels remained constant from week 1 to week 4, with no significant changes. Brain/ 
plasma ratios ranged from 1.7 in week 1 to 1.3 in week 4, when steady sate was reached. (All 
values are represented as a mean ± SD). * animals were sacrificed at a single time-point following 
each subsequent week of treatment. 
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Figure 6. MSI images showing weekly LIN distribution in the healthy rat brain following 
four weeks of multiple dosing. Images were acquired after each subsequent week of treatment. 
(KEY: C = after 1 week of treatment; D = after 2 weeks of treatment; E = after 3 weeks of 
treatment; F = after 4 weeks of treatment; 1 and 2 are the axial and coronal sections, 
respectively) 
 
 
 
 
 
 
 
 
 
 
 
 55 
 
Conclusion 
 
In this study we have proven that single doses may not be sufficient for LIN to penetrate the CNS. 
After a single week of multiple dosing peak concentrations were reached in the brain, and a steady 
state was reached within subsequent weeks of treatment.MSI was also used to demonstrate LIN’s 
unique distribution in the brain, where it localises at the brainstem which could potentially protect 
against infectious agents entering via systemic circulation. This makes LIN a potential silver bullet 
in the struggle to effectively combat neurological infections, especially during a time when CNS 
infections are responsible for such high morbidit0y and mortality rates worldwide. 
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Abstract 
Introduction:	Given the recent explosion of mass spectrometric imaging (MSI), it has become 
easier to assess drug tissue localisation without the use of radiolabeling and other more 
complex methods (such as PET and MRI). For MSI tissue preparation is of utmost importance, 
however, the lung in particular does pose some difficulties with imaging since it is made up of 
a number of air-filled alveoli.  These organs are known to collapse when the thoracic cavity is 
pierced, losing its structural integrity and giving poor histological representation for drug 
distribution analysis.   
Hypothesis: The use of cryoprotectants as a tissue inflation media will aid in the preservation 
of the lung’s structural integrity during MSI experiments involving small molecule distribution. 
Methods: Various established cryoprotectants (DMSO, PvP, ethylene glycol, sucrose, DMEM, 
control serum, OCT) were selected as lung inflation media for MSI analysis of gatifloxacin 
(GAT).  Female Sprague-Dawley rats were treated with GAT (10 mg/kg.b.w) via i.p. injection.  
After 15 min the animals were terminated by halothane overdose, and each set of tissue inflated 
with a specific agent.  Cryosections were made and MSI conducted to determine drug tissue 
distribution. 
Results: During the early stages of the experimental procedure some crypreservatives were 
eliminated due to difficulties with sample preparation.  While others displayed excellent 
preservation of the tissue structure and integrity.  Following MSI analysis, some agents showed 
homogenous drug distribution while some displayed heterogeneous distribution favoring the 
basal periphery. Taking into account the physiology of the lung and previous MRI 
investigations of its perfusion, it is expected that a systemically administered drug would 
localize in the basal areas.  DMSO and DMEM proved to display this distribution pattern while 
keeping structural integrity intact. However, the later was ruled out since it showed complete 
suppression of GAT in solution. 
Conclusion: From the cryoprotectants selected for this study, DMSO is the most promising 
lung inflation media focusing on small molecule distribution via MSI. 
Keywords: lung inflation, cryopreservation, MALDI-MSI, drug distribution, gatifloxacin 
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Introduction 
Historically, lung disorders have been a major health concern leading to acute, chronic and 
life threatening complications.  The importance of the histological evaluation of the 
respiratory system dates back to the 1920’s when used for the diagnosis of small cell cancer, 
which was believed to be an oat cell sarcoma of the mediastinum [1].  With recent 
advancement in imaging technologies and new pharmaceutics, histochemistry has 
significantly improved, e.g.  mass spectrometric imaging (MSI) at the forefront as an 
important analytical tool [2], making these conditions and associated pathologies easier to 
target. Numerous publications have demonstrated the value of small molecule MSI as an 
alternative, label-free approach in drug distribution studies [3, 4].  Our research group is 
currently investigating the localization and distribution of anti-tuberculosis (TB) drugs in the 
rat brain using this approach [5-7].   However, an ideal pharmacological agent should also 
enter the lung (the primary infection site).  Although these drugs can be quantified using LC-
MS/MS, this does not afford the privilege of spatial information, which is required to help 
curb and manage pulmonary disorders.  A few studies in which MSI has provided spatial 
information of small molecules and endogenous substances in the lung have been reported, 
however the information can be misleading due to the structural integrity of the tissue [4, 8-
10].  In order for clinicians to effectively combat disease, the distribution and behaviour of 
new drugs in healthy tissue needs to be investigated.  
The lung is the respiratory centre of the body and facilitates efficient gaseous exchange 
through of a number of air-filled sacs, the alveoli. It is enclosed in a double membrane, called 
the pleura [11].   The trachea, bronchi and bronchioles make up the conducting zone of the 
respiratory system which carries inhaled air to the gas exchange surface [11].  In order for the 
organ to efficiently carry out its physiological functions, these alveoli are maintained in an 
“open” state by the balance between alveolar pressure (pressure in the alveoli), intrapleural 
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pressure (pressure in the intrapleural space) and transpulmonary pressure (pressure gradient 
across the lung walls) [11].    These pressures are also responsible for keeping the lung stable 
between breaths and preventing it from collapsing.  The pressure is closely maintained by the 
tissue and its associated anatomical structures including the diaphragm, the pleural walls and 
the thoracic cavity [11].  When the organ has to be removed for analysis, the thoracic cavity 
is pierced and the pressure balance is disturbed, as a result the alveolar tissue collapses and 
structural integrity is compromised [12].   
For many years histologists have used inflation of the lung as a technique to maintain its 
structural integrity during staining and subsequent analysis [13, 14].  This allows for the 
maintenance of the lung in a state that more closely resembles its physiological appearance, 
while preserving all histological features. Formalin is commonly employed to keep the lungs 
inflated, but it is used primarily as a fixative and introduced over time, since the minimum 
fixation time is 72 hours it is highly likely that displacement of the drug would occur giving 
false spatial information [13].  This process will have adverse effects on the distribution of 
molecules especially for MSI analyses since tissues are frozen soon after removal from the 
animal in order to prevent post-operative changes.  The situation can be circumvented with 
the use of a cryoprotective substance as an inflation medium.  There are currently many 
agents employed for the cryopreservation of tissues (cryoprotectants), which effectively 
maintain tissue integrity during cold storage [12, 15-17].   This study serves as an 
investigation into the use of various established cryprotectants as inflation media.  It will 
enable the development of an optimized procedure for the preparation of lung tissues 
focusing on small molecule distribution for MSI whilst preserving the structural integrity.  
Previous studies employing MSI, have mainly reported on its use in TB infection models and 
a single study using DESI-MSI in a healthy animal [4, 9, 18].  However, extra care was not 
taken to maintain structural integrity and to preserve tissue histology, this could lead to 
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misleading drug distribution. In order to obtain a true representation of drug distribution in 
the lung, a healthy rat model was chosen to evaluate the use of different cryoprotectants in 
the absence of physiological interferences.  For the purpose of this study, gatifloxacin (GAT) 
was chosen as the candidate drug. It is an 8-methoxy fluoroquinolone (Figure SI1) with 
activity against a broad spectrum of infectious agents and is commonly used in the treatment 
of pulmonary and respiratory infections [19]. In our lab GAT was previously shown to reach 
a high maximum concentration  (Cmax )in the lung [20].  
Materials and Methods 
Chemicals and reagents 
All chemicals and reagents were purchased from Sigma Aldrich (St Louis, USA) unless 
otherwise stated. The GAT standard was purchased from DLD Scientific (Durban, South 
Africa). CHCA (α-cyano-hydroxy cinnamic acid) was purchased from Bruker (Bruker, 
Germany). 
Animal experiments 
The use of animals in this study was approved by the University of KwaZulu-Natal’s 
institutional Animal Research Ethics Committee (approval number 006/15/2015).  Female 
Sprague-Dawley rats (n =3 per cryoprotectant) with an average body weight of 120 ± 10 g 
were housed in polycarbonate cages in air-conditioned rooms (50-70% humidity and between 
21-24oC) with a 12 hr light/dark cycle.  The animals were dosed (i.p.), the injection site was 
sterilized using alcohol and 0.5 ml of GAT was delivered into the peritoneal cavity of the 
animal using a sterile 25 gauge needle. The animals were then euthanized after 15 min, as 
previously described [20].  
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 Post-mortem surgery 
All procedures were adapted from the University of KwaZulu-Natal’s Approved Standard 
Protocols for Animal Research. After euthanasia, the animals were bled via cardiac puncture. 
The animal was then placed in a supine position and an incision made in the laryngeal area of 
the experimental animal to reveal the c-shaped rings of the trachea.  The trachea was then 
clamped below the larynx using a pair of artery forceps, following which thoracic cavity was 
opened to expose the lungs.  A sterile steel ball gavage needle (22G x 1.0” w/ 1.25mm ball) 
was then inserted into the trachea to inflate each lung with 1.5ml of the cryoprotectant. The 
tissues were then removed from the animal and cooled on ice for 15 min, before being 
gradually frozen using liquid nitrogen vapor [15].  The tissues were then stored in a bio-
freezer at -80oC, until tissue preparation for MSI.   
Cryoprotectants 
All of the cryoprotectants used in this study have previously displayed cryoprotective 
properties and are used depending on the application [12, 15-17]. We also selected two 
cryoprotectants that were previously used for MSI.  The cryoprotectants used were a 10% 
sucrose solution, 10 % dimethy-sulfoxide (DMSO), 10 % ethylene glycol, serum from an 
untreated animal as used in tissue banking [15], 5 % polyvinyl-pyrolidinone (PvP), 
hypothermosol (a commercially available cryoprotectant) [15], a modified Dulbelco’s 
modified eagle medium (DMEM) as reported by Mancia et al. [16, 17] and a modified 
optimal cutting temperature (OCT) medium as reported by Berry et al [12]. 
Tissue preparation 
The tissues were sectioned using a Leica CM 1100 cryotome (Leica, Germany) fitted with a 
glass anti-roll plate.  The thickness of the sections had to be increased from the commonly 
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used 12 µm to 20 µm, since the tissue was crumbling at thinner sectioning due to the single 
cell layers of the lung.  The sections were mounted on indium-titanium oxide (ITO) coated 
slides (Bruker, Germany).  The slides were then dried at room temperature for 15 min before 
being washed with 100 mM ammonium (pH 10) acetate to remove endogenous soluble-
ionization suppressants, lipids and cell debris as recommended by Shariatgorji et al. [21].  
The slides were then dried overnight in a vacuum desiccator, before being coated with the 
MALDI matrix (CHCA) using an ImagePrep (Bruker, Germany).  The slides were prepared 
using an ImagePrep method consisting of 5 phases each with an increasing laser voltage 
ranging from 0.007 V to 0.6 V.  This is used to monitor matrix thickness in real time and 
ensure an average droplet size of 20 µm, according to Bruker specifications.  In order to 
obtain an optical image, the slides were scanned using an HP Laserjet PCL 3055 scanner 
prior to MSI analysis. 
MSI analysis 
We found that MSI acquisition parameters previously described by our lab for imaging of 
GAT in brain tissue worked well and also provided good sensitivity for lung samples [20]. In 
brief, this method monitored the transition 376 m/z > 358 m/z (Figure SI2) by collecting data 
in both the parent and fragment mode allowing for the visualization of GAT. The laser power 
was set at 60% and 500 shots were summed up from each spot during a random walk of the 
tissue using an autorun method to prevent bias. In order to ensure the consistency of the 
image intensity scale across all analyses a 10 000 ng/ml spot of GAT was made on each slide 
adjacent to the tissue, since our quantification study showed GAT concentrations up to 
5277.16 ng/ml [20] in the whole lung and our maximum intensity would not exceed 10 
000ng/ml. All spectra were normalized using the total ion count (TIC) method which reduces 
any potential suppression caused by the matrix. This was done so spectra from each image 
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acquisition could be projected onto the same intensity scale [22]. The limit of detection for 
lung was 500 pg/ml, determined by spotting varying concentrations on untreated tissue 
(Figure SI2). 
MALDI-TOF Quantification 
Quantification was carried out in triplicate on the Bruker Autoflex III 1KHz SmartBeam 
system.  Briefly, calibration samples were prepared in the cryoprotectant (either DMSO or 
DMEM) and standard concentrations of GAT (100 – 1000ng/ml) was spotted on blank 
conductive indium titanium oxide (ITO)-coated glass slides.  A standard curve was plotted 
using linear regression and the transition 376 m/z to 358 m/z, a fragment from the parent GAT 
molecule as we have previously described [20].  In order to quantify the amount of GAT in 
the lung sections the overall average spectra were generated for each tissue section which 
showed good localization and structural preservation, the intensity of our peak of interest was 
then used to determine the concentration from the standard curve  [9]. 
Results and Discussion 
From the cyroprotectants selected for the study, a few had to be eliminated prior to the MSI 
analysis due to various difficulties encountered during the sample preparation steps.  The first 
problem was with the use of modified OCT as an inflation medium.  The highly viscous 
nature of OCT made it difficult to inflate the lung utilizing a syringe.  This does not rule out 
the use of OCT for other cold applications since it has been effectively used as an embedding 
medium for cryosectioning and is known to provide good spatial resolution when imaging 
proteins and lipids in the lung, but requires an additionally washing step to remove excess 
media [12].  The second issue encountered was with sucrose; inflation was easily possible, 
however the tissue fractured upon cooling.  This phenomenon may be due to the formation of 
freezing artifacts, such as the sugar crystals, that destroy cell membranes and compromising 
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structural integrity.  The third unsuccessful cryoprotectant was serum; it is possible to inflate 
the lung with serum and maintain the tissue in a sound state, although during the collection of 
the sections from the cryostat, the serum became jelly-like with an increase in temperature 
and sections were damaged.  The other cryoprotectants used facilitated smooth sample 
preparation and showed excellent preservation of the exterior structure of the lung as seen in 
Figure 1.  
 
 
 
Figure 1. Comparison of (A) uninflated and (B) inflated rat lung.  In (A) the lung has 
collapsed and extensive folding of the walls can be observed, as shown by the black markers 
( ). (B) The lung with inflation and its structural integrity is maintained shown by the 
consistency of the shape of the wall. 
Prior to image acquisition and analysis, literature regarding the physiology of the lung was 
consulted to determine the most probable areas of drug localization. The base of the lung 
receives the greatest amount of blood flow due to the higher pulmonary arterial pressure and 
the effects of gravity while the converse is true for the upper portions [11, 23].  This is further 
supported by MRI investigations into the perfusion of the healthy lung, these studies show 
that the basal portions of the lung receive a significantly larger proportion of the pulmonary 
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blood flow [24-26].  This proves that the tissue does not have uniform blood flow decreasing 
the possibility of homogenous distribution [11].  Based on the physiology and MRI findings, 
it is expected that GAT would display the basal localization (Figure 2) since it is 
administered systemically using i.p. 
 
 
 
 
 
 
Figure 2. Basic lung structure together with expected regions of drug distribution based on 
the physiology of tissue blood flow. 
Figure 3 shows the results of the MSI analysis starting with frames A1 and A2 as the 
uninflated control lung.   The drug distribution is shown throughout the lung (A1), since the 
tissue collapses and the MSI data collected is the result of multiple layers of cells overlaying 
each other.  When evaluating the H&E stain (A2) poor preservation of the lung ultrastructure, 
was observed. In frames B1 and B2, the ethylene glycol inflation depicts the ultrastructure of 
the lung being well preserved however the MSI analysis showed widespread distribution of 
GAT with low signal intensity, ruling out ethylene glycol as an ideal inflation medium.  A 
similar distribution pattern was observed with PvP (C1), this could be due to its adhesive 
properties which would cause the alveoli and lung walls to aggregate together.  The 
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ultrastructure of the lung was also very poorly preserved (C2), due to the crystallization of 
PvP and the formation of freezing artifacts. Figure (D1) and (D2) shows the results of 
utilizing hypothermosol, a commercially available cryopreservant.  
 
 
 
Figure 3. MSI results and H&E stain for each of the cryoprotectants used.  Frames A1-F2 
represent MSI data while A2-F2 are the H&E stains for the corresponding tissue section that 
was used in the image acquisition (mag 2.5x).  (Key: A-uninflated lung; B- ethylene glycol; 
C- PvP; D- hypothermosol; E- DMEM; F- DMSO) 
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The findings showed low signals together with poor tissue preservation, at low temperatures 
since it is normally used as a cold storage medium between 2-8oC. DMEM and DMSO were 
the most promising cryoprotectants (E1 and E2 and F1 and F2, respectively), both displayed 
good tissue integrity, ultrastructural preservation and the distribution pattern followed the 
expected pattern based on the physiological properties of the lung [11].  The localization 
observed when the tissue was inflated using DMEM, is probably due to its ability to easily 
penetrate the cells as demonstrated in experiments involving the transduction of peptides into 
mammalian cells [27, 28].  This seems to have caused a displacement of GAT from multiple 
layers of cells and its accumulation in the lung walls (Figure 3-E1.).  DMSO was the most 
effective cryopreservative for the distribution of the drug.  This is based on MRI studies 
which showed the same distribution patterns of elastase  [29], where the compound is 
localized around the basal periphery of the lung.  This is supported by modeling experiments 
which showed 12-15% of the central area of the tissue consisting of the conducting zone of 
the respiratory system [30, 31], responsible for the passage of air. This pattern can also be 
explained using the physiological properties of blood flow in the lung, that states that the 
basal portion receives approximately one third of the total supply [11], which would unlikely 
lead to widespread distribution of a drug administered systemically. 
GAT was then quantified in each section, using quantitative mass spectrometric imaging (Q-
MSI), which is becoming an accepted method for determination of drug concentration [32, 
33].  A recent study displayed its effectiveness as a quantitative technique, when MSI was 
conducted following in vivo MRI of the heart and showed a great degree of correlation 
between the results with high spatial resolution [33].  Calibration curves using DMSO and 
DMEM, were conducted in triplicate to investigate the suitability of these solvents for 
standard preparation and to determine their correlation co-efficients.  The DMSO calibration 
curve was created (Figure 4) with a correlation co-efficient of R2 = 0.9666.  However, all of 
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the attempts to create a standard curve using DMEM, showed complete suppression of the 
GAT signal.  This is a combination of  the interaction of the drug with the mediums’ complex 
mixture of components (ranging from amino acids, to vitamins and other supplements) and 
GAT’s amphoteric nature [34].  Using the DMSO calibration curve, the mean drug 
concentration in the DMEM inflated lung was 3357.87 ± 402.47ng/ml (Figure 5) whereas in 
our previous study it was 5277.16 ng/ml, in whole lung homogenate. This provides further 
evidence that DMEM causes the displacement of the drug from several layers of cells and 
leads to its deposition in the lung walls, accounting for the distribution pattern.  The GAT 
concentration in the uninflated (214.87 ± 57.89ng/ml) vs. the DMSO (348.28 ± 22.01ng/ml) 
inflation are very similar showing that no displacement of the drug occurs. DMEM may still 
have applications for the MSI of  endogenous proteins and lipids in lung tissue when used as 
a perfusion agent as previously demonstrated [16, 17].  
 
 
 
 
Figure 4.  Calibration curve. Plot of GAT concentrations (100 – 1000ng/ml in DMSO), on an 
ITO coated slide, with images of each spot shown adjacent to the graph. 
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Figure 5. The concentration of GAT on each slide was determined using linear regression, 
the sections inflated with ethylene glycol and hypothermosol could not be quantified.  
(Sections were quantified in triplicate, n=3) 
The results reveal that the optimum cryoprotectant for the inflation of rat lung, for the 
purpose of small drug MSI may be DMSO (Figure 3 - F1 and F2); with good tissue 
preservation and structural integrity.  The most important point in the favor of DMSO was 
that the distribution patterns observed closely resemble MRI studies showing the distribution 
of elastase in the lung [29].  This argument was also supported by the physiological 
properties of the respiratory system. This study does not discount the cryprotective properties 
of the other agents used in this study, as they may be suitable for other applications. 
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Conclusion 
This study demonstrated that DMSO is a suitable cryoprotectant as an inflation medium for 
biomedical MSI of the lung. It preserves the structural integrity and enables good spatial 
resolution of small drug molecules using MSI analysis. Since the distribution pattern 
observed with GAT is similar to that of elastase, we can also conclude that drug distribution 
in the lung is not bias based on particle size. The advantage of this technique is that current 
methods have low spatial resolution, in the order of millimetres while with MSI this is 
increased to micrometres.  Moreover, this paper provides an alternative method for the 
preparation of lung tissues to produce images similar to those acquired using MRI. This study 
provides scientists with an optimized procedure for the preparation of lung tissue, while 
taking into account its structural characteristics. 
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Abstract 
 
Rifampicin (RIF) is a major component for short course chemotherapy against tuberculosis, 
since it is active against rapidly metabolizing as well as dormant bacteria.  According to 
the Lipinski rules, rifampicin should not enter the blood brain barrier.  Visualization of 
tissue drug distribution is of major importance in pharmacological studies; thus far imaging 
of RIF in the brain has been limited to positron emission tomography (PET).  We propose 
using matrix-assisted laser desorption ionization-mass spectrometry imaging techniques as 
a suitable alternative for the visualization and localization of drug tissue distribution. Using 
liquid chromatography mass spectrometric (LCMS) technique we were able to quantify the 
concentrations of RIF in the uninfected rat brain, we paired this with MALDI MSI to show 
the time dependent manner in which RIF is able to enter the brain. Our results show that 
even at the minute concentrations measured with LCMS/MS we were able visualize the 
drug and show its exact distribution in the rat brain.  Other available methods require 
nuclear labeling and the detection of gamma rays produced by labeled compounds in order 
to visualize the compound and its localization, MALDI MSI is a more recently developed 
technique, which can provide detailed information on drug distribution in tissues when 
compared to other imaging techniques.  This study shows that without any requirement for 
complex pre-processing we are able to produce images with a relatively improved 
resolution and localization than those acquired using more complex imaging methods, 
showing MALDI MSI to be an invaluable tool in drug distribution studies. 
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Introduction 
 
Short course chemotherapy (SCC) is currently the only effective treatment available for 
pulmonary tuberculosis (TB) as well as extra pulmonary forms such as TB meningitis. 
Tuberculosis meningitis (TBM) occurs more frequently in HIV-infected children [1] than 
adults; and lower CD4+ counts are associated with severe infection and poor outcomes [2, 
3]. Rifampicin (RIF) is the most important drug in SCC as it is the only anti-TB drug 
capable of effectively killing rapidly metabolizing as well as dormant bacteria [4].  It 
inhibits RNA polymerase of the bacteria which is the enzyme responsible for DNA 
transcription by forming a stable drug-enzyme complex at 37oC with a binding constant of 
10-9 M [5].  However, oral administration of RIF leads to low bioavailability due to the 
high first pass effect and auto induction [6].  In vitro studies have even shown that orally 
administered RIF does not effectively reach tuberculosis granulomas in lung alveoli [7].  
 
RIF is a drug that one would typically not expect to enter the brain due to its size.  Drugs 
that are able to diffuse through the blood brain barrier are normally < 400 Da and have less 
than 8 hydrogen bonds [8].  RIF is still able to penetrate the blood brain barrier, although 
it only obeys one of the conditions for Lipinski’s rule of five due to its lipophilicity [9].  
Several studies have shown the presence of RIF in the brain with five reporting on the 
quantification by measurements of this drug in cerebrospinal fluid (CSF) [10-14].  After 
oral dosing, concentrations of RIF in the CSF, determined by fluorometric and 
microbiologic procedures, were reported to be only slightly above its minimum inhibitory 
concentration (MIC) for Mycobacterium tuberculosis [14].  In contrast to oral dosing, 
human studies on intravenous administration of standard doses of RIF reported a more 
favorable penetration into CSF and cerebral extracellular space [11, 13].  But CSF 
determination of drug concentration is not an accurate measure of the amount of the 
compound that actually enters the brain, as CSF is only a fluid produced by the choroid 
plexus and not an anatomical feature of the brain [15].  It is therefore necessary to study 
the amount of drug directly in the brain as a true measure of its neuroprotective potential.  
Mindermann et al., reported the first direct measurement of rifampicin concentrations in 
various compartments of the human brain and this was achieved via a microdialysis probe 
inserted into the cortex and found that concentrations of this drug in a brain tumor is not a 
true reflection of its concentration in a normal brain [16, 17].  Qosa et al. recently reported 
the first quantification of RIF directly from rat brain homogenate while investigating the 
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clearance of amyloid-β and they found that RIF crossed the blood brain barrier and had a 
protective effect against Alzheimer’s disease.  The concentration of RIF was comparable 
to patients receiving therapeutic doses [18].   
 
Visualizing the exact localization of drugs in tissue is an essential tool in drug distribution 
studies, as this will allow researchers to investigate whether or not the drug reaches its 
desired site of action and be a determining factor in its neuroprotective efficacy.  This is 
especially important for drugs such as RIF since it has a high degree of plasma protein 
binding (approximately 80%), leaving only about 20% to diffuse into CSF [19].  The most 
common methods for tissue distribution employs radio-labeled drugs for imaging via 
positron emission tomography (PET), magnetic resonance imaging (MRI) and X-ray 
computerized tomography (CT) [20].  Liu et al. reported the use of positron emission 
tomography (PET) quantified radio labeled RIF in the brain; this study which compared 
the permeability of the three frontline TB chemotherapeutics concluded that they entered 
through the blood brain barrier of baboons with RIF showing the least penetration [21].  
The study concluded that the predicted concentration of RIF in the infected baboons was 
3-4 times above the MTB minimum inhibitory concentration, which confirms the 
suitability of the drug for treating CNS TB infections.  MALDI MSI is an attractive research 
tool which serves as an alternative to the use of radio-labeled compounds that are less 
widely available [22].  This method can precisely depict the anatomical distribution of a 
compound with a lateral resolution of a few tens of microns and is currently used for the 
development of drugs to treat CNS conditions such as Parkinson’s [23].  
This present study is aimed to investigate the penetration and distribution of RIF in the 
brain of healthy rats using MALDI MSI upon intraperitoneal application of the drug. 
 
Materials and methods 
 
Animals 
All animal experiments were undertaken with the approval of the Institutional Animal 
Ethical Committee of University of KwaZulu-Natal (UKZN), Durban, with the ethics 
number 067/14/Animal.  Healthy male Sprague dawley rats with average weight of 95 ± 
10 g were obtained from the Biomedical Resource Unit (BRU), University of KwaZulu-
Natal, Durban, South Africa.  Animals were housed at the BRU in polycarbonate cages in 
air-conditioned rooms (50-70% humidity and between 21-24oC) with a 12 hr light/dark 
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cycle.  Animals were allowed ad libitum access to drinking water and standard rat chow.  
 
Drug Administration and tissue sampling 
Animals (95 ± 10 g) were dosed with RIF (Sigma Aldrich, South Africa) of 10 mg/kg 
respectively, prepared in 10% DMSO and 90% ultrapure water, this dose was calculated 
based on the average body weight.  RIF was administered intraperitoneally (i.p.) to 6 groups 
of animals (n=3).  Animals were anaesthetized with halothane before blood was collected 
by cardiac puncture at 0, 20, 40, 60, 120, and 240 min post RIF administration in 
heparinized tubes.  Blood samples were immediately centrifuged at 12,000 × g for 10 min 
and aliquots of plasma (1.5 ml) and immediately stored at -80oC prior to analysis. 
 
Dissection and storage  
The rats were euthanized with halothane and termination was confirmed by the absence of 
breathing and dissection was performed immediately.  The lungs and brain were surgically 
removed and snap frozen in liquid nitrogen vapor before storage at -80oC.  
 
Sample preparation for MALDI-MSI 
Serial sections (10 µm thick) were sectioned from each biopsy and freeze thaw mounted 
onto an indium titanium oxide (ITO) coated glass slide (Bruker, Bremen, Germany) with a 
cryostat (Leica Microsystems CM1100, Wetzlar, Germany) using optimum cutting 
temperature (OCT) embedding medium and kept at −80 °C till needed for analysis.  Glass 
slides were removed from deep freeze and immediately transferred to a desiccator.  
Following 30 min desiccation time, the slides were scanned using a flatbed scanner (HP 
LaserJet 3055).  Matrix preparation was done by preparing 7 mg/ ml α-cyano-4-hydroxy 
cinnamic acid (CHCA) (Bruker, Bremen, Germany) matrix solution in 50% acetonitrile 
(ACN) containing 0.2% trifluoroacetic acid (TFA).  The matrix solution was sonicated for 
5 min and centrifuged at 9390 x g for 10 min before transferred to the ImagePrep (Bruker 
Daltonics).  This is a spraying device that automatically deposits matrix solution onto the 
tissue in a consistent manner.  In short, aerosol is generated by vibrating spay generator 
producing tiny droplets (average droplet size of ≈20 µm) under controlled conditions.  
 
 
 
 
  
 
80 
MALDI-MSI Analysis 
Standard solutions of RIF were analyzed using MALDI TOF MS operated both at 
reflectron and LIFT modes respectively with the aid of the Autoflex III MALDI TOF/TOF 
1 KHz smartbeam laser (Bruker Daltonics, Germany) and FlexControl acquisition software 
ran in positive ion mode.  The instrument was calibrated using standard peptides 
bradykinin, angiotensin II, angiotensin I and substance P spotted with CHCA matrix on the 
ground steel target (Bruker Daltonics, Germany) for m/z 700–1400.  Each spectrum was 
acquired from 200 laser shots. Tissue sections were imaged with spatial resolution from 
25–100 µm.  The MALDI images were displayed using the software FlexImaging 3.0 
(Bruker Daltonics, Germany). Spotting different concentrations (0.5, 1, 5, 10,100 and 500 
ng/mL respectively) of RIF with the matrix onto a brain section of an untreated animal was 
used to evaluate background signals interfering with the analyte.  The chosen matrix 
(CHCA) would not promote the detection of lipids [24].  The drug was mixed (1:2) with 
matrix solution and the different concentrations of RIF spotted on the tissue in a total 
volume of 3 µL.  The spots were analyzed in reflectron mode by collecting 200 shots per 
spot.  The MS/MS experiments were performed using a LIFT method optimized for the 
drug by specific tuning of the timing of the LIFT cell and of the precursor ion selector.  The 
LIFT method was calibrated with peptide calibration standards as mentioned above. The 
same method was used to perform MS/MS directly on RIF-matrix spotted tissue section 
and spectra were compared to the MS/MS spectra generated from of the drug standard only.  
For the initial analysis of the manually deposited spots, spectra consisting of 1000 laser 
shots were acquired in bundles of 5 x 200 shots and data was collected in the range between 
m/z 700–1000.  A product ion scan of the sodium adduct precursor ions (m/z 845) revealed 
a clear fragmentation pattern with the transition m/z 845 → 791	dominating the spectra with 
a laser power of 60%.  This transition represents the loss of CH3OH and sodium ion 
respectively.  An increase in the laser power led to production of other product ions but 
with less sensitivity.  The software Flex Imaging 3.0 was used to set up the acquisition of 
the imaging experiments.  The imaging MS/MS experiments were performed by collecting 
spectra with a raster width of 200 µm in the same m/z range as above.  The spectra were 
baseline subtracted (Convex hull) and smoothed (Savitzski golay) in the processing 
software during acquisition.  In LIFT mode, all spectra were normalized against total ion 
count (TIC) to reduce potential suppression by i.e. matrix hot spots.  We define the total 
ion current as the sum of all intensities in the mass range analyzed.  For this analysis, both 
fragment and parent spectra were acquired from each spot and 500 laser shots were summed 
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up in a random walk pattern from each position.  The RIF parent ion of m/z 845 served as 
a qualifier ion while m/z 791, a major fragment of RIF was used to visualize the brain 
sections in triplicate and m/z 773 further confirmed the fragment to be due to loss of water 
from the fragment.  
Quantification in biological samples 
The methods used for the extraction and detection of RIF followed those of Srivastava et 
al. (2012) with minor modifications [25].  Drug free tissues stored at -80oC to be used as 
matrix for calibration was homogenized in water at ratio of 3 mL of water for every 1g of 
tissue by using a manual tissue homogenizer.  Tissue concentrations of RIF were measured 
using LCMS/MS after protein precipitation with a 100% methanol ratio of 9:1 for plasma 
and lung while a ratio of 2:1 for brain tissue.  This was followed by refrigeration for 10 min 
and centrifugation at 15870 x g for 15 min, supernatants were filtered through Supelco 
hybrid solid phase extraction 30 mg phospholipid cartridges.  Matrices were spiked with 
standard drug concentrations to obtain quality control samples and calibration curve for 
quantification.  Recovery of the analyte and the internal standard were determined on the 
quality control samples of the 3 matrices. 
The samples were separated using an Ultimate 3000 LC system (Dionex, Sunnyvale, CA, 
USA) coupled to an amaZon speed ion trap (IT) equipped with ESI ion source from Bruker 
Daltonics (Bremen, Germany).  The IT-MS was operated in the ultrascan mode. The HPLC 
system was a Dionex Ultimate 3000, consisting of a binary pump, connected to an 
autosampler equipped with a 20 µL injection loop and the temperature of the column was 
maintained at 25 °C.  The flow rate was 0.4 mL min-1.  The analytical column was a 150 
mm × 3.0 mm (internal diameter) stainless-steel column YMC Triart C18, 3 µm from YMC 
Europe Gmbh (Dislanken, Germany).  The mobile phases were Milli-Q water (0.1% 
v/v formic acid) and ACN (0.1% v/v formic acid).  The gradient profile was initially from 
35% to 65% ACN in 7 min, then in next 3 min increased to 90% ACN (held 2 min), after 
which time the mobile phase was returned to the initial conditions (35% ACN) in 3 min. 
The MS was operated in the ESI positive mode and auto MSn spectra collection was 
applied. The MS settings were as follows: capillary outlet 4500 V, end plate voltage 500 
V.  Nebulizer was set to 1.5 bar and desolvation gas temperature was 210°C at a flow-rate 
of 8 L/min.  Positive ion mode MS spectra were obtained within a mass range of m/z 100-
1200.  Smart parameter setting (SPS) was set to m/z 823.5.  The ion charge control (ICC) 
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was set to 200,000 with a maximum accumulation time of 200 ms.  CID was performed 
using helium as collision gas. 
The MRM settings were as follows: isolation width for RIF was set at 4.0 and percentage 
amplification was set at 25% while for the internal standard (rifapentine), the isolation 
width was set at 1.0 and the percentage amplification was also set at 25%.  Collision energy 
- enhanced fragmentation mode ramping from 80-120%, fragmentation time 20 ms, 
isolation width m/z 4.  For MS/MS precursor selection, the most intense ions were isolated.  
The transitions were chosen to be m/z 823.5 → 791.5 for RIF, m/z 877.5 → 845.5 for the 
internal standard, this represents the loss of CH3OH in each case. 
All results were stored and analysed with Data Analysis 4.0 SP 5 (Bruker Daltonics) and 
Quant analysis. 
 
Results and Discussion 
 
MALDI MSI is not a quantitative method of evaluation and with only a single report on 
the direct measurement of the concentration of RIF in rat brain [17] we thought it would be 
necessary to create an effective and verified quantitative method for the determination of 
this drug in this tissue.  We developed an LCMS/MS method to quantify the amount of RIF 
in the plasma, lung and brain that had a relatively short run time of 15 min.  The retention 
times for RIF and its internal standard (rifapentine) were 8.5 and 9.6 min respectively as 
shown in Figure 1.  The limit of detection (LOD) was evaluated as the lowest concentration 
that gave a signal-to-noise ratio of three for the analyte while the lower limit of 
quantification (LLOQ) was determined in six replicates based on the criterion that the 
analyte response at LLOQ is at least five times baseline noise and it is within the acceptable 
limit of accuracy and precision.   
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Figure 1. Extracted ion chromatogram and mass spectra of rifampicin (823.5 →791.5) and 
rifapentine (877.6 →845.6) respectively. 
The method demonstrated good sensitivity with a limit of detection for the analyte in 
plasma, lung and brain homogenates of 0.5ng/mL.  We chose 50 ng/mL as the limit of 
quantification for the plasma and 1 ng/mL for lung and brain homogenates respectively.  
The calibration curves were linear with at least 0.995 in each case, a linear range of 50-
1200 ng/mL for plasma samples and 1-150ng/mL for lung and brain homogenates were 
obtained in each case.  The extraction method for the analyte and internal standard from 
the matrices proved to be efficient with mean recoveries of at least 87% for each compound.  
Plasma concentration-, lung concentration- and brain concentration-time curves of RIF are 
shown in Figure 2.  The relevant pharmacokinetic parameters, including Tmax, Cmax, T1/2 
and AUC, are listed in Table 1.  In plasma, RIF reached a Cmax of 7952.90ng/mL after a 
Tmax of 60 min, which is in accordance with lower values of several studies [26-29].  In the 
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lung, the Cmax was 3110.38ng/mL with a similar Tmax of 60 min.  Curves for both the plasma 
and lung concentrations showed similar trends, where there were steady initial increases in 
drug concentrations followed by a gradual decrease until trough concentrations were 
reached at 240 min.  Compared to the lung and brain concentrations, the plasma had greater 
amounts of RIF with AUC’s that were significantly higher.   
 
Figure 2. The concentration-time curve for plasma, lung and brain respectively, after a 10 
mg/kg intraperitoneal dose of RIF.  This represents the data obtained from plasma, lung 
and brain homogenates of a single animal used for the study.  Data acquired with LC/MS. 
 
The observed results for plasma concentrations of RIF are in agreement with that of data 
reported [18, 30].  The AUC and the Cmax values in the lung homogenates was about half 
of that in the plasma.  The Tmax (120 min) observed in the brain homogenate was twice that 
observed in both the plasma and lung matrices respectively.  Poor brain permeability was 
also observed for RIF after its intraperitoneal administration of 20mg/kg to healthy mice 
which was twice the dose administered in our research but yet with relatively close plasma 
and brain concentrations [18].   
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Table 1: Quantitative analysis (LCMS/MS) of RIF in plasma, lung and brain 
homogenates.  
Parameters 
 
Plasma  
(ng/mL) 
Lung  
(ng/mL) 
Brain  
(ng/mL) 
20 mins 
 
5926.90 ± 0.61 1701.00 ± 2.12 11.27 ± 0.40 
40 mins 
 
6665.80 ± 0.98 2969.89 ± 9.51 60.49 ± 1.14 
60 mins 
 
7952.90 ± 7.80 3110.38 ± 9.66 73.52 ± 1.21 
120 mins  
 
4925.50 ± 5.21 2293.06 ± 5.56 89.27 ± 0.91 
240 mins 
 
2413.10 ± 0.64 900.97 ± 1.18 30.24 ± 0.6 
Tmax (min) 
 
60 60 120 
Cmax (ng/mL) 
 
7952.90 ± 7.80 3110.38 ± 9.66 89.27 ± 0.91 
AUC 0-4 (ng x 
min/mL) 
1,158,042 748,269.6 
 
14,224.70 
T½ (min) 165 172 
 
208 
Presented data originates from one animal only and n=3 corresponds to three injections to 
the HPLC, values are expressed as mean ± S.D.  
 
This result is not strange as it has been earlier reported [17] that only about 0.3-1% of the 
RIF plasma concentration penetrates into the brain.  The lower availability of RIF in the 
brain is also associated with the rapid penetration of this drug into other tissues as observed 
in the mean lung concentrations in our study.  It readily diffuses into most organs, tissues, 
bones and body fluids, including exudates into TB infected lung cavities [31].  About 20% 
of serum concentration has been observed in the saliva and other high concentration 
therapeutic concentrations appeared in the lachrymal glands, tears and urine [32].  The 
lateral ventricles houses the choroid plexus, which is responsible for producing the CSF 
found in the brain.  In our study, we have found that the lateral ventricles to be devoid of 
RIF (Figure 3), thus implying that RIF may not be entering or leaving the brain via the 
CSF; this has not been previously demonstrated. 
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Figure 3. Quantitative analysis of brain tissue homogenates together with the images of 
the MSI.  The tissue sections represent different time points, as well as axial (a) and coronal 
(b) sections shown at 100 µm resolution.  Using the images at 40 min as an example we 
have shown the cortex (indicated by the red arrow) and the lateral ventricles (indicated 
by the red oval) in the axial section.  In the coronal section the cortex is also shown 
(indicated by the red arrow).  The results show the time-dependent penetration of RIF 
into brain tissue, as shown in the shape of the curve but also as demonstrated by the steady 
development of the bright pink to white color in the tissue sections representing the 
presence of the drug as visualized by m/z 791 ± 0.01. 
 
 
There is approximately 40 µL of CSF in the rat brain and the entire volume is turned over 
every 2 hours [26], this could produce a wash out effect and be responsible for the high 
concentrations of RIF observed at the brain stem.  A previous report that demonstrated the 
use of PET imaging on baboon brain [21], which observed the penetration of RIF through 
the blood brain barrier of diseased and healthy animals, however they did not comment of 
the availability of RIF in the brain CSF.  The axial and coronal views (Figure 3), supports 
this theory with the observed presence of RIF concentration at the brain stem in the time 
dependent images.  The high density of the drug in the cortex and striatum in our findings 
are in keeping with those found in mice [27]. The detected RIF in the isocortex region of 
the brain support the point that administration of RIF reduces brain injury after both 
permanent and transient focal cerebral ischemia in mice [27-29].  The mechanisms 
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expediting such effects of RIF may involve fortification against oxidative stress and or the 
activation of glucocorticoid receptors in areas of the hippocampal formation [27-29]. 
In conclusion, the novelty of this study is two-fold.  Firstly, we were able to show that 
MALDI imaging is a sensitive and powerful tool for evaluating drug distribution, even at 
low concentrations, in the brain as in the case of RIF when compared to other anti-
tuberculosis drugs such as isoniazid, or pyrazinamide which have better penetration into 
brain tissue [21]; hence the exploration of the sensitivity of MALDI imaging.  Secondly, 
we were able to demonstrate the time-dependent manner in which RIF penetrates into the 
brain.  This data, despite being collected in an uninfected model, is highly significant as it 
allows us to determine the minimum doses reaching the brain in the early course of an 
infection and its distribution.  This will enable us to evaluate the drug’s location and if the 
drug is reaching the therapeutic doses in the brain required to treat TB associated meningeal 
infections [30].  The MALDI-TOF/TOF method developed for this study had a relatively 
reasonable run time.  The main advantage of this LIFT method is that both parent and 
fragments of the analyte can be determined consecutively, providing adequate information 
of adducts formed in the process.  The transition of RIF from its sodium adduct m/z 
845→791 made its mapping successful on the brain sections. 
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Abstract  
 
Tigecycline (TIG), a derivative of minocycline, is the first in the novel class of glycylcyclines 
and is currently indicated for the treatment of complicated skin structure and intra-abdominal 
infections.  A selective, accurate and reversed-phase high performance liquid chromatography-
tandem mass spectrometry (HPLC-MS/MS) method was developed for the determination of 
TIG in rat brain tissues.  Sample preparation was based on protein precipitation and solid phase 
extraction using Supel-Select HLB (30mg/1mL) cartridges.  The samples were separated on 
YMC Triart C18 column (150 mm x 3.0 mm. 3.0 µm) using gradient elution.  Positive 
electrospray ionization (ESI+) was applied for the detection mechanism using multiple reaction 
monitoring (MRM) mode.  The method was validated over the concentration range of 150-
1200 ng/mL for rat brain tissue.  Precision and accuracy for all brain analyses had a mean of 
9.2% and 100.7% respectively and were within the acceptable limits stated in the method 
validation guidelines.  The mean extraction recovery in rat brain was 83.6%.  This validated 
method was successfully applied to a pharmacokinetic study in female Sprague Dawley rats 
which were given a dose of 25 mg/kg TIG intraperitoneally at various time points. 
Keywords: LC-MS/MS; Tigecycline; rat brain tissues 
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Introduction 
 
Antimicrobial resistance (AMR) is a current disturbing global trend which results when 
microorganisms offer resistance to an antimicrobial agent that was originally effective against 
it.  Resistant micro-organisms such as fungi, viruses, bacteria and most parasites are able to 
survive routine antimicrobial therapies such as common antivirals, antibiotics, antimalarials 
and antifungals, such that ordinary medicines become fruitless and infections spread, 
increasing the risk of uncontrollable spread of infections [1, 2].  The misuse of antimicrobial 
medicines accelerates this natural phenomenon of resistant strain evolution and encourages the 
spread of AMR.  Previous studies have reported that therapeutic failure and negative clinical 
outcomes emanate from sub-therapeutic dosing of antibiotics which leads to the development 
of antibiotic resistance if the suitable adjustments to the dose are not made [3, 4].  In today’s 
clinical trials, several types of biochemical and genetic mechanisms of resistance are 
demonstrated by most bacterial strains.  These include β-lactamase production, mutation, 
efflux pumps, altered target sites, horizontal gene transfer and decreased antimicrobial agent 
penetration [2, 5, 6].   
Therefore the identification and development of new antibiotics, predominantly those with new 
modes of action is crucial to assist in treating these infections.  TIG is one such promising 
antimicrobial agent, which is a synthetic derivative of minocycline and the first of the novel 
glycylcycline class of broad-spectrum antibiotics (see Figure 1 for chemical structures).   
1(a)                                                                                    1 (b) 
  
Figure 1. Chemical structures of tigecycline (a) and minocycline (b) 
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TIG has demonstrated an expanded broad spectrum of in vitro activity and clinical potency 
against both Gram negative and Gram positive aerobic and anaerobic bacteria.  It is also not 
affected by most of the common mechanisms of antibiotic resistance used by bacteria to resist 
antibiotic therapy, due to steric hindrance afforded by the bulky D-ring substituent [7].  TIG is 
the key in the containment of complicated multi-organism infections and is officially accepted 
for the treatment of a number of pathologies including intra-abdominal infections, complicated 
skin and skin structure infections and community-acquired pneumonia [8-10].  Infections of 
the central nervous system (CNS) are amongst the diseases with the most severe outcomes, 
from both social and individual points of view.  Amongst these disorders is acute bacterial 
meningitis, which is a life threatening infectious disease.  Despite its high efficacy against 
multidrug-resistant (MDR) pathogens, TIG is currently being reviewed for the treatment of 
meningeal infections based on studies of it in cerebrospinal fluid (CSF) [11-13].  TIG 
concentrations were lower when compared to other drugs in the tetracycline family at the same 
dose and it was concluded that inflamed meninges might be increasing TIG concentrations by 
facilitating the drug’s penetration into CSF [14].  In a couple of cases, the CSF concentrations 
were determined to be lower than the minimum inhibitory concentration (MIC) [12, 13], but in 
most of the reported cases were constantly above the MIC [15-17].  These results warrant 
further investigations into the neuroprotective properties of TIG.  
Furthermore, CSF concentrations in spine is not the same as CSF concentrations in brain 
therefore measuring the concentration of drug in spinal cord CSF is considered incorrect [18].  
Data on the actual measurement of TIG in the brain are still scarce, with only a single study 
evaluating the antibiotic levels in cerebral tissue using a microbiological agar diffusion assay 
with Staphylococcus aureus ATCC 6538P as the indicator microorganism [19].  Recent 
publications have not reported any literature that demonstrates the development and validation 
of a sensitive and selective assay for the determination of TIG in rat brain tissues.  Therefore 
an accurate and sensitive analytical method to quantify TIG in the brain is an important tool 
that is lacking.  During the past decade, highly significant technological advancements in mass 
spectrometry have resulted in a great impact on drug discovery, development and analysis [20, 
21].  Currently, LC-MS/MS is a very popular analytical method for the determination and 
quantification of most drugs in biological samples and various pharmaceutical formulations 
[22, 23].  As recently summarized by Xie et al. [24], several HPLC methods coupled with MS 
have been used for the determination and quantification of TIG at low concentrations in plasma 
samples because of the high sensitivity and specificity of this technique [23].  All the current 
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published analytical methods for TIG are generally aimed only at analyzing the drug in 
solution, body fluids or tissues other than the brain.  We are currently interested in studying 
the neuroprotective properties of antibiotics for resistant strains of microorganisms [25].  The 
aim of the present study was to develop an accurate and selective LC-MS/MS method for the 
determination of TIG in rat brain tissues to be applied in a pharmacokinetic study after 
intraperitoneal (i.p.) administration of TIG in healthy rats. 
Materials and methods 
Chemicals and reagents 
 
TIG and minocycline (internal standard) standards were purchased from DLD Scientific 
(Durban, South Africa).  The chemical structures of the analytes are shown in Figure 1.  
Acetonitrile (ACN), formic acid, trifluoroacetic acid (TFA) and methanol (MeOH) were of 
analytical grade all from Sigma–Aldrich (Munich, Germany).  Ultra-pure water was obtained 
using a Milli-Q purification system from Millipore Corporation (Bedford, MA, USA).  
Deuterated internal standard (IS) is recommended whenever possible; however, this was not 
commercially available for TIG, therefore we decided to use structurally similar minocycline.  
Chromatographic conditions 
 
The analytical column was a YMC Triart C18 (150 mm × 3.0 mm i.d. 3 µm) stainless-steel 
column, from YMC Europe Gmbh (Dislanken, Germany).  The mobile phase was a mixture of 
Millipore water (0.1% v/v formic acid) (A) and 1:3 MeOH: ACN (0.1% v/v formic acid) (B), 
which resulted in a reasonable total run time of 25 min.  The flow rate was 0.4 mL min-1 and 
the column oven temperature was set at 25 oC.  The gradient profile was developed from 5% 
to 95% ACN in 15 min, (held 5 min), after which time the mobile phase was returned to (5% 
ACN) in 5 min. 
 
Standard stock, calibration standards and quality control sample preparation 
 
Stock solutions of TIG, (1 mg/mL) were prepared in methanol and stored at -20 oC.  Serial 
dilutions of these solutions were prepared in mobile phases A and B (50:50, v/v) for the 
calibration curve and quality control (QC) samples.  Stock solution of 1 mg/mL of IS in 
methanol was also prepared and diluted with the same diluents to prepare working solutions.  
Calibration standard plasma and brain samples were prepared as follows: working standard 
solutions and IS (at a concentration level of 500 ng/mL) were spiked into 200 µL of plasma 
and blank brain tissue homogenates of untreated rats to yield a linear range from 300 to 2000 
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ng/mL and 150 to 1200 ng/mL for the calibration curve of plasma and brain respectively.  QC 
plasma (300, 900, 1800 ng/mL) and brain samples (150, 600, 1000 ng/mL) were prepared in 
the same way. 
 
Instrumentation and Mass spectrometric analysis 
Identification and determination of TIG and minocycline was performed using an Agilent 
Series 1100 HPLC (Shimadzu Corporation, Kyoto, Japan), with an online degasser, gradient 
pump and an autosampler coupled to a time of flight mass spectrometer analyzer (MicrOTOF-
Q II, Bruker, Germany).  Electrospray was used as an ion source, the optimized conditions 
were as follows: collision energy: 32 eV, nebulizer pressure: 1.5 bar, dry gas: 8.0 L/min and 
temperature of dry gas: 200 ºC.  The profile spectra were acquired in positive mode in the mass 
range of 150-1600 m/z with mass resolving power over 16000.  Mass calibration was performed 
prior to each run.  Data was processed by Data Analysis software (Bruker, Germany) and 
extracted ion chromatograms of all analytes were plotted.  For each analysis, 3 µL of sample 
solution was injected by an autosampler.   
Plasma and brain tissue samples 
  
Drug free plasma samples were purchased from Life Technologies (Burlington, ON, Canada) 
and stored at -20oC prior to analysis.  Plasma samples were allowed to thaw at room 
temperature before analysis.  Rat brains were weighed, cut into small pieces using scissors and 
mixed with ultra-pure water (3 µL/mg tissue).  The tissues were then homogenized using a 
glass ‘pestle and mortar’ homogenizer and all homogenate was stored at -80 °C until analysis.  
 
Sample preparation  
  
To precipitate the proteins in the biological samples, aliquots of 200 µL plasma samples were 
added into 1 mL Eppendorf tubes, spiked with IS solution at a concentration level of 500 ng/mL 
and the mixture slightly vortexed.  Subsequently, 600 µL 0.1% TFA in ACN was added into 
the Eppendorf tubes, then vigorously mixed for 1 min and the precipitated protein was removed 
by centrifugation at 12000 rpm for 10 min.  The supernatants from plasma and brain were 
filtered through 30 mg/1 mL Supel-Select HLB (High Lipid Binding) cartridges or 100 mg/1 
mL DSC-18 SPE cartridges (Sigma Aldrich, Munich, Germany) and the cartridge which gave 
the highest recovery for each respective matrix was used.  After protein precipitation, the 
cartridges were conditioned with 2 mL methanol:water in a ratio of 1:1 and were eluted using 
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0.1% TFA in ACN.  The filtered samples were dried under a gentle stream of nitrogen and then 
combined with 200 µL of mobile phase (50% A:B).  All the vials containing samples were 
vortexed briefly and transferred into autosampler vials for injection into the chromatographic 
system.  All thawing of frozen plasma and brain tissue samples was done at room temperature.  
For the brain tissue samples, the IS was added to 200 µL brain homogenates samples.  After 
addition of 10 µL IS solution, the homogenized tissue sample was thoroughly mixed.  
Subsequent extraction procedure of the drug from the rat brain tissue samples was the same as 
described for the plasma.  To improve sensitivity, a further procedure to concentrate the 
samples was used.  1 mL brain homogenate samples were lyophilized overnight in a VirTis 
freeze dryer (SP Scientific, Germany).  The lyophilized powder was re-suspended in 600 µL 
0.1% TFA in ACN and 10 µL IS solution was added.  After vortexing for 1 min, the suspension 
was centrifuged, extracted and processed as described for plasma.  For the brain samples, the 
supernatant was dried under vacuum at room temperature, samples were reconstituted in 200 
µL mobile phase and an aliquot was injected for LC-MS/MS analysis.  
 Method validation 
 
The bioanalytical method was validated according to the criteria laid out in the European 
Medicines Agency Guideline for bioanalytical method validation (EMA) [26].   
Specificity and selectivity 
 
The specificity and selectivity of the method was evaluated by analyzing six individual spiked 
brain samples and blank samples after i.p. administration of TIG.  Two blank brain samples 
spiked with an IS concentration of 500 ng/mL were also prepared and examined for matrix 
interferences.  Interferences from the matrix which could produce similar mass spectra to the 
target compound were investigated to reveal true analytical selectivity.  Each blank sample was 
tested for the effect of matrix interferences at the retention times of analytes and IS.  In 
accordance with the validation guideline [26], absence of interferences is accepted where the 
response is less than 20% of the LOQ for the analyte and 5% for the IS. 
 
Linearity and carry over effect 
 
To evaluate the linearity of the method, seven calibration standards were studied over a 
calibration range of 150-1200 ng/mL for TIG in rat brain homogenate.  Each calibration curve 
consisted of a blank sample, a zero sample and seven calibration concentration levels, among 
which blank and zero samples were necessary only to confirm the absence of interferences.  
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The calibration curves were constructed by plotting peak area ratios of calibration standards to 
the IS versus the nominal concentrations of analytes.  Carry-over effects were assessed, with 
relevant criteria, by injecting blank samples followed by the calibration standard at the highest 
concentration.  Linearity of the calibration curve was determined using linear regression 
analysis and also evaluated by its slope, intercept and correlation coefficient.  The limit of 
detection (LOD) was calculated using a signal to noise ratio of 3:1.  The lower limit of 
quantification (LLOQ) was determined as the lowest concentration of analytes with coefficient 
of variation (CV) not exceeding 20% and accuracy in the range of 80–120%.  Carry over in the 
blank should not exceed 20% of the LLOQ and 5% for the IS [26]. 
Precision and accuracy 
 
To investigate the intra- and inter-day precision and accuracy, QC samples were determined at 
three different concentrations for six replicates.  The precision of the method was given by the 
coefficient of variation (CV) and accuracy was evaluated by recovery.  The acceptable limit of 
CV was <20% for the LLOQ, and ≤15% for low quality control (LQC), medium quality control 
(MQC) and high quality control (HQC) samples according to the EMA guidelines.  A 
percentage difference in mean value of the observed concentration and nominal concentrations 
of QC samples was used to calculate accuracy.   
Matrix effect and recovery 
 
Matrix effects were determined by using a calculated ratio of the peak area in the presence of 
matrix (measured by analyzing blank matrix spiked after extraction with analyte), to the peak 
area in absence of matrix (pure solution of the analyte) and expressed as a percentage.  These 
tests should be done at a low and at a high level of concentration (maximum of three times the 
LLOQ and close to the upper limit of quantification, ULOQ).  Recovery is the extraction 
efficiency of an analytical process, given as a percentage of the known amount of an analyte 
carried through the sample extraction and processing steps of the method.  The extraction 
recovery of TIG was carried out at the three QC levels (300, 900 and 1800 ng/mL) and (150, 
600 and 1000 ng/mL) in five replicates for plasma and brain respectively.  
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Stability Studies  
 
An assay of three replicates of QC samples at low and high concentrations were used to 
estimate stabilities of TIG in rat brain homogenate under the following conditions: short-term 
stability after storage in a Virtis freeze dryer (-70 oC) for 24 h and post-preparative stability 
after 24 h in the auto-sampler maintained at 25 oC.  In agreement with the guideline [26], QC 
samples were analyzed against a calibration curve, obtained from freshly prepared calibration 
standards.  The obtained concentrations are compared to the nominal concentrations and the 
mean concentration at each level should be within ±15% of the nominal concentration.  The 
stock solution stabilities of TIG and IS were demonstrated following storage at -20 oC.   
 
Animals 
 
All animal experiments were undertaken with the approval of the Institutional Animal Ethical 
Committee of University of KwaZulu-Natal (UKZN), (Approval Reference: 001/15/Animal) 
Durban.  Female Sprague Dawley rats (weight 145 ± 20 g) were purchased from the Biomedical 
Resource Unit (BRU), University of KwaZulu-Natal, Durban, South Africa.  Animals were 
housed under standard conditions of temperature, humidity and 12 hour light/dark cycle with 
food and water provided ad libitum and allowed to acclimatize in the laboratory for one week 
prior to experiment.  Seven groups of female Sprague Dawley rats (n = 3) were administered 
an i.p. dose (25mg/kg) TIG dissolved in a 10% DMSO aqueous solution.  The intraperitoneal 
doses were chosen based on doses used in a previous study of the tetracyclines in brain-to-
plasma distribution studies in the rat [27].  Animals were anaesthetized with halothane before 
blood and tissue collection.  Blood samples were collected by cardiac puncture into heparinized 
tubes at 0, 5, 30, 60, 120, 240, 360 and 480 min after the i.p. dose.  Blood samples were 
immediately centrifuged at 3500 rpm for 10 min and aliquots of plasma (1.5 mL) immediately 
stored at -80 oC prior to analysis.  Animal organs were gently frozen in liquid nitrogen vapor 
before storage in labeled freezer bags at -80 oC.  
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Application to Pharmacokinetic Study  
 
Maximum concentration (Cmax) of TIG and time to reach Cmax (Tmax) were determined directly 
from the rat plasma and brain concentration-time curves.  All the other pharmacokinetic 
parameters were determined using non-compartmental analysis (STATA 13.0).  The area under 
the curve (AUC0→480) was calculated by the linear trapezoidal rule.  
Results and discussion 
LC-MS method development 
 
During method development, various parameters were evaluated to optimize mass 
spectrometry detection conditions, chromatography and sample extraction. 
Development of MS-TOF method 
 
Initially, to identify target analytes at low concentrations the ESI-MS-TOF parameters were 
optimized using a single variable procedure for all tested parameters of ESI source and mass 
spectrometer.  Obtaining the highest abundance of m/z values corresponding to ions of the 
analyte and the IS provided a high sensitivity of the developed method.  Both the target analyte 
and IS gave good response in positive ion mode since ESI is the preferred ionization technique 
for polar analytes like these tetracyclines.  The best chromatographic conditions were obtained 
by testing different mobile phases consisting of acetonitrile-water and methanol-water in order 
to provide adequate selectivity in a reasonably short separation time.  Modifiers such as 
ammonium formate, TFA and acetic acid were tested.  Due to its high miscibility with organic 
solvents, formic acid was selected and this resulted in improved peak symmetry and ionization 
efficiency for TIG and IS.   
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Figure 2. MS/MS transitions of tigecycline and minocycline 
Figure 2 shows the proposed structural characterization for each of the peaks observed by LC-
MS/MS.  TIG was observed as a protonated molecule, [M+H]+ , at m/z 586.29.  As reported in 
literature, the product ion tandem mass spectrum of m/z 586 showed fragment ions of m/z 569, 
513 and 456 [8].  Loss of NH3 from [M+H]+ generated m/z 569 observed as a double charge, 
m/z 285 and the product ion at m/z 513 represented loss of the t-butylamino group from the t-
butylaminoacetylamino side chain while loss of the entire t-butylaminoacetylamino side chain 
generated m/z 456.  Minocycline generated a protonated molecule, [M+H]+ , at m/z 458. 
 
MS/MS analysis 
 
For MS/MS precursor selection the two most intense ions were isolated.  The equipment was 
set up in multiple reaction monitoring (MRM) mode and transitions for TIG from 586.2 m/z → 
513.2 m/z was monitored for double charge as 257.1 m/z.  For IS, a transition from 458.2 m/z 
→ 441.2 m/z which was monitored for double charge as 221.1 m/z was used.  The coupling of 
LC with MS/MS detection whilst monitoring a set of precursor ions and product pairs resulted 
in high specificity since only the ions derived from the analyte of interest and IS were 
monitored.   
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Method validation 
 
After suitable optimization of the chromatographic separation conditions, a reproducible 
separation of TIG from plasma was achieved. Figure 3 (a) represents typical chromatograms 
of blank plasma and brain, Figure 3 (b) blank plasma and brain spiked with IS at 500 ng/mL 
and TIG at LQC level.  Typical retention time for TIG was 7.1 min.  From these chromatograms 
and peaks, it was concluded that adequate optimization had been done and the method could 
be used for further analyses.  Typical linear regression equations of the calibration curves for 
different matrices were y=0.541616 x + 0.193140 and y=0.326337 x + 0.032136 (where y was 
the peak area ratio of the analyte to the internal standard and x the concentration of the analyte), 
while the mean regression coefficients of the calibration curves were 0.9991 and 0.9981 in 
plasma and brain, respectively.  Calibration curves of TIG were established and were linear 
over a concentration range of 300-2000 ng/mL for plasma and 150-1200 ng/mL for brain tissue 
and this was shown in Figures S1 and S2.  To complete the method validation, batches 
consisting of duplicate calibration standards at each concentration level were analyzed on three 
different days.  In each batch, QC samples at 300; 900; 1800ng/mL and 150; 600; 1000ng/mL 
in plasma samples and brain tissue respectively were assayed in sets of six replicates.  The 
LLOQ was evaluated by analyzing six replicates of spiked samples at the concentration of 300 
ng/mL for plasma and 150ng/mL for brain homogenate.  The LOD was 100ng/mL and 50 
ng/mL for plasma and brain homogenate respectively. 
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Figure 3. Representative LC – MS/MS extracted ion chromatograms of m/z 257.1 obtained 
from (a) blank matrix, (b) low QC plasma and brain samples (c) plasma and brain samples at 
Tmax, (30 min and 120 min respectively) 
Intra- and inter-day precisions was determined by an assay of five replicates of QC samples at 
low, medium and high concentrations on the same day and on three different days.  Under the 
current method validation conditions [26], a satisfactory precision, accuracy and 
reproducibility of TIG in solution were obtained by analyzing the QC samples.  The intra- and 
inter-day precisions (%RSD) were <5.0% and the accuracies (%) were within the range of 98.9-
106%.  These results showed that the repeatability and reproducibility of the method were 
adequate and they fall within the acceptance criteria of the guidelines.  The results are presented 
in Table 1.  No significant carry-over from the analyte and IS was observed in the double blank 
after subsequent injection of the highest calibration standard (aqueous and extracted) at the 
retention time of analyte. 
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Table 1. Accuracy and precision for Tigecycline in different biological matrices. 
aConcentration level (ng/mL)  LQC MQC HQC 
Plasma     
Theoretical conc. [ng/mL]  300.0 900.0 1800.0 
 
Intra-day     
Mean concentrationa  296.8 944.1 1811.1 
Accuracy (%)  98.1 104.9 100.6 
% RSD   2.9 1.1 2.1 
Inter-day     
Mean concentrationa  298.1 954.2 1822.6 
Accuracy (%)  99.4 106.0 101.3 
% RSD   0.5 1.0 0.6 
Brain     
Theoretical conc. [ng/g]  150 600 1000 
Intra-day     
Mean concentrationa  158.8 532.2 1054.9 
Accuracy (%)  108.0 88.7 105.5 
% RSD   9.3 10.4 7.9 
Inter-day     
Mean concentrationa  156.7 540.7 1049.5 
Accuracy (%)  104.4 90.1 104.9 
% RSD  
 
 5.3 7.1 3.4 
 
 
 
 
RSD relative standard deviation (a n = 6) 
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Extraction recovery and matrix effect  
 
Systematic sample preparation protocols to remove unwanted components and to selectively 
extract the compounds of interest are an essential part of every bioanalytical workflow since 
many biological samples are complex.  Proteins can be denatured using acids, organic solvents 
or heat, or can be removed using ultrafiltration cut-off membranes [28].  Subjection of brain 
homogenates to protein precipitation and filtration through an SPE cartridge provided clean 
extracts of brain homogenate samples containing the target analyte.  Unclean samples 
containing phospholipids normally result in imprecision of data, increased baseline, shift in 
retention time and distortion or tailing of a chromatographic output.  The absence of all the 
above mentioned characteristics in all analyses was used to determine whether the extracts 
were ‘clean’ or not.  Initially, two techniques protein precipitation and solid phase extraction 
(SPE) were investigated to determine the optimal extraction procedure, since brain tissues 
contain high level of phospholipids.  Different solvents and modifiers such as MeOH, ACN, 
formic acid (FA) and trifluoroacetic acid (TFA) were tested in the precipitation protocol.  
Although precipitation removes a huge amount of proteins to give high recoveries, 
phospholipids remain in the extract and an additional clean-up step was required, hence a 
justification for the SPE technique, which was adapted from Pena et al. to obtain better 
separation and peak shapes [29].  From the two cartridges tested, Supel-Select HLB cartridge 
showed optimum results since analyte recovery was high (84.1%) and results were highly 
reproducible across all the trials.  This can be attributed to the fact that the hydrophilic, 
lipophilic balanced Supel-Select HLB cartridge is resistant to sorbent drying which affects 
most C18 cartridges.  A clear comparison of the two cartridges has been given and illustrated 
in Table S1.  Also, Zhu et al. selected this sorbent for routine analysis of tetracyclines in water 
samples [30].  Active silanol sites of the octadecylsilylated silica support material interact with 
the polar groups of the tetracyclines [31].  Since both TIG and minocycline are polar 
compounds, they could have been insufficiently retained on the C18 sorbent.  This reduced 
retention resulted in lower recoveries because of analyte breakthrough during the sample 
loading step.  Results from the optimized protein precipitation and SPE method, developed and 
optimized using 0.1% TFA in ACN, showed low interferences and high mean recoveries of 
TIG from brain: 88.7±3.4, 82.9±1.9, 81.7±3.1% for concentrations 150, 600 and 1000 ng/ml 
respectively.  TFA in ACN was also appropriate since it disrupts drug-protein binding during 
sample pre-treatment.  These results confirmed the suitability of the method for analysis of rat 
brain samples (Table 2.).  Analyte breakthrough is one of the disadvantages associated with 
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SPE.  Although this could be used as an explanation behind the unusual trend for recoveries to 
worsen with increasing spiking concentrations, extraction recoveries for 100 and 50 ng/ml 
(LOD) which were obtained during the optimization process (data not shown) did not confirm 
this trend since they were lower than those for 150 ng/ml.  This effect could have been caused 
by slight changes in flow rates during the optimization process. 
‘Matrix effect’ is a term generally used to explain the difficulties encountered during analysis 
of biological samples.  Endogenous and exogenous compounds are usually the main cause of 
these effects [32].  When these undesired matrix effects co-elute with target analytes in the 
course of chromatographic separation before MS analysis, this results in ion 
suppression/enhancement as well as decrease or magnification in sensitivity of analytes over a 
period of time, imprecision of data, increased baseline, shift in retention time and distortion or 
tailing of a chromatographic output.  When matrix effects and possible ionization suppression 
or enhancement of TIG and IS were examined, the relative standard deviation of the mean peak 
areas of TIG and IS were <5% for the brain samples, which indicated small differences in 
ionization efficiency when the biological matrices were used.  As shown in Table 2., the matrix 
effects for TIG were within the range of 98.0 – 103.1% and 97.8 – 104.4% for plasma and brain 
respectively indicating that ion suppression or enhancement by endogenous components was 
not affecting the repeatability of the method. 
Table 2.  Recoveries and matrix effects of Tigecycline in different biological samples. 
Concentration level 
 
aMean recovery (%) %RSD aMatrix effect (%) %RSD 
(ng/mL)     
Plasma     
LQC 
 
 
ISII 
86.7 7.1 103.1 1.6 
MQC  80.2 11.1 98.2 0.9 
HQC  82.4 9.7 98.0 1.4 
Brain     
LQC                         88.7 3.4 98.9 2.1 
MQC 82.9 1.9 104.4 1.8 
HQC 81.7 3.1 97.8 0.5 
RSD relative standard deviation   (a n=6) 
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1.1.1 Stability studies 
An assay of three replicates of QC samples at low and high concentrations were used to 
estimate stabilities of TIG in rat brain under the following conditions: short-term stability after 
storage in a Virtis freeze dryer (-70 ℃) for 24 h and post-preparative stability after 24 h in the 
auto-sampler maintained at 25 ℃.  No significant degradation occurred from any of the above 
mentioned experiments and TIG was stable in tissue homogenate samples.  The stability tests 
results are summarized in Table 3.  The TIG stock solutions prepared in MeOH were confirmed 
to be stable at -20 ℃ for 30 days (data not shown). 
 
Table 3. Stability of brain homogenate samples 
Storage          
Concentration  
(ng/mL) Accuracy %RSD 
          Added  Found   
Auto-sampler, at 25 ℃ 
for 24 h 
         150 
         1000 
137.6 
940.9 
91.7 
94.1 
2.5 
3.0 
 
Freeze-drier, at -70 ℃ 
for 24 h 
         150 
         1000 
152.8 
1053.8 
101.9 
105.4 
3.4 
1.1 
RSD relative standard deviation   (n=3) 
 
 
 
 
 
 
 
 
 
  
 
107 
Application of method 
  
Brain distribution studies  
 
To investigate its suitability for pre-clinical pharmacokinetic studies, the analytical method 
described above was used for the determination of TIG in rat plasma and brain after i.p. 
administration of a single dose (25mg/kg).  Maximum concentration (Cmax) of TIG and time to 
reach Cmax (Tmax) were determined directly from the mean plasma concentration-time profile 
of TIG (Figure 4).  All pharmacokinetic parameters were summarized in Table 4. 
 
 
 
Figure 4. Mean plasma and brain concentration-time profiles for tigecycline after i.p. 
administration of a single dose of 25 mg/kg to healthy female rats (mean ± SD, n=3). 
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The overall shape of the plasma concentration-time profile was consistent with previous studies 
in which TIG was administered intraperitonealy [33].  After i.p. administration, TIG was 
absorbed rapidly.  The concentration of the drug was easily detected and quantified in the 
plasma samples collected up to 480 min post dose and all the concentrations were above LOQ 
of the analytical procedure.  As can be seen in (Figure 4), after i.p. administration, the plasma 
concentration of TIG first decreased rapidly from 30 min to 60 min and then more slowly 
thereafter.  Similar parameters and trends are reported by Goessens et al. for i.p. administration 
of TIG in which absorption occurs rapidly within the first 30 min, followed by distribution 
around 60-120 min then elimination [33].  TIG reached a peak concentration of 4332.8 ng/mL 
and 376.9 ng/mL at Tmax=30 min and Tmax= 120 min, in plasma and brain respectively.  TIG 
brain concentrations rose gradually up to the Tmax after administration, amounting to 
approximately 10% of the plasma concentrations.  The mean brain-plasma ratio, in terms of 
area under the curve (AUC 0-480), was 0.12.  These results are comparable with the data from 
the studies done on penetration of antibiotics into the CNS where TIG reached CSF 
concentrations of approximately 10% of those found in serum with non-inflamed meninges 
[11, 14].  It is unknown whether these distribution ratios reflect the true extent of brain-to-
blood ratios since the plasma protein binding of TIG was not determined in this experiment 
with rats.  However, in man the plasma protein binding ranges from 71-89%. Therefore there 
is a possibility that brain uptake ratios based on total plasma concentrations underestimates the 
uptake of the unbound drug which is actually available for distribution in the brain [7, 34, 35]. 
Table 4. Plasma and brain concentration of TIG after i.p. administration of 25mg/kg 
Parameters Plasma Brain 
Tmax (min) 30  120    
Cmax (ng/mL) 4333 ± 4.6 377 ± 4.8 
AUC 0-480 (ng x min/mL) 986,666.5 125,043.2 
T ½   (min)                                            140 131 
Values are expressed as mean ± %RSD, n=3 
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Data on brain-to-plasma distribution of TIG are still scarce and only a few studies have 
evaluated penetration of TIG into tissues and CSF.  Drug distribution into the brain is regulated 
by many processes, including plasma pharmacokinetics, plasma protein binding, passive and 
active transport across the blood-brain barrier.  Once the drug penetrates into the brain, bulk-
flow, diffusion, passive and active extra-intracellular exchange take control of its distribution.  
However, Westerhout questioned the usefulness of CSF concentrations as a predictor of brain 
target site concentrations [18].  The study concluded that CSF is only a fluid produced by the 
choroid plexus hence it is not an accurate measure of the actual amount that enters the brain.  
We believe that our study is the first to show the quantification of TIG in brain tissue using 
LC-MS/MS technique.  The data we have acquired show moderate concentrations of the drug 
in the brain which are above most proposed MIC values [15].  Therefore TIG can be considered 
as a potential neuroprotective agent which has an added advantage of overcoming multi-drug 
resistance.  However, other studies suggest that inflamed meninges may facilitate penetration 
of the drug to the brain [12, 14].  Rodvold et al. were the first to describe CSF penetration of 
TIG and they discuss that multiple doses may be needed to allow adequate accumulation of 
TIG into bone and tissue [11, 36].  Recently another study proposed increased dosages of TIG 
for severe infections due to multidrug-resistant bacteria [37].  They concluded that TIG was 
tolerated at a higher than standard dose and therefore further trials with higher and multiple 
doses in an infected model may enable sufficient accumulation of this molecule in the brain.  
Since drug formulation is a vital factor for delivery into the brain, future studies may also 
consider encapsulating the drug into nasal spray or nanoparticles and use this validated method 
to study the pharmacokinetic parameters. 
HPLC has been extensively used for the estimation of TIG in biological samples [11, 13, 24, 
36].  However, relatively few parameters such as mobile phase composition, analysis time, 
reproducibility, detection limit and obtaining a suitable IS have been reported, making it 
difficult for these few methods to be used for widespread applications [24].  Although there is 
a lot of literature reporting sample clean up prior to LC-MS/MS analysis, a few publications 
provide the necessary details [29].  In our study, a clear comparison between two types of SPE 
cartridges (as illustrated in Table S1), a detailed protein precipitation and SPE extraction 
method for lipid preparation from brain tissue samples has been described.  Comparing our 
chromatographic methods with that of Hoffmann et. al which resulted in a total run of 60 min, 
our gradient elution was delivered for 25 min, using a new composition of the mobile phase 
[8].  Precision and accuracy for all analyses were within the acceptable limits, which is in 
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agreement with reported literature and the validation guidelines, hence making this method 
more suitable to measure TIG in brain. 
Conclusion 
 
An accurate HPLC-MS/MS method was optimized and validated for the determination of TIG 
in rat plasma and brain tissues.  Efficient sample preparation was performed for both matrices 
as observed from the mean recoveries of above 82% in all analyses.  The procedure was 
successfully applied to investigate a single dose pharmacokinetic study in female rats.  The 
results in this study showed that the assay is highly reproducible and can be used for 
pharmacokinetic investigations in further clinical studies.  The LC-MS/MS assay reported in 
this work is the first quantitative method for determination of TIG in rat brain tissues.  
However, moderate amounts of this glycylcycline accumulated in the brain compared to the 
tetracycline family of drugs.  Based on the reported data, this method has potential for several 
pharmacological applications and can be adapted to brain and other tissue concentration 
measurements of various new derivatives in the tetracycline family. 
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Abstract 
 
1. The penetration of tetracyclines into the brain has been widely documented.  The aim 
of this work was to develop a matrix assisted laser desorption ionization-mass 
spectrometry imaging (MALDI MSI) method for molecular histology of doxycycline 
(DOX) in the healthy rat brain. 
2. The time dependent distribution was investigated after an i.p. dose of 25mg/kg at 0, 5, 
30, 120, 240, 360 and 480 min post dose.  LC-MS/MS was used to quantify the drug in 
plasma and brain homogenates and MALDI MSI was used to determine the distribution 
of the analyte.  
3. Within the first hour post dose, the drug showed slow accumulation into the plasma and 
brain tissues.  DOX brain concentration gradually increased and reached a peak (Cmax) 
of 1034.9ng/mL at 240 min post dose, resulting in a brain plasma ratio of 31%.  The 
images acquired by MSI matched the quantification results and clearly showed drug 
distribution over the entire rat brain coronal section from 5 min and its slow elimination 
after 360 min post dose.   
4. Our findings confirm that MALDI MSI provides an advanced, label free and faster 
alternative technique for xenobiotic distribution such as DOX in tissues, making it an 
essential drug discovery tool for other possible neuroprotective agents. 
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Introduction  
Studies in the early 1990s showed that tetracyclines display neuro-protective properties in 
rodent models of chronic and acute neurodegeneration [1-3].  These findings resulted in an 
explosion of similar projects showing that tetracyclines, especially the semi-synthetic 
minocycline and DOX, easily cross the blood-brain barrier and hold great potential as 
therapeutic agents for the treatment of bacterial meningitis [4-7].  Both neurological and 
pharmaceutical research requires an understanding of the complex biochemistry of these drugs 
and their interactions in the brain and other tissues at a molecular level.  In the clinical history 
of drug development, several labelled procedures such as basic immunohistochemistry (IHC), 
positron emission tomography (PET), computerized tomography (CT), magnetic resonance 
imaging (MRI) and whole body autoradiography (WBA) have been used to give detailed 
molecular imaging of biological tissues [8-10]. 
Basic histological techniques, IHC, MRI and spatial frequency domain imaging (SFDI) have 
been used in previous studies demonstrating the neuroprotective effects of DOX [7, 11-14].  
Linderberg et al. investigated the effect of pre- and post-natal administration of DOX on 
neuronal recombination.  They found that varying time points of administration yielded 
different recombination patterns as evidenced by a nuclear fast red stain [13].  In a separate 
study, Jantzie et al. showed the putative neuroprotective effects of DOX on hypoxia ischemia 
(HI) using an immunostaining approach [15].  Their work showed that the drug significantly 
decreased caspase-3 immunoreactivity, promoted neuronal survival, inhibited microglial 
activation and reduced reactive astrocytosis in vulnerable brain regions which included the 
hippocampal formation, thalamus, striatum, cerebral cortex and white matter tracts [15].  The 
same research team also used fluoro-jade staining to prove that DOX reduces amino acid levels 
in rat pups when they investigated the effect of drug administration on amino acid and 
neurotransmitter levels [6].  A recent study has used SFDI to detect blood perfusion and 
changes in brain cellular composition by measuring the amount of light reflected by the tissue 
and reduced scattering coefficients.  Immunohistochemical methods were employed to 
determine if removal of DOX from the diet in mice would result in expected trends such as a 
decrease in neuronal cells and an increase in inflammatory microglia and astrocytes.  Removal 
of the drug was associated with progressive loss in forebrain neurons and structural changes in 
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the cortex were quantified by comparing the average optical density of the neuronal staining in 
the cortex [14].   
Biological, fluorometric and high performance liquid chromatography (HPLC) assays have 
also been described for the determination of DOX concentration in standard solutions, body 
fluids and tissues [16].  During the past decade, highly significant technological advancements 
in mass spectrometry have resulted in great advancements in drug discovery, development and 
analysis [17, 18].  We are currently interested in developing new mass spectrometric methods 
and alternative imaging techniques to study the neuroprotective potential of antibiotics and 
their time dependent penetration and distribution in brain tissues [19-21].  Today, MALDI MSI 
is an imaging technique which has gained more attention and is frequently being used in the 
drug development industry as a result of its fast, label-free approach [22-25].  The aim of the 
present study was to develop an MSI method as an alternative for molecular histology of DOX 
by investigating its time dependent penetration and distribution in the brain of healthy rats.   
 
Materials and methods  
Chemicals and reagents 
DOX and the internal standard (IS) minocycline were purchased from DLD Scientific, 
(Durban, South Africa).  Acetonitrile (ACN), formic acid, trifluoroacetic acid (TFA) and 
methanol were of analytical grade all from Sigma–Aldrich (Munich, Germany).  Ultra-pure 
water was obtained using a Milli-Q purification system from Millipore Corporation (Bedford, 
MA, USA).  
Drug Administration and tissue sampling 
All animal experiments were undertaken with the approval of the Institutional Animal Ethical 
Committee of University of KwaZulu-Natal (UKZN), (Approval Reference: 001/15/Animal) 
Durban, South Africa.  Female Sprague Dawley rats (weight 115 ± 20 g) were purchased from 
the Biomedical Resource Unit (BRU) at UKZN.  Animals were housed under standard 
conditions of temperature, humidity and 12 h light/dark cycle with food and water provided ad 
libitum and allowed to acclimatize in the laboratory for one week prior to experiment.  Seven 
groups of female Sprague Dawley rats (n = 3) were administered an i.p. dose (25mg/kg) DOX 
dissolved in a 10% DMSO aqueous solution.  The i.p. doses were chosen based on doses used 
in a previous study of the tetracyclines in brain-to-plasma distribution studies in the rat [26].  
Animals were anaesthetized with halothane before blood and tissue collection.  Blood samples 
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were collected by cardiac puncture into heparinized tubes at 0, 5, 30, 120, 240, 360 and 480 
min after the i.p. dose.  All blood and tissue samples were handled as described in Shobo et al. 
[20].  Blood samples were immediately centrifuged at 3500 rpm for 10 min and aliquots of 
plasma (1.5 mL) immediately stored at -80 °C prior to analysis.  Brains were gently frozen in 
liquid nitrogen vapor before storage in labeled freezer bags at -80 oC.  
 
Quantification in biological samples 
 
LC-MS/MS 
Chromatographic conditions 
Identification and determination of DOX and minocycline was performed using an HPLC 
Agilent Series 1100, with an online degasser, gradient pump and an autosampler coupled to a 
time-of-flight mass spectrometer analyzer (MicrOTOF-Q II, Bruker, Germany).  For each 
analysis, 3 µL of sample solution was injected by an autosampler.  The analytical column was 
a 150 mm × 3.0 mm 3 µm i.d stainless-steel column YMC Triart C18, from YMC Europe Gmbh 
(Dislanken, Germany).  The mobile phase was prepared from Millipore water (0.1% v/v formic 
acid) (A) and 1:3 MeOH: ACN (0.1% v/v formic acid) (B).  The flow rate was 0.4 mL min-1 
and the temperature of the column oven was set at 25 ºC.  The gradient profile was developed 
from 5% to 95% ACN in 15 min, (held 5 min), after which time the mobile phase was returned 
to (5% ACN) in 5 min. 
Mass spectrometry analysis 
Electrospray ionisation (ESI) was used in all analyses.  The optimized conditions were as 
follows: nebulizer pressure: 1.5 bar, dry gas: 8.0 L/min and temperature of dry gas: 200 ºC.  
The profile spectra were acquired in positive mode in the mass range of m/z 150-1600 with 
mass resolving power over 16000.  Data were processed by Data Analysis software (Bruker, 
Germany) and extracted ion chromatograms of all analytes were plotted.  Electrospray 
ionization time-of-flight mass spectrometry (ESI-TOF-MS) parameters were optimized using 
a single variable procedure for all tested parameters of ESI source and mass spectrometer.  The 
best chromatographic conditions were obtained by testing different mobile phases consisting 
of acetonitrile-water and methanol-water in order to provide adequate selectivity in a 
reasonably short separation time.  Modifiers such as ammonium formate, TFA and acetic acid 
were tested.  Due to its high miscibility with organic solvents, formic acid was selected and 
this resulted in improved peak symmetry and ionization efficiency for DOX and IS.   
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The protonated molecular ions, [M+H]+, of DOX and IS observed in full-scan mass spectra 
were m/z 445.2 and 458.2 respectively.  For MS/MS precursor selection the two most intense 
ions were isolated.  The mass spectrometer was operated in positive ion mode using MRM 
mode to monitor the mass transitions.  A set of precursor ion or product pairs was selected and 
monitored in this method.  To quantify the analyte, its most intense transition was chosen.  As 
reported in literature, the MS/MS transitions m/z 445.2→ 428.1 and m/z 458.2 → 441.2 were 
also selected for this analytical assay for DOX and IS respectively [27, 28].  The coupling of 
LC with MS/MS detection whilst monitoring a set of precursor ions/ product pairs resulted in 
high selectivity because only the ions derived from the analytes of interest were monitored.   
Recovery was given as a percentage of the known amount of an analyte carried through the 
sample extraction and processing steps of the method.  Matrix effects was determined by using 
a calculated ratio of the peak area in the presence of matrix (measured by analyzing blank 
matrix spiked after extraction with analyte), to the peak area in absence of matrix (pure solution 
of the analyte) expressed as a percentage.   
 
MALDI-MSI 
 
Sample preparation 
Optimal cutting temperature (OCT) was used as a medium to mount the tissue onto the chuck 
of the cryostat and serial sections (10 µm thick) were obtained from each biopsy and thaw 
mounted onto an indium titanium oxide (ITO) coated glass slide (Bruker, Bremen, Germany) 
with the aid of a cryostat (Leica Microsystems CM1100, Wetzlar, Germany) and stored at −80 
°C until needed for analysis.  Glass slides were removed from cryostat and immediately 
transferred to a desiccator for drying.  Following overnight desiccation time, the slides were 
scanned using a flatbed scanner (HP LaserJet 3055).  Matrix preparation was achieved by using 
7 mg/mL α-cyano-4-hydroxy cinnamic acid (CHCA) (Bruker, Bremen, Germany) matrix 
solution in 50% ACN containing 0.2% TFA.  The matrix solution was sonicated for 5 min and 
transferred to the ImagePrep (Bruker Daltonics), which automatically and consistently deposits 
matrix onto the slide under controlled conditions.  The total thickness of matrix layer deposited 
on all slides determined by the optical sensor was 1.5 V.  The pre-developed Image prep 
method which had 5 phases all included spraying, incubation and drying times respectively.   
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Image Acquisition  
 
All experimental methods were developed according to the guidelines for mass spectrometry 
imaging [29].  Reflectron and LIFT modes for MALDI TOF MS operation, with the aid of 
Autoflex III MALDI TOF/TOF 1 KHz smartbeam laser (Bruker Daltonics, Germany) and data 
acquired using FlexControl (version 3.4, build 119) software in positive ion mode.  Calibration 
of the instrument was done using DOX with CHCA as the matrix on the ground steel target 
(Bruker Daltonics, Germany) for m/z 200–600.  Spatial resolution from 100 µm was used for 
the MALDI imaging of the tissue sections and the images were analyzed using the software 
FlexImaging 3.0 (Bruker Daltonics, Germany).  Spotting various concentrations (10, 100, 200 
and 300 ng/mL respectively) of DOX with the matrix onto a brain section of an untreated 
animal was used to evaluate background signals that may interfere with the analyte and to 
determine a limit of detection.  The spots were analyzed in reflectron mode by collecting 200 
shots per spot and spectra collected.  To perform the MS/MS experiments, a LIFT method was 
optimized for the drug by specific tuning of the timing of the LIFT cell and of the parent ion 
selector.   
Using the same method, MS/MS was performed directly on DOX-matrix spotted tissue section 
and spectra were compared to the MS/MS spectra generated from that of the drug standard 
only.  For the initial analysis of the manually deposited spots, spectra consisting of 1000 laser 
shots were acquired in bundles of 5 x 200 shots and data was collected in the range between 
m/z 200–600 with a laser frequency of 200 Hz, mass window range of 2 Da and the 
digitalization rate was 2 GS/s.  Laser power of 60% was used and an increase in the laser power 
led to production of other product ions but with less sensitivity.  The software Flex Imaging 
3.0 build 54 was used to set up the acquisition of the imaging experiments.  Using the same 
m/z range given above, MS imaging experiments were performed by collecting spectra with a 
raster width of 100 µm.  The spectra were baseline subtracted (Convex hull) and smoothed 
(Savitzski golay) in the processing software during acquisition.  In LIFT mode, all spectra were 
normalized against total ion count (TIC) to reduce influences by matrix hot spots.  We define 
the total ion count as the sum of all intensities in the mass range analyzed.  For this analysis, 
both fragment and parent spectra were acquired from each spot and 500 laser shots were 
summed up in a random walk pattern from each position.   
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Application to a Pharmacokinetic Study  
 
Maximum concentration (Cmax) of DOX and time taken to reach Cmax (Tmax) were determined 
directly from the rat plasma and brain concentration-time curves.  All the other 
pharmacokinetic parameters were determined using non-compartmental analysis (STATA 
13.0).  The area under the curve (AUC0→480 min) was calculated by the linear trapezoidal rule. 
Results and Discussion 
 
HPLC-MS/MS Analysis 
After adequate optimization of the chromatographic separation conditions, a reproducible 
separation of DOX from plasma and brain homogenates was achieved. Figure 5.shows the 
proposed structural characterization of DOX for the peaks observed by LC-MS/MS.  Retention 
times for DOX and IS were 11.5 and 8.6 min respectively. Figure 6 (a) represents typical 
extracted ion chromatograms of blank plasma and brain homogenates and Figure 6 (b) blank 
plasma and brain spiked with DOX and IS at LLOQ level.   
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Figure 5. MS/MS transition of DOX as acquired on the liquid chromatography-quadrupole 
time of flight mass spectrometer 
Typical linear regression equations of the calibration curves for different matrices were 
y=1.364861 x + -0.099180 and y=0.342497 x + -0.0079773 (where y was the peak area ratio 
of the analyte to the internal standard and x the concentration of the analyte), while the mean 
regression coefficients of the calibration curves were 0.998 and 0.997 in plasma and brain 
homogenates, respectively.   
 
Figure 6. Representative LC – MS/MS extracted ion chromatograms for m/z 428.1obtained 
from (a) blank matrix, (b) low QC plasma sample containing 300ng DOX and 500ng IS. 
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Calibration curves of DOX were established and were linear over a concentration range of 300-
2000 ng/mL for plasma and 150-1200ng/mL for brain tissue and the results are illustrated in 
Figures S3 and S4.  The limit of detection (LOD), calculated using a signal to noise ratio of 
3:1, was 100ng/mL for plasma and 50 ng/mL for brain.  High mean recoveries: 88% and 85% 
in plasma and brain homogenates respectively, were obtained from the optimized protein 
precipitation and SPE method.  Low interferences were also obtained and therefore it was 
concluded that efficient optimization had been done and the method could be used reliably 
throughout further analyses in experimental samples.  The matrix effects data indicated that 
there was no significant ion suppression/enhancement observed at the retention time of the 
analyte and IS.  All the results for recoveries and matrix effects are summarized in Table.   
 
Table 5. Recoveries and matrix effects of Doxycycline in different biological samples. 
Concentration level aMean 
recovery(%) 
%RSD aMatrix effect 
(%) 
%RSD 
(ng/mL)     
Plasma     
LQC 
 
 
ISII 
80.1 3.2 92.7 3.1 
MQC 81.9 2.5 95.3 2.2 
HQC 83.3 1.7 94.8 1.4 
Brain     
LQC 81.4 2.3 92.7 3.9 
MQC 82.5 1.9 91.2 2.6 
HQC          80.8           2.7 95.7 1.7 
RSD relative standard deviation   (a n=6) 
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To determine the suitability and effectiveness of this bioanalytical method for drug 
developmental pharmacokinetic studies, it was used for the quantification of DOX in plasma 
and brain after i.p. administration of a single dose (25mg/kg) to female Sprague Dawley rats.  
The plasma and brain concentration-time curves are shown in Figure 7.  Within the first hour 
after i.p. administration, DOX was slowly distributed into the plasma and brain tissues.  At t = 
120 min in plasma, DOX reached a peak concentration of 4535.1 ng/mL (Cmax).  This observed 
Tmax was in accordance with that in other studies in which DOX was administered 
intraperitoneally in mice or orally in ducks and in man [3, 16, 30].  Previous pharmacokinetic 
studies reported that DOX plasma concentrations of the same dose peaked at the same time 
despite the route of administration.   
 
Figure 7. Mean plasma and brain concentration-time profiles for DOX after i.p. 
administration of a single dose of 25mg/kg to healthy female rats (mean ± SD, n=3). 
It was concluded that parenteral administration routes (i.e. intravenous and i.p.), resulted in 
higher peak plasma concentrations at the same Tmax compared to the antibiotic being 
administered orally at the same dose [16].  All the pharmacokinetic parameters estimated in 
this study are summarized in Table 6. 
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Table 6. Pharmacokinetic data of DOX after i.p. administration of 25 mg/kg 
Parameters Plasma Brain 
Tmax (min) 120 240 
Cmax (ng/mL) 4535.1 ± 5.3 1034.9 ± 8.7 
AUC 0-480 (ng x min/mL) 1 581 371.0 370 186.2 
Values are expressed as mean ± SD, n=3 
The plasma curve displayed a double-peak phenomenon, which is a common characteristic of 
DOX and was also reported in fish, pigs, sheep and humans, with enterohepatic recirculation 
being the reason for the second peak in the concentration vs time curve [30-32].  Fagan et al. 
also reported a double peak phenomenon for i.p. administration of a similar tetracycline, 
minocycline, in which the drug was erratically absorbed and deposited in the peritoneal cavity 
[3].  Once the antibiotic is in the peritoneal cavity, it acts as ‘depot’ injection, slowly releasing 
the drug into the circulation system, usually peaking around 240 min after administration, 
which explains the second peak in our plasma concentration time curve [3].   
 
Brain Distribution Studies 
DOX brain concentrations rose gradually and reached a peak level (Cmax) of 1034.9ng/mL at a 
Tmax of 240 min after i.p. administration, resulting in approximately 31% of the plasma 
concentrations.  This was in close agreement with the preliminary studies by Colovic and 
Caccia which reported a DOX mean brain-plasma ratio of 0.31 at t = 240 min after 25mg/kg 
intravenous injection [26].  Early studies of DOX pharmacology and toxicology concluded that 
peak tissue concentrations were obtained slightly after peak plasma concentrations, within 120 
to 240 min post oral or i.p. administration in rats [14, 33].  Once the Cmax was reached, DOX 
depletion in the brain tissue was seen from the slow decrease in concentrations after 240 min 
as shown on the concentration time curve.  The mean brain-plasma ratio, in terms of area under 
the curve (AUC 0-480min), was 0.24, which implied that approximately a quarter of the total drug 
concentration in plasma managed to cross the blood-brain barrier  and entered the brain.  This 
result can also be explained by the fact that free DOX makes up only a small fraction of the 
total drug amount in the body due to the drug’s high lipophilicity and high protein binding 
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capacity (82-93%) [16, 34].  The levels of DOX reported in our rat brain quantification assay 
were closely related to the findings in a previous study which reported mean drug levels of 
867.1 ng/mL in brain tissue after a single 10mg/kg i.p. administration of DOX [6].  However, 
our data reported a higher mean Cmax, which could be attributed to the higher dose and a more 
sensitive MS detection in our current study as compared to UV.  Based on previous dose-
response studies performed by Jantzie et al., DOX reached a therapeutic dose when 10 mg/kg 
of the drug was administered intraperitoneally [15].  Although DOX has been reported to have 
higher minimum inhibitory concentrations (MICs) [35], our quantification data reported a 
mean Cmax which is above the MICs of most common bacteria which might cause meningeal 
infections [36].   
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MALDI-MS Imaging  
 
Figure 8. Typical spectrum of DOX parent and fragments, during the acquisition of data on 
the spotted rat brain section using the LIFT mode in the MALDI-MSI technique 
After method optimization of the MALDI-MSI experiment for DOX, reproducible analyses 
were obtained from the spotted tissue.  The DOX parent ion of m/z 445.4 and fragment with 
m/z 428.1 were used to visualize the distribution of the drug in the brain sections in triplicate 
on each slide.  This transition was chosen for the MSI assay because during the method 
development and optimization in the LIFT mode, the m/z 428 had the highest intensity (as 
shown in Figure 8).  The same transition was used in our LC-MS/MS quantification study and 
in literature [27, 28].  An increase in the laser power led to production of other product ions 
but with lower sensitivity.  The result of the limit of detection which was calculated using a 
signal to noise ratio of ≥3 reported a value of 100 ng/mL (as shown in Figure 9). 
The images showed widespread distribution of DOX in the entire rat brain, with the highest 
concentration in the cerebral cortex (as shown in Figure 9).  The antibiotic was readily detected 
at 5 min after administration as indicated by the high colour intensities observed in the brain 
sections, mainly in the cortex and hippocampal formation.  The intensity increased with time, 
which showed the penetration and accumulation of the drug into the brain.  This trend was also 
observed when analysing the LC-MS/MS quantification data in the brain.   
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Figure 9. Haemotoxylin and Eosin (H and E) stain (top left) and spots of standard solutions 
(10, 100, 200, and 300 ng/mL) of DOX with the matrix on a brain section for the 
determination of limit of detection (top right). 
Coronal brain images displayed were acquired from 0 min to 480 min after intraperitoneal 
administration of DOX (25mg/kg) to rats, using LIFT mode with both parent and fragments 
simultaneously (data represents mean values, n=3).  Mass filter applied was m/z 428 ± 0.1% 
represented by the rainbow colour scale bar, these data represents mean ± standard deviation 
(SD).  Images 5 to 240 min displayed entry and distribution of DOX into the coronal (C) and 
hippocampal (H)section of the rat brain and 360 to 480 min the gradual elimination of the drug 
from the tissues.  C = Cortex, H = Hippocampal formation. 
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At 360 min the highest intensity can be observed in the peripheral cortex, which suggested that 
the drug was slowly beginning to localize in the cortical region.  The designed MSI technique 
allowed us to track the distribution of DOX in cerebral tissue over time after i.p. administration.  
Significant elimination of the drug was only seen in the images of the brain tissue sections from 
360 to 480 min, which indicated that the drug persisted in the tissue over significant time before 
it was eliminated.  This was expected and was consistent with other studies which reported that 
a single injection of this antibiotic had a long half-life of about 12-24 hours [16, 34].   
The major findings of MRI and histological studies in which DOX was administered to rats 
with induced brain injury reported a higher density and concentration of the drug in areas where 
injury was induced, thus the drug significantly reduced brain injury and inhibited neuro-
inflammation [11, 12, 37].  In another study using an immunohistochemistry approach, the 
neuroprotective properties of DOX were examined and it was discovered that the drug 
localized in the hippocampus, thalamus cerebral cortex, striatum, and subcortical and peri-
ventricular white matter of the brain [15].  These regions constitute a larger area of the brain 
and can therefore be correlated with our findings that showed the drug was readily detected in 
the entire brain.  However these studies do not show the exact location of DOX since they use 
the brain injury as a marker for the presence of the drug.  This could lead to false conclusions 
since it is possible that improvements in injury are caused by the DOX-induced release of 
neurotransmitters and other factors which may be responsible for this.  The advantage of using 
MALDI MSI is that we are able to identify the presence of the drug by looking for parent and 
fragment masses, making this a more reliable, sensitive and accurate technique. 
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Conclusion 
 
The MSI technique as a new method for molecular histology was successfully applied for the 
investigation of the time dependent penetration and distribution of DOX administered by i.p. 
injection in the brain of healthy rats, adding to its success as a neuroprotective agent.  The 
quantification data and images were in agreement with previous studies, which reported the 
neuroprotective properties of DOX.  These encouraging results suggest great potential 
applicability of the MALDI MSI technique for the direct analysis of tetracyclines, and other 
possible neuroprotective agents, making it an essential drug discovery tool with respect to 
histology.  Using DOX as an example, it is clear that these techniques can be easily optimized 
for use and detection of known and developmental drugs.   
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Abstract 
 
Fluoroquinolones are broad-spectrum antibiotics with efficacy against a wide range of 
pathogenic microbes associated with respiratory and meningeal infections.  The potential 
toxicity of this class of chemical agents is a source of major concern and it is becoming a 
global issue.  The aim of this study was to develop a method for the brain distribution and 
the pharmacokinetic profile of gatifloxacin in healthy Sprague-Dawley rats, via MALDI 
MSI and quantitative LC-MS/MS.  
We developed a sensitive LC-MS/MS method to quantify gatifloxacin in plasma, lung and 
brain homogenates.  A pharmacokinetic profile was observed where there is a double peak 
pattern; a sharp initial increase in the concentration soon after dosing followed by a steady 
decline until another increase in concentration after a longer period post dosing in all the 
three biological samples was observed.  The imaging results showed the drug gradually 
entering the brain via the blood brain barrier and into the cortical regions from 15-240 min 
post dose.  As time elapses the drug leaves the brain following the same path as it followed 
on its entry and finally concentrates at the cortex.   
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Introduction 
 
Fluoroquinolones are a promising class of antibiotic with a broad spectrum of bactericidal 
activities [1, 2].  It is well established that these chemical agents have side effects such as 
dizziness, restlessness, insomnia, tremor, hallucination, depression, anxiety and convulsion 
[3-5].  In 2013, the United States Food and Drug Administration (FDA) warned that this 
group of drugs may cause permanent peripheral neuropathy [6].  Neurotoxicity is 
dependent on the penetration of drugs into the blood brain barrier (BBB), and this feature 
protects the central nervous system (CNS) from neurotoxic substances circulating in the 
blood [7].  
 
Few studies had attempted the use of positron emission tomography (PET) to quantify and 
localize fluoroquinolones in vivo [8-13] but they had either failed to report the 
concentration or show convincing localization of this class of antibiotics in the brain of the 
models they had worked on.  This is mostly because the lipophilic properties of the 
compound might have been altered due to the attachment of a radioactive group on the 
analyte [14] or the method lacks sensitivity.  [18F] ciprofloxacin had earlier been shown not 
to penetrate the BBB in human subjects [8] and consequently could not be quantified using 
this technique, however labeled ciprofloxacin had earlier been quantified in rat brains using 
high performance liquid chromatography (HPLC)-spectrophotometry technique [15].  
Unlabeled ciprofloxacin had initially been quantified and shown in rats to instantaneously 
penetrate the BBB using the HPLC technique, with obtained values higher than that in the 
cerebrospinal fluid (CSF) [16].  [18F] trovafloxacin and [18F] fleroxacin on the other hand 
had been quantified in the brain using PET, however, low concentrations and non-definitive 
images were reported in animal and human subjects [9, 10, 17, 18].   
 
It is therefore necessary to study the amount of drug directly in the brain using a more 
sensitive technique as a true measure of its neurotoxicity.  The choice of gatifloxacin (GAT) 
in our study was based on the earlier warning issued by the FDA on the neurotoxic potential 
of this class of drug [6].  In addition, GAT is in the forefront of the tuberculosis (TB) 
pipeline and it is currently not in use for multi-drug regimen. 
 
Traditionally, radiolabelled drugs have been employed for imaging in drug distribution 
studies by magnetic resonance imaging (MRI), autoradiography, X-ray computerized 
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tomography (CT), and PET [19].  However, these methods are expensive and only show 
total drug-related materials [20].  Matrix assisted laser desorption ionization mass 
spectrometry imaging (MALDI MSI) is a label free technique, which offers the advantage 
of determining the distribution of parent drug and metabolites simultaneously [21-24].  We 
have recently shown that combination of Liquid chromatography tandem mass 
spectrometry (LC-MS/MS) with MALDI MSI provides better correlation than PET 
imaging technique [25-28].  The aim of this study was to establish methods for the 
preclinical evaluation and localization of fluoroquinolones in the rat brain by using LC-
MS/MS and MALDI MSI as sensitive tools for its determination.  
 
Materials and Methods  
 
Animals 
All animal experiments were undertaken with the approval of the Institutional Animal 
Ethical Committee of University of KwaZulu-Natal (UKZN), Durban (Ethics number: 
006/15/Animal) and adequate measures were taken to minimize pain or discomfort.  
Healthy female Sprague-Dawley rats with average weight of 135 ± 20 g were housed in 
polycarbonate cages in air-conditioned rooms (50-70% humidity and between 21-24oC) 
with a 12 hr light/dark cycle.  Animals were allowed ad libitum access to drinking water 
and standard rat chow.  
 
Drug Administration and tissue sampling 
Animals were dosed with GAT (DLD Scientific, South Africa) at 10 mg/kg prepared in 
10% DMSO and 90% ultrapure water, this dose was calculated based on the average body 
weight of the animals.  GAT was administered intraperitoneally (i.p.) to 9 groups of animals 
(n=3).  Animals were anaesthetized with halothane before blood was collected by cardiac 
puncture at 0, 15, 30, 60, 90, 120, 150, 180, 240 min post GAT administration in 
heparinized tubes.  Blood samples were immediately centrifuged at 3500 rpm for 10 min 
and aliquots of plasma (1.5 mL) were immediately stored at -20o C prior to analysis. 
 
Dissection and storage  
The rats were euthanized with halothane and termination was confirmed by the absence of 
breathing and dissection was performed immediately.  The lungs and brains were surgically 
removed and snap frozen in liquid nitrogen vapor prior to storage at -80oC.  
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Sample preparation for MALDI MSI 
Serial sections (10 µm thick) from the mid brain of the same animal were sectioned from 
each biopsy thaw mounted onto an indium titanium oxide (ITO) coated glass slide (Bruker, 
Bremen, Germany) with a cryostat (Leica Microsystems CM1100, Wetzlar, Germany) 
using optimum cutting temperature (OCT) embedding medium and stored at -80 °C until 
analysis.  Glass slides were removed from deep freeze and immediately transferred to a 
desiccator.  Following 30 min desiccation time, the slides were scanned using a flatbed 
scanner (HP LaserJet 3055).  The α-cyano-4-hydroxy cinnamic acid (CHCA) matrix (7 
mg/mL) was prepared in 50% acetonitrile (ACN) containing 0.2% trifluoroacetic acid 
(TFA).  The matrix solution was sonicated for 5 min and centrifuged at 10,000 rpm for 10 
min before transfer to the ImagePrep (Bruker Daltonics).  This is a spraying device that 
automatically deposits matrix solution onto the tissue in a consistent manner.  In short, 
aerosol is generated by vibrating spray generator producing tiny droplets (average droplet 
size of ≈20 µm) under controlled conditions.  
 
MALDI MSI Analysis 
A standard solution of GAT was analyzed using matrix assisted laser desorption ionization 
time of flight mass spectrometry (MALDI TOF MS) operated both at reflectron and 
MALDI MS/MS (LIFT) modes respectively with the aid of the Autoflex III MALDI 
TOF/TOF 1 KHz smartbeam laser (Bruker Daltonics, Germany) and FlexControl 
acquisition software ran in positive ion mode.  The instrument was calibrated using 
standard peptide mix, which included arginine, alanine spotted with CHCA matrix on the 
ground steel target (Bruker Daltonics, Germany) for m/z 200-700.  Each spectrum was 
acquired from 200 laser shots.  Tissue sections were imaged with spatial resolution from 
25-100 µm.  The MALDI images were displayed using the software FlexImaging 3.0 
(Bruker Daltonics, Germany).  Spotting different concentrations (0.5, 1, 5, 10, 100 and 500 
ng/mL respectively) of GAT with the matrix onto a brain section of an untreated animal 
was used to evaluate background signals interfering with the analyte.  The drug was mixed 
(1:2) with matrix solution and the different concentrations of GAT spotted on the tissue in 
a total volume of 3 µL.  The spots were analyzed in reflectron mode by collecting 200 shots 
per spot.  The LIFT experiments were performed using a method optimized for the drug by 
specific tuning of the timing of the LIFT cell and of the precursor ion selector.  The LIFT 
method was calibrated with peptide calibration standards and also a standard solution of 
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GAT as mentioned above.  The same method was used to perform MS/MS directly on 
GAT-matrix spotted tissue section and spectra were compared to the MS/MS spectra 
generated from the drug standard only. Spotting various concentrations (5, 10, 100, 250 
and 500 ng/mL respectively) of GAT with the matrix onto a brain section of an untreated 
animal was used to evaluate background signals that may interfere with the analyte and to 
determine limit of detection (LOD).  For the initial analysis of the manually deposited spots, 
spectra consisting of 1000 laser shots were acquired in bundles of 5 x 200 shots and data 
was collected in the range between m/z 200-700.  A product ion scan of the protonated 
precursor ions (m/z 376) revealed a clear fragmentation pattern with the transition m/z 376 
→ 358	dominating the spectra with a laser power of 60%.  An increase in the laser power 
led to production of other product ions but with less sensitivity.  The software Flex Imaging 
3.0 was used to set up the acquisition of the imaging experiments.  The imaging MS/MS 
experiments were performed by collecting spectra with a raster width of 100 µm in the 
same m/z range as above.  The spectra were baseline subtracted (Convex hull) and 
smoothed (Savitzski Golay) in the processing software during acquisition.  In LIFT mode, 
all spectra were normalized against total ion count (TIC) to reduce potential suppression 
by matrix hot spots.  We define the total ion count as the sum of all intensities in the mass 
range analyzed.  For this analysis, both fragment and parent spectra were acquired from 
each spot and 500 laser shots were summed up in a random walk pattern from each position.  
The product ion, m/z 358 from the transition m/z 376 > m/z 358 was used to visualize the 
distribution of GAT in the brain sections in triplicate. 
 
Analytical method 
The HPLC system was coupled to an AmaZon ion trap (IT) equipped with ESI ion source 
from Bruker Daltonics (Bremen, Germany) operated in the ultrascan mode.  The HPLC 
system was a Dionex Ultimate 3000, consisting of a binary pump, connected to an 
autosampler equipped with a 20 µL injection loop and the temperature of the column was 
maintained at 25°C.  The analytical column was a 150 mm × 3.0 mm (internal diameter) 
stainless-steel column YMC Triart C18, 3 µm from YMC Europe Gmbh (Dislanken, 
Germany).  The flow rate was 0.4 mL min-1.  The mobile phases were Milli-Q water (0.1% 
v/v formic acid) and ACN (0.1% v/v formic acid).  The gradient profile was gradually 
increased from 10% to 40% ACN in 7 min, then in next 3 min increased to 90% ACN (held 
2 min), after which time the mobile phase was returned to the initial conditions (10% ACN) 
in 3 min. 
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The MS was operated in the electrospray ionization (ESI) positive mode and auto MSn 
spectra collection was applied.  The MS settings were as follows: capillary outlet 5500 V, 
end plate voltage 500 V.  Nebulizer was set to 1.5 bar and desolvation gas temperature was 
210°C at a flow-rate of 8 L/min.  Positive ion mode MS spectra were obtained within a 
mass range of m/z 100-1200.  Smart parameter setting (SPS) was set to m/z 376.1.  The ion 
charge control (ICC) was set to 200000 with a maximum accumulation time of 200 ms.  
Operation of the collision induced dissociation was performed using helium as collision 
gas.  The MRM settings were as follows: isolation width for GAT was set at 4.0 and 
percentage amplification was set at 0.5% while for the internal standard (ciprofloxacin), 
the isolation width was set at 5.0 and the percentage amplification was set at 2%.  Collision 
energy - enhanced fragmentation mode ramping from 60-180%, fragmentation time 40 ms, 
isolation width m/z 4.  For MS/MS precursor selection, the most intense ions were isolated.  
The transitions were chosen to be m/z 376.1 → 332.1 for GAT, m/z 332.0 → 288.0 for the 
internal standard (IS).  All results were stored and analysed with Data Analysis 4.0 SP 5 
(Bruker Daltonics) and Quant analysis. 
 
Preparation of the samples 
The extraction and quantification of GAT were done as described previously, with minor 
modifications [29-31].  Control tissues stored at -80oC to be used as matrix for calibration 
were homogenized in 3 mL of water for every 1g of tissue with a manual tissue 
homogenizer.  Gatifloxacin concentration was measured using LC-MS/MS after protein 
precipitation with a 100% methanol (9:1) for plasma, 4:1 for brain homogenate, and 3.33:1 
for lung homogenate respectively.  This was followed by centrifugation at 15,000 rpm for 
10 min (4oC) and supernatants were filtered through Supel-select 30 mg HLB, Discovery 
DSC-18 (50 mg) and Discovery DSC-18 (100 mg) cartridges.  The extraction recoveries of 
GAT were performed on three quality control samples (QC) for each level (low, medium 
and high) and assayed in three replicates.  Recoveries of the GAT were calculated by 
comparing its peak area in the processed biological samples with the corresponding peak 
area acquired from an aqueous solution at the same concentration.  Plasma and lung 
homogenate had 30, 600 and 900 ng/mL as concentrations of their QC samples while the 
brain homogenate had 3, 25 and 35 ng/mL as QC samples.  Calibration curves were drawn 
for individual matrices using the optimized method of extraction.  
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Data analysis 
Pharmacokinetic parameters were calculated via trapezoidal rule using Stata software 
(version 13.0).  And other statistical calculations like mean and standard deviation were 
determined by analyzing the individual rat plasma profiles using non-compartmental 
equations in Microsoft Excel. 
 
Results and discussion 
 
We developed an LC-MS/MS method to quantify the amount of GAT in the plasma, lung 
and brain, with a relatively short run time of 15 min.  And since there is no single report on 
the measurement of the concentration of GAT in rat brain homogenate using this technique, 
it would be essential to create an effective and valid quantitative method for the 
determination of this drug in this tissue.  The retention times for internal standard 
(ciprofloxacin) and GAT were 7.5 and 8.3 min respectively as shown in Figure 1.  The 
LC-MS/MS method demonstrated good sensitivity with a LOD for the analyte in plasma, 
lung and brain homogenates of 0.5ng/mL.  The LOD was evaluated as the lowest 
concentration that gave a signal-to-noise ratio of three for the analyte while the LLOQ was 
determined in six replicates based on the criterion that the analyte response at LLOQ is at 
least five times baseline noise and it was within the acceptable limit of accuracy and 
precision of between 80–120% of nominal concentration for accuracy and not exceeding 
20% relative standard deviation (%RSD) respectively.  The limit of quantification was 10 
ng/mL for both plasma and lung while the brain homogenate had 1 ng/mL.  The calibration 
curves were linear with at least 0.996 mean regression value in each case, a linear range of 
10-1200 ng/mL for both plasma and lung samples and 1-50ng/mL for brain homogenates 
was obtained.  The extraction method for the analyte and internal standard from the 
matrices proved to be efficient with mean recoveries of at least 90% as shown in Table 1.  
The suitability of this method was validated by its use for the quantification of the analytes 
in the biological samples.  
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Figure 1. Extracted ion chromatogram and mass spectra of ciprofloxacin (m/z 
332.0→288.0) and GAT (m/z 376.1→332.1) respectively. 
 
 
Plasma concentration-, lung concentration- and brain concentration-time curves of GAT 
are shown in Figure 2. while the relevant pharmacokinetic parameters, including Tmax, 
Cmax, elimination rate (Ke) and AUC0→240, are listed in Table 2.    
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Table 1: Recoveries of GAT in different biological sample 
 
 
 
 
 
 
 
 
 
 
 
 
*RSD= Relative standard deviation 
 
 
 
 
 
 
 
 
 
 
Concentration 
level 
Mean recovery 
(%) 
%RSD 
Plasma   
LQC 93.3 5.7 
MQC 91.6 6.0 
HQC 90.5 4.2 
Lungs   
LQC 92.1 4.6 
MQC 90.7 3.1 
HQC 90.1 3.9 
Brain   
LQC 93.9 4.2 
MQC 92.2 3.2 
HQC 92.0 3.1 
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Figure 2. Mean brain concentration-time profile of gatifloxacin (n=3) and the data were 
obtained using LC/MS.  Coronal brain images from 0 min to 240 min after intraperitoneal 
administration of GAT (50 mg/kg) to rats, acquired using LIFT mode with a mass window 
of m/z 358 ± 0.1% for its visualization.  These data represents mean ± standard deviation 
(SD) respectively of time points 0 min to 240 min.  The H&E stained coronal brain section 
is located in the middle of the brain images (C= cortex; H= hippocampus).  
 
 
In plasma, maximum GAT concentration (Cmax) obtained was 659.15ng/mL approximately 
30 min (Tmax) after dosing.  However, in the lung, the Cmax was 5277.16ng/mL 15 min post-
dose.  Similar trends were observed in the curves for the three matrices, where there were 
steady initial increases in drug concentrations followed by a gradual decrease with a distinct 
peak observed at 150 min after the Cmax in all the three matrices before lowest 
concentrations were reached at 240 min, and is similar to an earlier study [32].  The Cmax 
observed in the brain homogenate (228.48ng/mL) was about one third that observed in the 
plasma and was in accordance with earlier reports [33-36].  This value is above the MIC90 
(0.125µg/mL) obtained against pneumococcal meningitis [37].  
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Table 2. Quantitative analysis (LC-MS/MS) of GAT in plasma, lung and brain 
homogenates 
 
Parameters Plasma 
(ng/mL) 
Lung 
(ng/mL) 
Brain 
(ng/mL) 
15 min 612.81±77.04 5277.16±70.16 214.45±2.58 
30 min 659.15±49.76 3410.76±23.99 228.48±1.51 
60 min 360.29±49.76 1887.33±71.76 208.43±2.82 
90 min 105.17±13.6 729.28±49.88 110.04±1.00 
120 min 121.13±9.58 770.51±44.04 110.89±1.11 
150 min 163.15±5.12 1466.31±24.54 143.09±1.80 
180 min 39.46±13.86 295.77±36.13 63.66±0.97 
240 min 23.43±1.64 132.47±13.61 13.24±0.28 
Tmax (min) 30 15 30 
Cmax (ng/mL) 659.15±49.76 5277.16±70.16 228.48±1.51 
AUC0→∞ (ng x 
min/mL) 
48,993.83 318,786.50 28,794.03 
T½ (min) 60 40       90    
Ke 0.0197 0.0248            0.0264    
*Values are expressed as mean ± S.D of samples taken from the three animals except the 
brain samples, ran at three different days 
 
Brain and CSF penetration of between 15-50% of plasma concentration had earlier been 
observed for GAT after a loading dose of 15.60mg/kg and subsequent maintenance doses 
of 3.35mg/kg/h intravenously for 4 hours to healthy Wistar rats [37, 38] and our findings 
(approx. 35%) were within the acclaimed range.  The developed MALDI MSI method had 
a transition of m/z 376 > m/z 358 and was chosen for the MSI assay because during the 
method development and optimization in the LIFT mode, the m/z 358 had the highest 
intensity as shown in Figure 3.  An increase in the laser power led to production of other 
product ions but with lower sensitivity.  The method had a LOD of 10 ng/mL with a signal 
to noise ratio of at least 3:1.  Image representatives of the MSI investigations for serial 
brain coronal sections from the same animal analyzed in triplicate are shown with drug 
mean concentration-time profile in Figure 2 from 0-240 min time points.  Characteristic 
spectra obtained in the MSI study are in Figure 3, which revealed the chosen transition.  
Typical reproducible serial coronal sections from the mid-brain of the same animal 
analyzed in triplicate is shown in Figure 4.  
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Figure 3. Typical spectra obtained during the optimization of the MALDI MSI study. 
 
 
 
 
 
 
Figure 4. Typical reproducible images obtained for the imaging of three serial coronal 
sections from the mid-brain of the same animal. 
 
The imaging results showed localization of GAT across all the time points in the cortical 
regions.  The images revealed the initial rapid penetration of the drug via the cerebral 
capillary network of the BBB into the cortical regions of the rat brain at 15 min and 30 min.  
The drug enters the brain via the endothelial tight junctions of the cerebral capillary 
network whose entry point is found adjacent to the superior sagitial sinus [7].  This is 
responsible for the distribution pattern observed at 30 min, where the drug can be seen 
concentrated at the cortical region.  Images acquired at 60 and 90 min showed a diffusion 
of the drug into the hippocampus area of the brain section and remained at both regions 
until 120 min post-dose.  Thereafter, the drug completely localized at the cortex of the brain 
as shown in the images for time points 120-240 min.  Our study has shown the transport of 
GAT through the BBB using MALDI MSI and this has not been previously demonstrated 
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in other studies of fluoroquinolone transport in the brain [33, 38-41].  Ooie et al [38] 
investigated the penetration of GAT through the BBB of dogs and rats.  Their findings 
observed no significant difference in GAT concentration between the cortex and 
cerebellum in both animals [38].  However, this does not deviate from the results of our 
imaging studies as shown in the localization of the drug in cortical regions of the coronal 
brain images.  Our findings have also been validated by another study that involved the 
quantitative brain microdialysis on the mechanism of quinolones distribution in the central 
nervous system which assumed that an efflux transport system for quinolones at the BBB 
might be responsible for the restricted distribution of this class of drugs in the brain [33, 
39].  The results obtained in this study was in agreement with the investigation of Lui et al, 
they studied the uptake of GAT and other fluoroquinolones by assessing BBB penetration 
invitro and in rats [39], their findings also confirmed that GAT penetrated the BBB as 
reported.  As presented in our results, the presence of this drug in the brain was supported 
in a recent study [40] aimed to ascertain the effect of oral single dose of GAT in male albino 
rat on the concentrations of amino acid monoamine neurotransmitters and 
acetylecholinesterase activities in the frontal cortex and hippocampus brain areas, they 
noted elevations in monoamine level in the hippocampus and reduction in the dopamine 
level with such increase translated to a susceptibility to seizures [40, 42] and this seizure 
inducing activity has previously been reported [33, 43-45] as a side effect.  A reduction in 
the serotonin level in the prefrontal cortex was also reported [40, 45], a finding which 
supplement as a symptom of depression [46, 47] caused by penetration of the drug through 
the BBB.  
 
The known penetration and localization of GAT in the rat brain supplements our findings 
and that of others, it further confirms the penetration of the therapeutic agent through the 
blood brain barrier and hence its localization while strengthening the use of MALDI MSI 
as a valuable tool for drug mapping in biological tissues.  
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Conclusion 
 
This study has shown that LC-MS/MS and MALDI MSI can be used as complementary 
methods when investigating drug distribution in the brain for preclinical applications.  
MALDI MSI has provided adequate and distinct information on the distribution of a 
fluoroquinolone in normal rat brain tissues.  For the first time, MALDI MSI has shown the 
penetration of GAT through the BBB and has proven to be a relatively informative method.  
The utilization of this model has shown that GAT penetrates the healthy brain tissues and 
its distribution in particular regions of the brain.   
 
Conflict of interest 
 
Authors declare no conflict of interest with the information contained in this work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
148 
References 
 
1. Soni, K., Fluoroquinolones: chemistry & action—a review. Indo Glob J Pharm Sci, 
2012. 2: p. 43-53. 
2. Somasundaram, S. and K. Manivannan, An overview of fluoroquinolones. Annual 
Review & Research in Biology, 2013. 3(3): p. 296-313. 
3. Akahane, K., M. Kato, and S. Takayama, Involvement of inhibitory and excitatory 
neurotransmitters in levofloxacin-and ciprofloxacin-induced convulsions in mice. 
Antimicrobial agents and chemotherapy, 1993. 37(9): p. 1764-1770. 
4. De Sarro, A., et al., Effects of novel 6-desfluoroquinolones and classic quinolones on 
pentylenetetrazole-induced seizures in mice. Antimicrobial agents and chemotherapy, 
1999. 43(7): p. 1729-1736. 
5. Sarro, A. and G. Sarro, Adverse reactions to fluoroquinolones. An overview on 
mechanistic aspects. Current medicinal chemistry, 2001. 8(4): p. 371-384. 
6. Administration, U.S.F.a.D., FDA drug safety communication: FDA requires label 
changes to warn of risk for possibly permanent nerve damage from antibacterial 
fluoroquinolone drugs taken by mouth or by injection. UCM365078. pdf, 2013. 
7. Abbott, N.J., et al., Structure and function of the blood–brain barrier. Neurobiology of 
disease, 2010. 37(1): p. 13-25. 
8. Brunner, M., Langer, O., Dobrozemsky, G., Müller, U., Zeitlinger, M., Mitterhauser, 
M., Wadsak, W.,Dudczak, R., Kletter, K., Müller, M., [18F] Ciprofloxacin, a new 
positron emission tomography tracer for noninvasive assessment of the tissue 
distribution and pharmacokinetics of ciprofloxacin in humans. Antimicrobial agents 
and chemotherapy, 2004. 48(10): p. 3850-3857. 
9. Fischman, A.J., et al., Pharmacokinetics of 18F-labeled trovafloxacin in normal and 
Escherichia coli-infected rats and rabbits studied with positron emission tomography. 
Clinical Microbiology and Infection, 1997. 3(1): p. 63-72. 
10. Fischman, A.J., et al., Pharmacokinetics of [18F] trovafloxacin in healthy human 
subjects studied with positron emission tomography. Antimicrobial agents and 
chemotherapy, 1998. 42(8): p. 2048-2054. 
11. Tewson, T., et al., The synthesis of fluorine-18 lomefloxacin and its preliminary use in 
human studies. Nuclear medicine and biology, 1996. 23(6): p. 767-772. 
12. Babich, J.W., et al., 18 F-labeling and biodistribution of the novel fluoro-quinolone 
antimicrobial agent, trovafloxacin (CP 99,219). Nuclear medicine and biology, 1996. 
23(8): p. 995-998. 
13. Fischman, A.J., Babich, J.W., Alpert, N. M., Vincent, J., Wilkinson, R. A., Callahan, 
R. J., Correia, J. A., Rubin, R. H., Pharmacokinetics of 18F-labeled trovafloxacin in 
normal and Escherichia coli-infected rats and rabbits studied with positron emission 
tomography. Clinical Microbiology and Infection, 1997. 3(1): p. 63-72. 
14. Wagner, C.C. and O. Langer, Approaches using molecular imaging technology—use of 
PET in clinical microdose studies. Advanced drug delivery reviews, 2011. 63(7): p. 
539-546. 
15. Naora, K., et al., Distribution of ciprofloxacin into the central nervous system in rats 
with acute renal or hepatic failure. Journal of pharmacy and pharmacology, 1999. 
51(5): p. 609-616. 
16. Katagiri, Y., et al., High-performance liquid chromatographic determination of 
ciprofloxacin in rat brain and cerebrospinal fluid. Chemical & pharmaceutical bulletin, 
1990. 38(10): p. 2884-2886. 
  
 
149 
17. Rubin, R.H., et al., Tissue pharmacokinetics of fleroxacin in humans as determined by 
positron emission tomography. International journal of antimicrobial agents, 1994. 4: 
p. S15-S20. 
18. Fischman, A.J., et al., Pharmacokinetics of 18F-labeled fleroxacin in rabbits with 
Escherichia coli infections, studied with positron emission tomography. Antimicrobial 
agents and chemotherapy, 1992. 36(10): p. 2286-2292. 
19. Matthews, P.M., I. Rabiner, and R. Gunn, Non-invasive imaging in experimental 
medicine for drug development. Current opinion in pharmacology, 2011. 11(5): p. 501-
507. 
20. Li, F., et al., MALDI-tandem mass spectrometry imaging of astemizole and its primary 
metabolite in rat brain sections. Bioanalysis, 2009. 1(2): p. 299-307. 
21. Sugiura, Y. and M. Setou, Imaging mass spectrometry for visualization of drug and 
endogenous metabolite distribution: toward in situ pharmacometabolomes. Journal of 
Neuroimmune Pharmacology, 2010. 5(1): p. 31-43. 
22. Khatib-Shahidi, S., et al., Direct molecular analysis of whole-body animal tissue 
sections by imaging MALDI mass spectrometry. Analytical chemistry, 2006. 78(18): p. 
6448-6456. 
23. Stoeckli, M., D. Staab, and A. Schweitzer, Compound and metabolite distribution 
measured by MALDI mass spectrometric imaging in whole-body tissue sections. 
International Journal of Mass Spectrometry, 2007. 260(2): p. 195-202. 
24. Castellino, S., M.R. Groseclose, and D. Wagner, MALDI imaging mass spectrometry: 
bridging biology and chemistry in drug development. Bioanalysis, 2011. 3(21): p. 2427-
2441. 
25. Shobo, A., Bratkowska, D.,Baijnath, S.,Naiker, S.,Bester, L.,Singh, S. D.,Maguire, G. 
E. M.,Kruger, H. G.,Govender, T, Visualization of Time-Dependent Distribution of 
Rifampicin in Rat Brain Using MALDI MSI and Quantitative LCMS/MS. Assay and 
drug development technologies, 2015. 13(5): p. 277-284. 
26. Bratkowska, D., et al., Determination of the antitubercular drug PA-824 in rat plasma, 
lung and brain tissues by liquid chromatography tandem mass spectrometry: 
Application to a pharmacokinetic study. Journal of Chromatography B, 2015. 988: p. 
187-194. 
27. Shobo, A., Bratkowska, D., Baijnath, S., Naiker, S., Bester, L. A., Singh, S. D., 
Maguire, G. E. M., Kruger, H. G. & Govender, T, Tissue Distribution of Pretomanid in 
Rat Brain via Mass Spectrometry Imaging. Xenobiotica 2015. 
28. Baijnath, S., Naiker,S., Shobo, A.,Moodley, C.,Adamson, J.,Ngcobo, B.,Bester, L. A. 
,Singh, S.,Kruger, G.,Naicker, T.,Govender,T., Evidence for the presence of 
Clofazimine and its distribution in the healthy mouse brain. Journal of molecular 
histology, 2015.1-7 
29. Sousa, J., et al., First liquid chromatography method for the simultaneous 
determination of levofloxacin, pazufloxacin, gatifloxacin, moxifloxacin and 
trovafloxacin in human plasma. Journal of Chromatography B, 2013. 930: p. 104-111. 
30. Sousa, J., et al., Analytical methods for determination of new fluoroquinolones in 
biological matrices and pharmaceutical formulations by liquid chromatography: a 
review. Analytical and bioanalytical chemistry, 2012. 403(1): p. 93-129. 
31. Tasso, L. and T. Dalla Costa, High performance liquid chromatography for 
quantification of gatifloxacin in rat plasma following automated on-line solid phase 
extraction. Journal of pharmaceutical and biomedical analysis, 2007. 44(1): p. 205-210. 
32. Saribas, Z., et al., Critical appraisal of air pouch infection model in rats. Annals of 
Clinical & Laboratory Science, 2012. 42(1): p. 50-56. 
  
 
150 
33. Ooie, T., et al., Quantitative brain microdialysis study on the mechanism of quinolones 
distribution in the central nervous system. Drug metabolism and disposition, 1997. 
25(7): p. 784-0789. 
34. Okezaki, E., et al., Structure-tissue distribution relationship based on physiological 
pharmacokinetics for NY-198, a new antimicrobial agent, and the related 
pyridonecarboxylic acids. Drug metabolism and disposition, 1988. 16(6): p. 865-874. 
35. Naora, K., et al., Enhanced entry of ciprofloxacin into the rat central nervous system 
induced by fenbufen. Journal of Pharmacology and Experimental Therapeutics, 1991. 
258(3): p. 1033-1037. 
36. Ichikawa, N., et al., Effect of fenbufen on the entry of new quinolones, norfloxacin and 
ofloxacin, into the central nervous system in rats. Journal of pharmacy and 
pharmacology, 1992. 44(11): p. 915-920. 
37. Lutsar, I., et al., Pharmacodynamics of gatifloxacin in cerebrospinal fluid in 
experimental cephalosporin-resistant pneumococcal meningitis. Antimicrobial agents 
and chemotherapy, 1998. 42(10): p. 2650-2655. 
38. Ooie, T., et al., Comparative distribution of quinolone antibiotics in cerebrospinal fluid 
and brain in rats and dogs. Journal of Pharmacology and Experimental Therapeutics, 
1996. 278(2): p. 590-596. 
39. Liu, X., D. Wang, and L. Xie, Correlation between quinolone uptakes by BCECs in 
vitro and brain-to-plasma concentration ratios in rats. European journal of drug 
metabolism and pharmacokinetics, 2005. 30(4): p. 249-254. 
40. Arafa, N.M.S., S.M. Rawi, and S.A. Mubarak, Exploration of the neurotoxicity of 
ciprofloxcin or gatifloxacin single dose in rat cortex and hippocampus. African Journal 
of Pharmacy and Pharmacology, 2015. 9(4): p. 65-73. 
41. Tamai, I., et al., Limited distribution of new quinolone antibacterial agents into brain 
caused by multiple efflux transporters at the blood-brain barrier. Journal of 
Pharmacology and Experimental Therapeutics, 2000. 295(1): p. 146-152. 
42. Kobayashi, K. and A. Mori, Brain Monoamines in Seizure Mechanism (Review). 
Psychiatry and Clinical Neurosciences, 1977. 31(3): p. 483-489. 
43. Moorthy, N., N. Raghavendra, and P. Venkatarathnamma, Levofloxacin-induced acute 
psychosis. Indian journal of psychiatry, 2008. 50(1): p. 57. 
44. Agbaht, K., et al., Ciprofloxacin-associated seizures in a patient with underlying 
thyrotoxicosis: case report and literature review. International journal of clinical 
pharmacology and therapeutics, 2009(47): p. 303-10. 
45. Rawi, S.M., N. Arafa, and M.M. El-Hazmi, Evaluation of the effects of ciprofloxcin or 
gatifloxacin on neurotransmitters levels in rat cortex and hippocampus. Afr J Pharm 
Pharmacol, 2011. 5(8): p. 993-1005. 
46. Juckel, G., A. Mendlin, and B.L. Jacobs, Electrical stimulation of rat medial prefrontal 
cortex enhances forebrain serotonin output: implications for electroconvulsive therapy 
and transcranial magnetic stimulation in depression. Neuropsychopharmacology, 
1999. 21(3): p. 391-398. 
47. Koenigs, M. and J. Grafman, The functional neuroanatomy of depression: distinct roles 
for ventromedial and dorsolateral prefrontal cortex. Behavioural brain research, 2009. 
201(2): p. 239-243. 
 
 
 
 
 
 
  
 
151 
Chapter 9 – Paper 8 
Tissue Distribution of Pretomanid in Rat Brain via Mass Spectrometry Imaging 
 
Adeola Shobo1, Dominika Bratkowska1, Sooraj Baijnath1, Suhashni Naiker1, Anou M. 
Somboro1, Linda A. Bester2, Sanil D. Singh2, Tricia Naicker1, Hendrik G. Kruger1, 
Thavendran Govender1* 
 
1 School of Pharmacy and Pharmacology, University of KwaZulu-Natal, Westville 
Campus, Durban 4000, South Africa.  
*e-mail: govenderthav@ukzn.ac.za 
2 Biomedical Resource Unit, University of KwaZulu-Natal, Westville Campus, Durban 
4000, South Africa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
152 
Abstract 
 
Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) 
combines the sensitivity and selectivity of mass spectrometry with spatial analysis to 
provide a new dimension for histological analyses of the distribution of drugs in tissue.  
Pretomanid is a pro-drug belonging to a class of antibiotics known as nitroimidizoles, 
which have been proven to be active under hypoxic conditions and to the best of our 
knowledge there have been no studies investigating the distribution and localisation of this 
class of compounds in the brain using MALDI MSI.  Herein we report on the distribution 
of pretomanid in the healthy rat brain after intraperitoneal administration (20 mg/kg) using 
MALDI MSI.  Our findings showed that the drug localises in specific compartments of the 
rat brain viz. the corpus callosum, a dense network of neurons connecting left and right 
cerebral hemispheres.  This study proves that MALDI MSI technique has great potential 
for mapping the pretomanid distribution in uninfected tissue samples, without the need for 
molecular labeling. 
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Introduction  
 
The World Health Organization estimated the death of 1.3 million people due to 
tuberculosis (TB) infections in 2013.  The presence of resistant strains of TB and also HIV-
TB co-infection have made this disease a global health priority [1].  Several anti-TB drugs 
are found in the new drug pipeline many of which have recently begun clinical trials [2, 3].  
The need for new regimens based on two or more novel agents is important in order to 
shorten the treatment of drug-susceptible (DS) and drug-resistant (DR) forms of TB.  
Pretomanid is in phase III clinical trials and has shown significant early bactericidal activity 
alone and in combination with the newly approved agent bedaquiline or with pyrazinamide 
(PZA) with or without moxifloxacin [4].  Furthermore, pretomanid, with or without 
clofazimine, has shown better sterilizing activities than other first-line anti-TB drugs, viz. 
rifampin, isoniazid, and PZA [5].  It has been found to be effective against both DS and 
multi-drug resistant (MDR-TB) Mycobacterium tuberculosis (MTB).  Additionally, it has 
shown potent bactericidal and sterilizing activity in mouse models of the disease.  From 
these results it appears that pretomanid offers great potential for shortening the current 
therapy as well as being a prospective treatment for MDR/XDR –TB [5]. 
 
Quantification of drugs in tissue homogenates is now mostly accomplished with LC-
MS/MS methods [6] within which spatial information is totally lost.  The need to identify 
the main cell target of anti-tubercular drugs and molecular interaction after such 
administration is of high importance [7].  Visualization of drug distribution in tissues is a 
relevant step towards evaluating drug activity and effects.  Whole body autoradiography 
[8, 9] and positron emission tomography [10] are currently used techniques to provide 
information on the spatial distribution of drugs in organs.  However, these approaches 
require the use of radiolabelled molecules and may not be able to distinguish the parental 
drug from its metabolites as structural information about molecules could be lost. 
 
Mass spectrometry imaging (MSI) can fill this information gap by providing drug 
distribution data with relatively minimal sample preparation.  MALDI MSI has become a 
powerful tool for the detection and localization of pharmaceuticals and proteins on-tissue, 
[11-15] which can be analyzed in situ while maintaining the morphological integrity of the 
sample.  An additional advantage of MSI is the fact that it does not require the use of 
  
 
154 
radiolabeled standards and compounds, so distribution studies can be performed as a more 
cost-effective technique earlier in the drug discovery process.  
 
Neurological regimens require an optimal and efficient delivery into the brain in order to 
assure appropriate distribution and concentration at the tissue level.  Drug transport through 
the blood-brain barrier (BBB) is crucial for maximizing therapeutic effects in brain 
diseases.  In the present work, we show the application of MSI to investigate the distribution 
of pretomanid, in the brain after intraperitoneal administration.  The quantification of this 
drug in the rat brain was confirmed by accurate full MS and MS/MS spectra [16].  Recently, 
a few authors have reported LC-MS/MS methods for the determination of pretomanid post 
administration and their application to pharmacokinetics in murine models [16-18].  
However, none of these studies have investigated the BBB penetration or brain distribution 
of this compound or others in its class.  To the best of our knowledge there have been no 
studies investigating the BBB penetration and brain distribution of this promising new class 
of anti-TB compounds using MALDI MSI.   
 
Materials and methods 
 
Reagents and standards 
 
The pretomanid standard was obtained from DLD Scientific (Durban, South Africa).  The 
4-hydroxy-α-cyanocinnamic acid (HCCA), and indium tin oxide (ITO) glass slides 
required for MALDI MSI were purchased from Bruker Daltonics (Bremen, Germany).  
Trifluoroacetic acid, sodium hydroxide and dimethyl sulfoxide (DMSO) were purchased 
from Sigma-Aldrich (Steinheim, Germany).  Acetonitrile (ACN), formic acid, methanol 
(MeOH), ethanol (EtOH) were of analytical grade all from Sigma Aldrich.  Ultra-pure 
water was obtained using a Milli-Q purification system from Millipore Corporation 
(Bedford, MA, USA). 
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Animals 
All animal experiments were undertaken with the approval of the Institutional Animal 
Ethical Committee of University of KwaZulu-Natal (UKZN), Durban, with the approval 
number 069/14/Animal.  Healthy female Sprague-Dawley rats weighing 130 ± 10g were 
obtained from the Biomedical Resource Unit (BRU), University of KwaZulu-Natal.  
Animals were housed at the BRU in polycarbonate cages in air-conditioned rooms (50-
70% humidity and between 21-24oC) with a 12 hr light/dark cycle.  Animals were allowed 
ad libitum access to drinking water and standard rat chow.  
 
Drug administration and tissue sampling 
Pretomanid was weighed and prepared based on the average weight of animals to 20mg/kg 
using 40% DMSO in ultra pure water.  The drug was administered intraperitoneally (i.p.) 
to 8 groups of animals (n=3).  Animals were anaesthetized with halothane before blood was 
collected by cardiac puncture at 0, 15, 30, 60, 120, 240, 360, and 480 min post dose.  The 
rats were euthanized with halothane and termination was confirmed by the absence of 
breathing and dissection was performed immediately.  The brains were surgically removed 
and snap frozen in liquid nitrogen vapour before storage at −80oC. 
 
Sample preparation for MALDI-MSI 
Optimal cutting temperature (OCT) was used as a medium to mount the tissue onto the 
chuck of the cryostat and serial sections (10 µm thick) were obtained from each biopsy and 
thaw mounted onto an indium titanium oxide (ITO) coated glass slide (Bruker, Bremen, 
Germany) with the aid of a cryostat (Leica Microsystems CM1100, Wetzlar, Germany) and 
stored at −80 °C till needed for analysis.  Glass slides were removed from deep freeze and 
immediately transferred to a desiccator.  Following 30 min desiccation times, the slides 
were scanned on a flatbed scanner (HP LaserJet 3055).  Matrix preparation was done by 
preparing 7 mg/ml α-cyano-4-hydroxy cinnamic acid (CHCA) (Bruker, Bremen, Germany) 
matrix solution in 50% acetonitrile (ACN) containing 0.2% trifluoroacetic acid (TFA).  The 
matrix solution was sonicated for 5 min before transferring to an Image Prep (Bruker 
Daltonics).  This is a spraying device that automatically deposits matrix solution onto the 
tissue in a consistent manner.  Briefly, aerosol is generated by vibrating spray generator 
producing tiny droplets (average droplet size of ≈20 µm) under controlled conditions.  The 
pre-developed Image prep method had 5 phases which all included spraying, incubation 
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and drying times respectively.  The total thickness of matrix layer deposited on all slides 
determined by the optical sensor was 1.5 V.  
 
MSI Analysis 
For all MSI analyses, it is important to give details of parameters, protocols and equipment 
for any experiment [19].  Standard solutions of pretomanid were analyzed using MALDI 
TOF MS operated both at reflectron and LIFT modes respectively with the aid of the 
Autoflex III MALDI TOF/TOF 1 KHz smartbeam laser (Bruker Daltonics, Germany) and 
data acquired using FlexControl (version 3.4, build 119) software in positive ion mode.  
The LIFT mode allows a re-acceleration of ions in such a way that all fragment ions 
penetrate far enough into the reflector to provide a spectrum of fragment ions with 
improved spectral resolution.  The instrument was calibrated using standard peptides and 
standard concentrations of the drug spotted with HCCA matrix on a ground steel target 
(Bruker Daltonics, Germany) for m/z 100-500.  Each spectrum was acquired from 200 laser 
shots with a laser frequency of 200 Hz.  Tissue sections were imaged with spatial resolution 
of 100 µm.  The MALDI images were displayed using the software Flex Imaging 3.0 
(Bruker Daltonics, Germany).  Spotting various concentrations (5, 10, 100, 250 and 500 
ng/mL respectively) of pretomanid with the matrix onto a brain section of an untreated 
animal was used to evaluate background signals that may interfere with the analyte and to 
determine a limit of detection.  The spots were analyzed in reflectron mode by collecting 
200 shots per spot.  The MS/MS experiments were executed using the LIFT method 
optimized for the drug by exact tuning of the timing of the LIFT cell and of the precursor 
ion selector.  This method has the major advantage of acquiring data for both parent and 
fragments of the analyte consecutively, providing adequate information on the analyte.  The 
LIFT method was calibrated as earlier mentioned and the same method was used to perform 
MS/MS directly on pretomanid-matrix spotted tissue section and spectra were compared to 
the MS/MS spectra generated from of the drug standard only.  For the initial analysis of the 
manually deposited spots, spectra consisting of 1000 laser shots were acquired in bundles 
of 5 x 200 shots and data were collected in the range between m/z 100–500 with a laser 
frequency of 200 Hz, mass window range of 2 Da and the digitalization rate was 2 GS/s.  
A product ion scan of the parent ion (m/z 360) revealed a clear fragmentation pattern with 
the transition m/z 360 → 344	dominating the spectra with a laser power of 60%.  An increase 
in the laser power led to production of other product ions but with lower sensitivity.  The 
software, Flex Imaging version 3.0 build 54 was used to set up the acquisition of the 
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imaging experiments.  The imaging MS/MS experiments were performed by collecting 
spectra with a raster width of 100 µm in the same m/z range as above.  The spectra were 
baseline subtracted (Convex hull) and smoothed (Savitzski golay) in the processing 
software during acquisition.  In LIFT mode, all spectra were normalized against total ion 
count (TIC) to reduce influences by matrix hot spots.  We define the total ion count as the 
sum of all intensities in the mass range analyzed.  For this analysis, both fragment and 
parent spectra were acquired from each spot and 500 laser shots were summed up in a 
random walk pattern from each position.  The pretomanid parent ion of m/z 360 and 
fragment with m/z 344 were used to visualize the distribution of pretomanid in the 3 serial 
brain sections from the same animal in triplicate.  
 
Results  
 
The results of the MSI optimization are shown in Figure 1, the spectra show the transition 
of pretomanid from parent ion m/z 360→344.  This transition was chosen for the MSI assay 
because during the method development and optimization in the LIFT mode, the m/z 344 
had the highest intensity (as shown in Figure 1).  An increase in the laser power led to 
production of other product ions but with lower sensitivity.  This made it possible for the 
visualization and mapping of the drug in the brain sections.  The [M-16u]+• ion, 
corresponding to an oxygen loss, was observed in all cases as a significant peak.   
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Figure 1. Spectra acquired using LIFT-positive mode; (A) typical spectrum obtained 
during the optimization of pretomanid on the brain tissue sections, (B) spectrum of the 
parent ion, and (C) spectrum of the fragments obtained. 
 
This kind of fragmentation has been previously described for similar moieties [20, 21]. The 
result of the limit of detection as shown in Figure 2 reported a value of 10ng/mL.  From 
the results of the MSI experiments shown in Figure 3, it can be seen that the initial entry 
of the drug occurred via the cerebral capillary network of the BBB into the cortical regions 
(C) of the rat brain (15 and 30 min snapshots).  The drug might have diffused into the brain 
via the endothelial tight junctions of the cerebral capillary network whose entry point is 
found adjacent to the superior sagitial sinus [22] or possibly transported.  These might be 
responsible for the distribution pattern observed at 30 min, where it can be seen 
concentrating at the cortex (C). 
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Figure 2. Spots of standard solutions (5, 10, 50, 100, 250, and 500 ng/mL) of pretomanid 
with the matrix on a brain section for the determination of limit of detection. 
 
Pretomanid then distributed in the corpus callosum (CC) of the rat brain at 60 and 120 min 
time points shown in Figure 3.  The image at 60 min shows the diffusion of the compound 
from the C into the CC and its widespread distribution into other areas of the brain (Figure 
3).  At this point, the distribution of the drug seems higher in the CC over the C.  At 120 
min, there is a wide spread and time-dependent entry into the CC, although small traces of 
the drug can still be seen in the C.  At this time point we can also see the drug entering and 
concentrating at the CC until peak concentrations as previously reported [16] were reached. 
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Figure 3. Coronal brain images acquired from 0 min to 480 min after intraperitoneal 
administration of pretomanid (20 mg/kg) to rats, acquired using LIFT mode with both 
parent and fragments simultaneously.  Red represents the parent ion with a mass window 
m/z 360 ± 0.1% and green is the fragment of the drug at m/z 344 ± 0.15%, these data 
represents mean ± standard deviation (SD) respectively.  Images 15 and 30 min respectively 
showed initial entry of pretomanid in a coronal section of the rat brain via the BBB and 60 
and 120 min revealed the distribution of pretomanid into the CC.  Images 240, 360 and 480 
min respectively displayed a diffusion of the drug into other parts of the brain. 
 
In the next phase, 240, 360 and 480 min respectively, we observed reduced intensity of the 
drug which might have been due to elimination of the drug since the cerebrospinal fluid is 
regularly produced by the choroid plexus for this purpose.  The images for the latter two 
time points indicate a steady decrease in the concentration of the drug in the CC, providing 
evidence of outward diffusion into neighbouring areas of the brain.  As evident in the 
images, the distribution of the drug at these time points does not vary greatly.  The exact 
mechanism of how the pretomanid leaves the CC is unclear, however by analysing the 
images we can postulate that the drug is able to slowly diffuse and dissipate throughout the 
brain until trough concentrations are reached as shown in Figure 4. 
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Figure 4. Drug-concentration time profile of pretomanid in the brain after intraperitoneal 
administration of 20mg/kg to rats [16].  Data represented are mean ± SD. 
 
Discussion 
 
The novelty of this study lies in the ability of MSI to show the localization of pretomanid 
in a healthy rat brain.  The significance of the use of uninfected rats in this study allows for 
the determination of the compounds distribution in the brain during the early course of an 
infection.  Coupled with quantification data via LCMS/MS, would allow us to determine if 
it reached the therapeutic doses required to treat the associated neurological infections [23].  
 
Pretomanid is a pro-drug belonging to a class of antibiotics known as nitroimidizoles, 
which have proven to become active under hypoxic conditions [24].  In a previous study, 
our research team developed, optimised and validated a LC/MS/MS method for the 
detection of pretomanid in rat plasma, lung and brain homogenates and the Cmax of the drug 
in the brain homogenate was 236.8ng/g with a Tmax of 120 min (as shown in the Figure 4) 
and the lowest concentration reported within the same time of our study was 161.5ng/g.  
The observed trend of the images could be paired with concentrations reported earlier [16] 
and this correlates with our findings.  The reported Cmax depicts that the concentration 
reached by the drug in the brain is within the therapeutic range for MTB as previously 
reported [25].  However, from the available work on this nitroimidizole we are able to make 
certain postulations regarding this unusual distribution pattern.  Upon the interpretation of 
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our acquired images, we were able to show the initial entry of the drug into the brain via 
the BBB, which is expected due its Log P value of 2.7 [26].  Using this information, we 
propose that pretomanid is able to diffuse into the neighbouring lateral ventricles and 
follows the rostral migratory stream to the olfactory area leading to the observed reduction 
in drug distribution after 120 min in the CC.  The findings we have presented in this paper 
together with previous reports indicate that the distribution and localisation of drugs in the 
brain vary among different groups of antibiotics depending on their structural and chemical 
properties [27-30]. 
 
We have developed for the first time a MALDI MSI method for the localization of 
pretomanid in rat brain tissues.  This study has shown the application of MALDI-MSI in 
evaluating the tissue distribution of the drug even at trough concentrations.  This study 
proves that this technique has great potential for drug distribution in uninfected as well as 
infected tissue samples, without the need for molecular labeling, highlighting the 
importance of this technique for pharmacological applications. Our study has shown that 
this chemical agent distributes at the CC and a reason for its location at this part of the brain 
might be because of the hypoxic nature of this feature. CC had previously been described 
as an area with rich blood supply but it is relatively hypoxic due to its fibrous structure [31] 
and pretomanid itself had earlier been reported as a pro-drug that is active under hypoxic 
conditions [24].  It has earlier been shown that infection leads to the development of an 
hypoxic environment that could aid the favourable concentration of this drug at the specific 
sites of infection, we suggest that investigations using infected models be used to further 
elucidate and explore the sterilizing potentials of pretomanid.  
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Chapter 10 - Summary 
 
In this series of projects, the value of MSI in the evaluation of new and promising anti-TB 
agents, have been demonstrated. Not only does this bode well for anti-mycobacterial agents 
this technique can also be applied to the evaluation of other anti-bacterial agents, especially in 
terms of tissue distribution and localization. This has great potential for streamlining the drug 
development process by either identifying or eliminating drug candidates during the early 
stages. This is possible due to some distinct advantages MSI has over other more commonly 
used molecular imaging modalities, such as PET and MRI. MSI can be seen as the future of 
molecular imaging and diagnostics, allowing for the high-throughput screening of a large 
sample size within a short period of time, requiring minimal sample preparation. In addition, 
this technique allows for the simultaneous identification of drugs, drug metabolites, bio-
markers, receptors etc., whereas other modalities are only able to detect one target molecule 
per an instance. Even with this versatility, the specificity of MSI is unquestioned since the 
molecular mass and signature of a compound is used to identify targets. The sum of all the MSI 
experiments carried out during this period has yielded interesting results in that no two anti-
bacterial agents have displayed the same CNS distribution. This proves that brain drug 
localization is highly preferential and is affected by the chemical properties of the drug and the 
physical properties of the BBB. Using these findings, we were able to show how MSI can be 
highly beneficial in the pre-clinical evaluation of anti-bacterial agents, specifically targeting 
extra-pulmonary-TB of the brain.  
 
In Chapter 1, we are the first to provide evidence that CFZ does in fact enter the brain, using 
MSI. This was in vast contrast to the popular belief that the drug does not penetrate the BBB. 
CFZ showed widespread distribution in the brain, with high concentrations in the lateral 
ventricles. This is especially significant since the lateral ventricles house the choroid plexus 
and is responsible for the production and circulation of CSF throughout the brain. In Chapter 
2, the same experimental approach was used to demonstrate the neuroprotective potential of 
LIN. MSI findings showed that the drug showed the greatest deposition in the brain stem, 
which forms the entry point of systemic blood vessels. This is important since the CNS is not 
the primary site of bacterial infections, which normally occur systemically and are 
haematogenously spread to the brain. By forming a “sentinel” in the brain stem, LIN has the 
potential to prevent the entry of infectious agents into the CNS. 
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In order for one to effectively evaluate TB drugs, the lung distribution of potential anti-
mycobacterials needed to be understood. However, we noted the difficulties associated with 
the preparation of lung tissue for MSI. This led to the conceptualization of Chapter 4. Herein 
lung inflation using cryoprotectants was used to preserve lung structure during the preparation 
stages, in order to provide more precise distribution data. Various established cryoprotectants, 
including commercially available agents were tested as potential inflation media. During the 
various stages in the preparation, challenges were encountered with the different agents, 
eventually it was found that a 10% DMSO solution was the most ideal cryoprotective agent, 
which preserves the structural integrity of the lung and provides accurate drug distribution data.  
 
In Chapters 5, 6, 7 and 8, we have demonstrated how LC-MS and MSI can be used for the 
evaluation of a wide range of antibiotics focusing on their applicability for CNS investigations 
centered around drug distribution in the brain. The findings revealed very significant results in 
that each antibiotic displayed some unique patterns of distribution and localization. This 
highlights how the chemical properties of a drug strongly influences its interaction with the 
BBB and subsequently influences its distribution to the various structures in the brain. These 
chapters also demonstrated the versatility and many applications of MSI, especially in terms 
of understanding drug behavior in the CNS. The results help us understand why the 
tetracyclines have been so effective in the treatment of brain disorders, this can now be 
attributed to their widespread tissue distribution in CNS. MSI was also used to prove that RIF, 
a typically large drug molecule, is able to permeate the brain in a time-dependent manner. This 
despite the drug failing many of the rules that predict drug entry into the CNS.  This technique 
can also be used to understand the neurotoxicity of certain classes of drugs such as the 
flouroquinolones and in this case, GAT. This technique was also used, with great effectiveness, 
in the evaluation of pretomanid, a drug currently under clinical trials and similarly be applied 
to the evaluation of other such antibiotics. These finding further emphasize how MSI can be 
used to streamline the drug development process and help in the selection and identification of 
promising candidates while eliminating less promising candidates. 
 
These series of experiments will pave the way for future research that will further cement the 
role of MSI as an invaluable tool in the drug development process. Studies to be carried out 
will include the investigation of the distribution of the anti-mycobacterial agents in the brain 
of TB-infected animals (such as mice and rabbits). This will also allow us to optimize our 
technique of lung inflation for the preparation of lungs containing TB lesions and granulomas, 
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thereby providing a new sample preparation protocol to be conducted in diagnostic 
laboratories. 
 
For future experiments, it will also be highly beneficial to study the effects of multiple doses 
on the distribution of PA-824, DOX, TIG, RIF and GAT, since antibiotics are not prescribed 
as single doses but rather as multiple dose treatment regimens. 
 
With all of the recent technological advancements in MSI applications, it is only natural that 
MSI will become an important technique in drug discovery, especially since it can be applied 
for the analysis of a wide range of tissue samples. MSI has the potential to be used in all aspects 
of drug metabolism pharmacokinetics (DMPK) and absorption, distribution, metabolism and 
excretion (ADME), especially due to its ability to measure a wide range of analytes (ranging 
from small drug molecules and their metabolites, to large endogenous proteins and lipids). 
 
A current trend in MSI experiments reveal that this technique can provide more detailed 
information on drug distribution at a cellular level, which would include MI of intracellular 
targets and drug interaction with these targets. However, in order to achieve this, higher 
resolution images of regions showing high levels of drug localization, will be acquired. Since 
this instrumentation is specialized and currently not accessible in South Africa, the next step 
of these projects will be carried out in collaboration with world leaders in the field of bio-
molecular imaging which is currently ongoing. 
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